NZ623291B2 - Tamper-resistant oral pharmaceutical dosage form comprising a pharmacologically active ingredient, an opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer - Google Patents
Tamper-resistant oral pharmaceutical dosage form comprising a pharmacologically active ingredient, an opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer Download PDFInfo
- Publication number
- NZ623291B2 NZ623291B2 NZ623291A NZ62329112A NZ623291B2 NZ 623291 B2 NZ623291 B2 NZ 623291B2 NZ 623291 A NZ623291 A NZ 623291A NZ 62329112 A NZ62329112 A NZ 62329112A NZ 623291 B2 NZ623291 B2 NZ 623291B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- dosage form
- pharmaceutical dosage
- acid
- opioid
- pharmacologically active
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title claims abstract description 393
- 239000003401 opiate antagonist Substances 0.000 title claims abstract description 127
- 229920000642 polymer Polymers 0.000 title claims abstract description 105
- 125000000129 anionic group Chemical group 0.000 title claims abstract description 92
- 239000002831 pharmacologic agent Substances 0.000 title claims abstract description 83
- 229920000233 poly(alkylene oxides) Polymers 0.000 title claims abstract description 74
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 61
- 239000000126 substance Substances 0.000 claims abstract description 52
- 210000003800 Pharynx Anatomy 0.000 claims abstract description 14
- 239000002895 emetic Substances 0.000 claims abstract description 14
- 230000000095 emetic Effects 0.000 claims abstract description 14
- 239000003349 gelling agent Substances 0.000 claims abstract description 8
- 239000004094 surface-active agent Substances 0.000 claims abstract description 8
- 239000000975 dye Substances 0.000 claims abstract description 6
- 239000003402 opiate agonist Substances 0.000 claims description 140
- 239000000203 mixture Substances 0.000 claims description 74
- -1 phosphoryl groups Chemical group 0.000 claims description 62
- 150000003839 salts Chemical class 0.000 claims description 39
- 239000011780 sodium chloride Substances 0.000 claims description 39
- 239000011159 matrix material Substances 0.000 claims description 33
- 238000000338 in vitro Methods 0.000 claims description 32
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycontin Chemical group O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims description 22
- 229960002085 oxycodone Drugs 0.000 claims description 22
- 238000009740 moulding (composite fabrication) Methods 0.000 claims description 18
- UZHSEJADLWPNLE-GRGSLBFTSA-N Naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims description 15
- 229960004127 Naloxone Drugs 0.000 claims description 15
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 13
- 239000000178 monomer Substances 0.000 claims description 13
- 230000002035 prolonged Effects 0.000 claims description 13
- 239000004014 plasticizer Substances 0.000 claims description 11
- 239000003963 antioxidant agent Substances 0.000 claims description 9
- 230000003078 antioxidant Effects 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- DQCKKXVULJGBQN-XFWGSAIBSA-N Naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 3
- 229960003086 Naltrexone Drugs 0.000 claims description 3
- 229940035295 Ting Drugs 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 3
- OZYUPQUCAUTOBP-QXAKKESOSA-N Levallorphan Chemical compound C([C@H]12)CCC[C@@]11CCN(CC=C)[C@@H]2CC2=CC=C(O)C=C21 OZYUPQUCAUTOBP-QXAKKESOSA-N 0.000 claims description 2
- 125000005250 alkyl acrylate group Chemical group 0.000 claims description 2
- 229960000263 levallorphan Drugs 0.000 claims description 2
- 230000035807 sensation Effects 0.000 claims description 2
- 238000003860 storage Methods 0.000 abstract description 30
- 239000002253 acid Substances 0.000 description 72
- 230000035492 administration Effects 0.000 description 51
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 51
- 230000003364 opioid Effects 0.000 description 46
- 230000035852 Tmax Effects 0.000 description 45
- 150000001875 compounds Chemical class 0.000 description 32
- 125000000524 functional group Chemical group 0.000 description 28
- 150000002500 ions Chemical class 0.000 description 26
- 230000000875 corresponding Effects 0.000 description 24
- 239000007788 liquid Substances 0.000 description 24
- 239000000463 material Substances 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 229920001577 copolymer Polymers 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 238000001125 extrusion Methods 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- 239000000470 constituent Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 150000002148 esters Chemical class 0.000 description 15
- 230000037242 Cmax Effects 0.000 description 14
- 230000002378 acidificating Effects 0.000 description 13
- 238000005259 measurement Methods 0.000 description 13
- 150000007513 acids Chemical class 0.000 description 12
- 230000036470 plasma concentration Effects 0.000 description 12
- 238000010298 pulverizing process Methods 0.000 description 12
- 239000011248 coating agent Substances 0.000 description 11
- 238000000576 coating method Methods 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 238000000926 separation method Methods 0.000 description 11
- 239000002202 Polyethylene glycol Substances 0.000 description 10
- 229940079593 drugs Drugs 0.000 description 10
- 229920001223 polyethylene glycol Polymers 0.000 description 10
- 229920003086 cellulose ether Polymers 0.000 description 9
- 239000003431 cross linking reagent Substances 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 9
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 9
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- RFIMISVNSAUMBU-UHFFFAOYSA-N 2-(hydroxymethyl)-2-(prop-2-enoxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC=C RFIMISVNSAUMBU-UHFFFAOYSA-N 0.000 description 8
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 8
- 229920001515 polyalkylene glycol Polymers 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000001856 Ethyl cellulose Substances 0.000 description 7
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 7
- 239000000556 agonist Substances 0.000 description 7
- 229920002678 cellulose Polymers 0.000 description 7
- 235000019325 ethyl cellulose Nutrition 0.000 description 7
- 229920001249 ethyl cellulose Polymers 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- 101700000038 mpas Proteins 0.000 description 7
- 239000003887 narcotic antagonist Substances 0.000 description 7
- 229920005862 polyol Polymers 0.000 description 7
- 150000003077 polyols Chemical class 0.000 description 7
- 239000012453 solvate Substances 0.000 description 7
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 6
- 210000001847 Jaw Anatomy 0.000 description 6
- XAPRFLSJBSXESP-UHFFFAOYSA-N Oxycinchophen Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=C(O)C=1C1=CC=CC=C1 XAPRFLSJBSXESP-UHFFFAOYSA-N 0.000 description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 6
- 230000003111 delayed Effects 0.000 description 6
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 6
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 6
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- 239000011732 tocopherol Substances 0.000 description 6
- 229920002554 vinyl polymer Polymers 0.000 description 6
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 description 5
- 229940086737 ALLYL SUCROSE Drugs 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- WVLOADHCBXTIJK-YNHQPCIGSA-N Hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 5
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 5
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000003042 antagnostic Effects 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 150000002170 ethers Chemical class 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 239000007888 film coating Substances 0.000 description 5
- 238000009501 film coating Methods 0.000 description 5
- 238000005755 formation reaction Methods 0.000 description 5
- KUQWZSZYIQGTHT-UHFFFAOYSA-N hexa-1,5-diene-3,4-diol Chemical compound C=CC(O)C(O)C=C KUQWZSZYIQGTHT-UHFFFAOYSA-N 0.000 description 5
- 229920001519 homopolymer Polymers 0.000 description 5
- 229960001410 hydromorphone Drugs 0.000 description 5
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 239000004570 mortar (masonry) Substances 0.000 description 5
- 239000008164 mustard oil Substances 0.000 description 5
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 5
- 229920001888 polyacrylic acid Polymers 0.000 description 5
- 238000006116 polymerization reaction Methods 0.000 description 5
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 4
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 4
- 235000002566 Capsicum Nutrition 0.000 description 4
- 240000000306 Carapichea ipecacuanha Species 0.000 description 4
- 229940063834 Carboxymethylcellulose Sodium Drugs 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- 210000004051 Gastric Juice Anatomy 0.000 description 4
- 210000000936 Intestines Anatomy 0.000 description 4
- 229960002900 Methylcellulose Drugs 0.000 description 4
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 4
- CXMXRPHRNRROMY-UHFFFAOYSA-N Sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 4
- 230000001055 chewing Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 4
- 239000006193 liquid solution Substances 0.000 description 4
- 230000018984 mastication Effects 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 229960005118 oxymorphone Drugs 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 description 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- 238000003856 thermoforming Methods 0.000 description 4
- OJHZNMVJJKMFGX-BWCYBWMMSA-N (4R,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;(2R,3R)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC OJHZNMVJJKMFGX-BWCYBWMMSA-N 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- 229940105329 Carboxymethylcellulose Drugs 0.000 description 3
- 229920002301 Cellulose acetate Polymers 0.000 description 3
- 235000005979 Citrus limon Nutrition 0.000 description 3
- 240000002268 Citrus limon Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- XJRBAMWJDBPFIM-UHFFFAOYSA-N Methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 3
- 229950008297 NALMEXONE Drugs 0.000 description 3
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 description 3
- OHKCLOQPSLQCQR-MBPVOVBZSA-N Nalmexone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(CC=C(C)C)[C@@H]3CC5=CC=C4O OHKCLOQPSLQCQR-MBPVOVBZSA-N 0.000 description 3
- 229940005483 OPIOID ANALGESICS Drugs 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 239000004952 Polyamide Substances 0.000 description 3
- 239000004698 Polyethylene (PE) Substances 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 210000000582 Semen Anatomy 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 229920001400 block copolymer Polymers 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 230000005591 charge neutralization Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 238000002845 discoloration Methods 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013312 flour Nutrition 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 150000002334 glycols Chemical class 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 238000009474 hot melt extrusion Methods 0.000 description 3
- KLGZELKXQMTEMM-UHFFFAOYSA-N hydride Chemical compound [H-] KLGZELKXQMTEMM-UHFFFAOYSA-N 0.000 description 3
- 238000011068 load Methods 0.000 description 3
- 239000011976 maleic acid Substances 0.000 description 3
- 150000002763 monocarboxylic acids Chemical class 0.000 description 3
- 229960005297 nalmefene Drugs 0.000 description 3
- 230000001264 neutralization Effects 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Polymers 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 239000004584 polyacrylic acid Substances 0.000 description 3
- 229920001281 polyalkylene Polymers 0.000 description 3
- 229920002647 polyamide Polymers 0.000 description 3
- 229920001610 polycaprolactone Polymers 0.000 description 3
- 239000004632 polycaprolactone Substances 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 229920000915 polyvinyl chloride Polymers 0.000 description 3
- 239000004800 polyvinyl chloride Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000007493 shaping process Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-N sulfonic acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 150000003628 tricarboxylic acids Chemical class 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- IUFVBLNYWMTPOB-UHFFFAOYSA-N 1,1,3-trioxo-4H-1$l^{6},2,4-benzothiadiazine-7-carboxylic acid Chemical compound N1C(=O)NS(=O)(=O)C2=CC(C(=O)O)=CC=C21 IUFVBLNYWMTPOB-UHFFFAOYSA-N 0.000 description 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
- DJENHUUHOGXXCB-UHFFFAOYSA-N 2-butyl-6-methoxyphenol Chemical compound CCCCC1=CC=CC(OC)=C1O DJENHUUHOGXXCB-UHFFFAOYSA-N 0.000 description 2
- FKWGCEDRLNNZOZ-GFCCVEGCSA-N 2-methyl-5-[(2R)-6-methylhept-5-en-2-yl]phenol Chemical compound CC(C)=CCC[C@@H](C)C1=CC=C(C)C(O)=C1 FKWGCEDRLNNZOZ-GFCCVEGCSA-N 0.000 description 2
- JVYNJRBSXBYXQB-UHFFFAOYSA-N 4-[3-(4-carboxyphenoxy)propoxy]benzoic acid;decanedioic acid Chemical compound OC(=O)CCCCCCCCC(O)=O.C1=CC(C(=O)O)=CC=C1OCCCOC1=CC=C(C(O)=O)C=C1 JVYNJRBSXBYXQB-UHFFFAOYSA-N 0.000 description 2
- 241000208140 Acer Species 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N Adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Antorphin Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 2
- VMWNQDUVQKEIOC-CYBMUJFWSA-N Apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 2
- 229960004046 Apomorphine Drugs 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 230000036912 Bioavailability Effects 0.000 description 2
- 235000007575 Calluna vulgaris Nutrition 0.000 description 2
- 240000002804 Calluna vulgaris Species 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N Capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 240000004160 Capsicum annuum Species 0.000 description 2
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 2
- 235000002283 Capsicum annuum var aviculare Nutrition 0.000 description 2
- 235000002284 Capsicum baccatum var baccatum Nutrition 0.000 description 2
- 240000008574 Capsicum frutescens Species 0.000 description 2
- 235000002568 Capsicum frutescens Nutrition 0.000 description 2
- HNEGQIOMVPPMNR-IHWYPQMZSA-N Citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- 240000004625 Citrus aurantiifolia Species 0.000 description 2
- 240000000560 Citrus x paradisi Species 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N Codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 229960001681 Croscarmellose Sodium Drugs 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- VWTINHYPRWEBQY-UHFFFAOYSA-N Denatonium Chemical compound [O-]C(=O)C1=CC=CC=C1.C=1C=CC=CC=1C[N+](CC)(CC)CC(=O)NC1=C(C)C=CC=C1C VWTINHYPRWEBQY-UHFFFAOYSA-N 0.000 description 2
- BPLQKQKXWHCZSS-UHFFFAOYSA-N Elemicin Chemical compound COC1=CC(CC=C)=CC(OC)=C1OC BPLQKQKXWHCZSS-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000333074 Eucalyptus occidentalis Species 0.000 description 2
- 229940044949 Eucalyptus oil Drugs 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N Galantamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N Glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 2
- 229940031574 HYDROXYMETHYL CELLULOSE Drugs 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N Hippuric acid Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 239000009471 Ipecac Substances 0.000 description 2
- 229940029408 Ipecac Drugs 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N Isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 229960004873 LEVOMENTHOL Drugs 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N Lauric acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229940041616 Menthol Drugs 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N Morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- DSLZVSRJTYRBFB-DUHBMQHGSA-N Mucic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 2
- BNWJOHGLIBDBOB-UHFFFAOYSA-N Myristicin Chemical compound COC1=CC(CC=C)=CC2=C1OCO2 BNWJOHGLIBDBOB-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- 229940051804 Natural opium alkaloid analgesics Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 102000003840 Opioid Receptors Human genes 0.000 description 2
- 108090000137 Opioid Receptors Proteins 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N Palmitic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000006002 Pepper Substances 0.000 description 2
- 235000016761 Piper aduncum Nutrition 0.000 description 2
- 235000017804 Piper guineense Nutrition 0.000 description 2
- 240000000129 Piper nigrum Species 0.000 description 2
- 235000008184 Piper nigrum Nutrition 0.000 description 2
- MXXWOMGUGJBKIW-YPCIICBESA-N Piperine Chemical compound C=1C=C2OCOC2=CC=1/C=C/C=C/C(=O)N1CCCCC1 MXXWOMGUGJBKIW-YPCIICBESA-N 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 229920000331 Polyhydroxybutyrate Polymers 0.000 description 2
- 229920001710 Polyorthoester Polymers 0.000 description 2
- 229920001451 Polypropylene glycol Polymers 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 229960003975 Potassium Drugs 0.000 description 2
- 206010039163 Right ventricular failure Diseases 0.000 description 2
- ZMQAAUBTXCXRIC-UHFFFAOYSA-N Safrole Chemical compound C=CCC1=CC=C2OCOC2=C1 ZMQAAUBTXCXRIC-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 241000220261 Sinapis Species 0.000 description 2
- 229940075582 Sorbic Acid Drugs 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- KWTWDQCKEHXFFR-SMDDNHRTSA-N Tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 235000015450 Tilia cordata Nutrition 0.000 description 2
- 235000011941 Tilia x europaea Nutrition 0.000 description 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N Tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 2
- 229960004380 Tramadol Drugs 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N Valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 125000005396 acrylic acid ester group Chemical group 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 229920001586 anionic polysaccharide Polymers 0.000 description 2
- 150000004836 anionic polysaccharides Chemical class 0.000 description 2
- 239000010692 aromatic oil Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000035514 bioavailability Effects 0.000 description 2
- 239000001390 capsicum minimum Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000004203 carnauba wax Substances 0.000 description 2
- 235000013869 carnauba wax Nutrition 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 235000013303 cayenne pepper Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 235000003373 curcuma longa Nutrition 0.000 description 2
- 239000001215 curcuma longa l. root Substances 0.000 description 2
- 229960001610 denatonium benzoate Drugs 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 150000002009 diols Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000003628 erosive Effects 0.000 description 2
- 229960004667 ethyl cellulose Drugs 0.000 description 2
- 239000010642 eucalyptus oil Substances 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 150000004676 glycans Polymers 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 229960005208 ipecacuanha Drugs 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- 230000000670 limiting Effects 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 229930014694 morphine Natural products 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229960000938 nalorphine Drugs 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 235000019477 peppermint oil Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002745 poly(ortho ester) Substances 0.000 description 2
- 239000011528 polyamide (building material) Substances 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 229920001707 polybutylene terephthalate Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 2
- 230000000069 prophylaxis Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 239000001327 prunus amygdalus amara l. extract Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 230000002269 spontaneous Effects 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000003460 sulfonic acids Chemical class 0.000 description 2
- 230000001502 supplementation Effects 0.000 description 2
- 230000002459 sustained Effects 0.000 description 2
- 229960005126 tapentadol Drugs 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- GXMBHQRROXQUJS-UHFFFAOYSA-N (2-hept-2-ynylsulfanylphenyl) acetate Chemical compound CCCCC#CCSC1=CC=CC=C1OC(C)=O GXMBHQRROXQUJS-UHFFFAOYSA-N 0.000 description 1
- FEIQOMCWGDNMHM-KBXRYBNXSA-N (2E,4E)-5-phenylpenta-2,4-dienoic acid Chemical compound OC(=O)\C=C\C=C\C1=CC=CC=C1 FEIQOMCWGDNMHM-KBXRYBNXSA-N 0.000 description 1
- OMDQUFIYNPYJFM-XKDAHURESA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[[(2R,3S,4R,5S,6R)-4,5,6-trihydroxy-3-[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- ZTHKPSBRWLGUIK-XORBCWOASA-N (2R,3R,4S,5S,6R)-2-[(2R,3S,4R,5R,6S)-6-[[(2R,3S,4R,5R,6R)-3-[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-[(2R,3S,4R,5R,6R)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]3[C@H](O[C@H](O[C@@H]4[C@H](O[C@H](O)[C@H](O)[C@H]4O)CO)[C@H](O)[C@H]3O)CO)O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](O[C@@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@@H](CO)O2)O)[C@H](O)[C@H]1O ZTHKPSBRWLGUIK-XORBCWOASA-N 0.000 description 1
- HKQOBOMRSSHSTC-DIBAFDJWSA-N (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol;[(2R,3R,4S,5R,6S)-4,5,6-triacetyloxy-3-[(2S,3R,4S,5R,6R)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl acetate;[( Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O.CC(=O)OC[C@H]1O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1O[C@H]1[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1.CCC(=O)OC[C@H]1O[C@@H](OC(=O)CC)[C@H](OC(=O)CC)[C@@H](OC(=O)CC)[C@@H]1O[C@H]1[C@H](OC(=O)CC)[C@@H](OC(=O)CC)[C@H](OC(=O)CC)[C@@H](COC(=O)CC)O1 HKQOBOMRSSHSTC-DIBAFDJWSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N (2Z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- SHGAZHPCJJPHSC-XFYACQKRSA-N (2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid Chemical compound OC(=O)/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-XFYACQKRSA-N 0.000 description 1
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3E)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 1
- RGPDIGOSVORSAK-STHHAXOLSA-N (4R,4aS,7aR,12bS)-4a,9-dihydroxy-3-prop-2-enyl-1,2,3,4,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one;chloride Chemical compound Cl.O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C RGPDIGOSVORSAK-STHHAXOLSA-N 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N (6R,7R)-3-[(carbamoyloxy)methyl]-7-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- WSPOMRSOLSGNFJ-VGOFMYFVSA-N (E)-chlorprothixene Chemical compound C1=C(Cl)C=C2C(=C/CCN(C)C)/C3=CC=CC=C3SC2=C1 WSPOMRSOLSGNFJ-VGOFMYFVSA-N 0.000 description 1
- 239000001124 (E)-prop-1-ene-1,2,3-tricarboxylic acid Substances 0.000 description 1
- SUBDBMMJDZJVOS-XMMPIXPASA-N (R)-omeprazole Chemical compound C([S@@](=O)C=1NC2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-XMMPIXPASA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical class C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N (±)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N 1,2,3-propanetrioltrinitrate Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- POTBKLVBOJZRNG-UHFFFAOYSA-N 1-hydroxy-2H-naphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)(O)CC=CC2=C1 POTBKLVBOJZRNG-UHFFFAOYSA-N 0.000 description 1
- LLSKXGRDUPMXLC-UHFFFAOYSA-N 1-phenylpiperidine Chemical class C1CCCCN1C1=CC=CC=C1 LLSKXGRDUPMXLC-UHFFFAOYSA-N 0.000 description 1
- CBQFBEBEBCHTBK-UHFFFAOYSA-N 1-phenylprop-2-ene-1-sulfonic acid Chemical compound OS(=O)(=O)C(C=C)C1=CC=CC=C1 CBQFBEBEBCHTBK-UHFFFAOYSA-N 0.000 description 1
- RPZANUYHRMRTTE-UHFFFAOYSA-N 2,3,4-trimethoxy-6-(methoxymethyl)-5-[3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane;1-[[3,4,5-tris(2-hydroxybutoxy)-6-[4,5,6-tris(2-hydroxybutoxy)-2-(2-hydroxybutoxymethyl)oxan-3-yl]oxyoxan-2-yl]methoxy]butan-2-ol Chemical compound COC1C(OC)C(OC)C(COC)OC1OC1C(OC)C(OC)C(OC)OC1COC.CCC(O)COC1C(OCC(O)CC)C(OCC(O)CC)C(COCC(O)CC)OC1OC1C(OCC(O)CC)C(OCC(O)CC)C(OCC(O)CC)OC1COCC(O)CC RPZANUYHRMRTTE-UHFFFAOYSA-N 0.000 description 1
- PRAMZQXXPOLCIY-UHFFFAOYSA-N 2-(2-methylprop-2-enoyloxy)ethanesulfonic acid Chemical compound CC(=C)C(=O)OCCS(O)(=O)=O PRAMZQXXPOLCIY-UHFFFAOYSA-N 0.000 description 1
- PADGNZFOVSZIKZ-UHFFFAOYSA-N 2-(chloromethyl)oxirane;hydrogen carbonate;prop-2-enylazanium Chemical compound NCC=C.OC(O)=O.ClCC1CO1 PADGNZFOVSZIKZ-UHFFFAOYSA-N 0.000 description 1
- MJIHNNLFOKEZEW-RUZDIDTESA-N 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzimidazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-RUZDIDTESA-N 0.000 description 1
- SZTBMYHIYNGYIA-UHFFFAOYSA-N 2-chloroacrylic acid Chemical compound OC(=O)C(Cl)=C SZTBMYHIYNGYIA-UHFFFAOYSA-N 0.000 description 1
- IJVRPNIWWODHHA-UHFFFAOYSA-N 2-cyanoprop-2-enoic acid Chemical compound OC(=O)C(=C)C#N IJVRPNIWWODHHA-UHFFFAOYSA-N 0.000 description 1
- WROUWQQRXUBECT-UHFFFAOYSA-N 2-ethylacrylic acid Chemical compound CCC(=C)C(O)=O WROUWQQRXUBECT-UHFFFAOYSA-N 0.000 description 1
- RVHOBHMAPRVOLO-UHFFFAOYSA-N 2-ethylbutanedioic acid Chemical compound CCC(C(O)=O)CC(O)=O RVHOBHMAPRVOLO-UHFFFAOYSA-N 0.000 description 1
- SHESIBIEPSTHMZ-UHFFFAOYSA-N 2-methoxy-3-methylphenol Chemical class COC1=C(C)C=CC=C1O SHESIBIEPSTHMZ-UHFFFAOYSA-N 0.000 description 1
- SZNYYWIUQFZLLT-UHFFFAOYSA-N 2-methyl-1-(2-methylpropoxy)propane Chemical compound CC(C)COCC(C)C SZNYYWIUQFZLLT-UHFFFAOYSA-N 0.000 description 1
- ZHCGVAXFRLLEFW-UHFFFAOYSA-N 2-methyl-3-(prop-2-enoylamino)propane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(C)CNC(=O)C=C ZHCGVAXFRLLEFW-UHFFFAOYSA-N 0.000 description 1
- AGBXYHCHUYARJY-UHFFFAOYSA-N 2-phenylethenesulfonic acid Chemical compound OS(=O)(=O)C=CC1=CC=CC=C1 AGBXYHCHUYARJY-UHFFFAOYSA-N 0.000 description 1
- ONPJWQSDZCGSQM-UHFFFAOYSA-N 2-phenylprop-2-enoic acid Chemical compound OC(=O)C(=C)C1=CC=CC=C1 ONPJWQSDZCGSQM-UHFFFAOYSA-N 0.000 description 1
- GQTFHSAAODFMHB-UHFFFAOYSA-N 2-prop-2-enoyloxyethanesulfonic acid Chemical compound OS(=O)(=O)CCOC(=O)C=C GQTFHSAAODFMHB-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- KISZTEOELCMZPY-UHFFFAOYSA-N 3,3-Diphenylpropylamine Chemical class C=1C=CC=CC=1C(CCN)C1=CC=CC=C1 KISZTEOELCMZPY-UHFFFAOYSA-N 0.000 description 1
- KFNGWPXYNSJXOP-UHFFFAOYSA-N 3-(2-methylprop-2-enoyloxy)propane-1-sulfonic acid Chemical compound CC(=C)C(=O)OCCCS(O)(=O)=O KFNGWPXYNSJXOP-UHFFFAOYSA-N 0.000 description 1
- BUJCVBRLTBAYCW-UHFFFAOYSA-N 3-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-2-(2-methoxyphenoxy)propan-1-one Chemical compound COC1=CC=CC=C1OC(CO)C(=O)C1=CC=C(O)C(OC)=C1 BUJCVBRLTBAYCW-UHFFFAOYSA-N 0.000 description 1
- OCISOSJGBCQHHN-UHFFFAOYSA-N 3-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=CC(O)=CC2=C1 OCISOSJGBCQHHN-UHFFFAOYSA-N 0.000 description 1
- AYKYXWQEBUNJCN-UHFFFAOYSA-N 3-methylfuran-2,5-dione Chemical compound CC1=CC(=O)OC1=O AYKYXWQEBUNJCN-UHFFFAOYSA-N 0.000 description 1
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 1
- NYUTUWAFOUJLKI-UHFFFAOYSA-N 3-prop-2-enoyloxypropane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCOC(=O)C=C NYUTUWAFOUJLKI-UHFFFAOYSA-N 0.000 description 1
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-Aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- GXLIFJYFGMHYDY-ZZXKWVIFSA-N 4-chlorocinnamic acid Chemical compound OC(=O)\C=C\C1=CC=C(Cl)C=C1 GXLIFJYFGMHYDY-ZZXKWVIFSA-N 0.000 description 1
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- PQUGCKBLVKJMNT-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-(trifluoromethyl)pyrazole Chemical compound C1=CC(OC)=CC=C1N1C(C=2C=CC(Cl)=CC=2)=CC(C(F)(F)F)=N1 PQUGCKBLVKJMNT-UHFFFAOYSA-N 0.000 description 1
- GKFPPCXIBHQRQT-UHFFFAOYSA-N 6-(2-carboxy-4,5-dihydroxy-6-methoxyoxan-3-yl)oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(OC)C(C(O)=O)O1 GKFPPCXIBHQRQT-UHFFFAOYSA-N 0.000 description 1
- WHJKCPTVEYZNOG-UHFFFAOYSA-N 6-(hydroxymethyl)-5-methoxy-2-[4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane-3,4-diol Chemical compound COCC1OC(OC)C(OC)C(OC)C1OC1C(O)C(O)C(OC)C(CO)O1 WHJKCPTVEYZNOG-UHFFFAOYSA-N 0.000 description 1
- JLVNEHKORQFVQJ-PYIJOLGTSA-N 6β-Naltrexol Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@H]3O)CN2CC1CC1 JLVNEHKORQFVQJ-PYIJOLGTSA-N 0.000 description 1
- 229940022659 Acetaminophen Drugs 0.000 description 1
- 229940091181 Aconitic Acid Drugs 0.000 description 1
- GTZCVFVGUGFEME-UHFFFAOYSA-N Aconitic acid Chemical compound OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 description 1
- 240000002290 Acorus calamus Species 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Adhd patch Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- 229940023808 Albuterol Drugs 0.000 description 1
- 229940062527 Alendronate Drugs 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- WNMJYKCGWZFFKR-UHFFFAOYSA-N Alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- KHOITXIGCFIULA-UHFFFAOYSA-N Alophen Chemical compound C1=CC(OC(=O)C)=CC=C1C(C=1N=CC=CC=1)C1=CC=C(OC(C)=O)C=C1 KHOITXIGCFIULA-UHFFFAOYSA-N 0.000 description 1
- OUJTZYPIHDYQMC-LJQANCHMSA-N Ambrisentan Chemical compound O([C@@H](C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C(O)=O)C1=NC(C)=CC(C)=N1 OUJTZYPIHDYQMC-LJQANCHMSA-N 0.000 description 1
- UIERETOOQGIECD-ARJAWSKDSA-N Angelic acid Chemical compound C\C=C(\C)C(O)=O UIERETOOQGIECD-ARJAWSKDSA-N 0.000 description 1
- XTEGVFVZDVNBPF-UHFFFAOYSA-N Armstrong's acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 1
- 241000758794 Asarum Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- VHGCDTVCOLNTBX-QGZVFWFLSA-N Atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 229960002507 Benperidol Drugs 0.000 description 1
- FEBOTPHFXYHVPL-UHFFFAOYSA-N Benperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 FEBOTPHFXYHVPL-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940051805 Benzomorphan derivative analgesics Drugs 0.000 description 1
- MAFMQEKGGFWBAB-UHFFFAOYSA-N Benzonatate Chemical compound CCCCNC1=CC=C(C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC)C=C1 MAFMQEKGGFWBAB-UHFFFAOYSA-N 0.000 description 1
- 229960003789 Benzonatate Drugs 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N Boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 235000006463 Brassica alba Nutrition 0.000 description 1
- 244000140786 Brassica hirta Species 0.000 description 1
- 235000011371 Brassica hirta Nutrition 0.000 description 1
- 235000011291 Brassica nigra Nutrition 0.000 description 1
- 240000003038 Brassica nigra Species 0.000 description 1
- RKLNONIVDFXQRX-UHFFFAOYSA-N Bromperidol Chemical compound C1CC(O)(C=2C=CC(Br)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 RKLNONIVDFXQRX-UHFFFAOYSA-N 0.000 description 1
- ZDIGNSYAACHWNL-UHFFFAOYSA-N Brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 description 1
- VOVIALXJUBGFJZ-VXKMTNQYSA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-VXKMTNQYSA-N 0.000 description 1
- 229960004436 Budesonide Drugs 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N Bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229960001058 Bupropion Drugs 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 229960004205 CARBIDOPA Drugs 0.000 description 1
- 235000017399 Caesalpinia tinctoria Nutrition 0.000 description 1
- 235000011996 Calamus deerratus Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N Camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N Carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960001631 Carbomer Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229940113118 Carrageenan Drugs 0.000 description 1
- AHOUBRCZNHFOSL-YOEHRIQHSA-N Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- 229960001777 Castor Oil Drugs 0.000 description 1
- 229960001668 Cefuroxime Drugs 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 229960002327 Chloral Hydrate Drugs 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N Chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N Chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 Chlorpromazine Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N Cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N Ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
- 229940001468 Citrate Drugs 0.000 description 1
- 229940040387 Citrus Pectin Drugs 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- 241000581364 Clinitrachus argentatus Species 0.000 description 1
- GMRWGQCZJGVHKL-UHFFFAOYSA-N Colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 description 1
- 229920002911 Colestipol Polymers 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N Crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 1
- 240000009138 Curcuma zedoaria Species 0.000 description 1
- 240000005497 Cyamopsis tetragonoloba Species 0.000 description 1
- JURKNVYFZMSNLP-UHFFFAOYSA-N Cyclobenzaprine Chemical compound C1=CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 JURKNVYFZMSNLP-UHFFFAOYSA-N 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-α-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- 229960003850 Dabigatran Drugs 0.000 description 1
- HXGBXQDTNZMWGS-RUZDIDTESA-N Darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- MJIHNNLFOKEZEW-UHFFFAOYSA-N Dexlansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
- DUGOZIWVEXMGBE-CHWSQXEVSA-N Dexmethylphenidate Chemical compound C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 DUGOZIWVEXMGBE-CHWSQXEVSA-N 0.000 description 1
- 239000004641 Diallyl-phthalate Substances 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N Dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
- XJQPQKLURWNAAH-UHFFFAOYSA-N Dihydrocapsaicin Chemical compound COC1=CC(CNC(=O)CCCCCCC(C)C)=CC=C1O XJQPQKLURWNAAH-UHFFFAOYSA-N 0.000 description 1
- RBOXVHNMENFORY-DNJOTXNNSA-N Dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N Diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229940051806 Diphenylpropylamine derivative analgesics Drugs 0.000 description 1
- 229940079896 Disodium Hydrogen Citrate Drugs 0.000 description 1
- UVTNFZQICZKOEM-UHFFFAOYSA-N Disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- 229940018602 Docusate Drugs 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N Doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 229960001389 Doxazosin Drugs 0.000 description 1
- JWJOTENAMICLJG-QWBYCMEYSA-N Dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 description 1
- 229940033643 Dutasteride / tamsulosin Drugs 0.000 description 1
- 101700045840 ECT Proteins 0.000 description 1
- AUVVAXYIELKVAI-CKBKHPSWSA-N Emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
- 229960002061 Ergocalciferol Drugs 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N Ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- 229960004943 Ergotamine Drugs 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N Esomeprazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N Ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- XLYMOEINVGRTEX-ARJAWSKDSA-N Ethyl hydrogen fumarate Chemical compound CCOC(=O)\C=C/C(O)=O XLYMOEINVGRTEX-ARJAWSKDSA-N 0.000 description 1
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229960004578 Ethylmorphine Drugs 0.000 description 1
- PYGWGZALEOIKDF-UHFFFAOYSA-N Etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- RZTAMFZIAATZDJ-UHFFFAOYSA-N Felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 description 1
- 229960003580 Felodipine Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N Fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 Fentanyl Drugs 0.000 description 1
- DCCSDBARQIPTGU-HSZRJFAPSA-N Fesoterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(CO)C=2)OC(=O)C(C)C)=CC=CC=C1 DCCSDBARQIPTGU-HSZRJFAPSA-N 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N Finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- NJMYODHXAKYRHW-DVZOWYKESA-N Flupentixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 description 1
- 229960002690 Fluphenazine Drugs 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine dihydrochloride Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- FJLGEFLZQAZZCD-MCBHFWOFSA-N Fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 1
- 229960004038 Fluvoxamine Drugs 0.000 description 1
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapen Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 1
- TZDUHAJSIBHXDL-UHFFFAOYSA-N Gabapentin enacarbil Chemical compound CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1 TZDUHAJSIBHXDL-UHFFFAOYSA-N 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 229960003980 Galantamine Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N Ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 Ganciclovir Drugs 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N Glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229960001381 Glipizide Drugs 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N Glycerol 3-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N Glyceryl behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N Glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- LEQAOMBKQFMDFZ-UHFFFAOYSA-N Glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 1
- 229940015043 Glyoxal Drugs 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- 229960002146 Guaifenesin Drugs 0.000 description 1
- INJOMKTZOLKMBF-UHFFFAOYSA-N Guanfacine Chemical compound NC(=N)NC(=O)CC1=C(Cl)C=CC=C1Cl INJOMKTZOLKMBF-UHFFFAOYSA-N 0.000 description 1
- 229960002048 Guanfacine Drugs 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 229920002456 HOTAIR Polymers 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N Haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- MLJGZARGNROKAC-VQHVLOKHSA-N Homocapsaicin Chemical compound CCC(C)\C=C\CCCCC(=O)NCC1=CC=C(O)C(OC)=C1 MLJGZARGNROKAC-VQHVLOKHSA-N 0.000 description 1
- 241000282619 Hylobates lar Species 0.000 description 1
- RKUNBYITZUJHSG-FXUDXRNXSA-N Hyoscyamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 description 1
- 229940015872 Ibandronate Drugs 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N Indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 229960000905 Indomethacin Drugs 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L Iron(II) sulfate Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229940045996 Isethionic Acid Drugs 0.000 description 1
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 1
- 229960002479 Isosorbide Drugs 0.000 description 1
- 229960005280 Isotretinoin Drugs 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N Itaconic acid Chemical compound OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 229940039371 Karaya Gum Drugs 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 229960000448 Lactic acid Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N Lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 230000035832 Lag time Effects 0.000 description 1
- 230000035648 Lag-time Effects 0.000 description 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N Lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- VRQVVMDWGGWHTJ-CQSZACIVSA-N Levomepromazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N Lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- WGFOBBZOWHGYQH-MXHNKVEKSA-N Lubiprostone Chemical compound O1[C@](C(F)(F)CCCC)(O)CC[C@@H]2[C@@H](CCCCCCC(O)=O)C(=O)C[C@H]21 WGFOBBZOWHGYQH-MXHNKVEKSA-N 0.000 description 1
- 229960000345 Lubiprostone Drugs 0.000 description 1
- 229940014456 MYCOPHENOLATE Drugs 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N Maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N Mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- DKMFBWQBDIGMHM-UHFFFAOYSA-N Melperone Chemical compound C1CC(C)CCN1CCCC(=O)C1=CC=C(F)C=C1 DKMFBWQBDIGMHM-UHFFFAOYSA-N 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N Memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- HNEGQIOMVPPMNR-NSCUHMNNSA-N Mesaconic acid Chemical compound OC(=O)C(/C)=C/C(O)=O HNEGQIOMVPPMNR-NSCUHMNNSA-N 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N Mesalazine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 229960003105 Metformin Drugs 0.000 description 1
- QXLPXWSKPNOQLE-UHFFFAOYSA-N Methylpentynol Chemical compound CCC(C)(O)C#C QXLPXWSKPNOQLE-UHFFFAOYSA-N 0.000 description 1
- 229960001344 Methylphenidate Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N Metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960000282 Metronidazole Drugs 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229960004023 Minocycline Drugs 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N Minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M Monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 description 1
- INAXVFBXDYWQFN-XHSDSOJGSA-N Morphinan Chemical class C1C2=CC=CC=C2[C@]23CCCC[C@H]3[C@@H]1NCC2 INAXVFBXDYWQFN-XHSDSOJGSA-N 0.000 description 1
- 229960004715 Morphine Sulfate Drugs 0.000 description 1
- 229960000951 Mycophenolic Acid Drugs 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 240000006984 Myristica fragrans Species 0.000 description 1
- VPYJNCGUESNPMV-UHFFFAOYSA-N N,N-bis(prop-2-enyl)prop-2-en-1-amine Chemical compound C=CCN(CC=C)CC=C VPYJNCGUESNPMV-UHFFFAOYSA-N 0.000 description 1
- CNCOEDDPFOAUMB-UHFFFAOYSA-N N-Methylolacrylamide Chemical compound OCNC(=O)C=C CNCOEDDPFOAUMB-UHFFFAOYSA-N 0.000 description 1
- HMWHERQFMBEHNG-AQQQZIQISA-N Naloxol Chemical class C([C@@H](N(CC1)CC=C)[C@]2(O)CC[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 HMWHERQFMBEHNG-AQQQZIQISA-N 0.000 description 1
- 229960005250 Naloxone Hydrochloride Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- NQDJXKOVJZTUJA-UHFFFAOYSA-N Nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 1
- 229960000689 Nevirapine Drugs 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- 229960001783 Nicardipine Drugs 0.000 description 1
- HNDXBGYRMHRUFN-CIVUWBIHSA-N Nicomorphine Chemical compound O([C@H]1C=C[C@H]2[C@H]3CC=4C5=C(C(=CC=4)OC(=O)C=4C=NC=CC=4)O[C@@H]1[C@]52CCN3C)C(=O)C1=CC=CN=C1 HNDXBGYRMHRUFN-CIVUWBIHSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- 229960002715 Nicotine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N Nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 Nifedipine Drugs 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N Nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 229960000227 Nisoldipine Drugs 0.000 description 1
- 229940014995 Nitroglycerin Drugs 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- VQEONGKQWIFHMN-UHFFFAOYSA-N Nordihydrocapsaicin Chemical compound COC1=CC(CNC(=O)CCCCCC(C)C)=CC=C1O VQEONGKQWIFHMN-UHFFFAOYSA-N 0.000 description 1
- IGBQSYZIGKWVKR-UHFFFAOYSA-N OC(=C)C(=O)OCCCS(O)(=O)=O Chemical compound OC(=C)C(=O)OCCCS(O)(=O)=O IGBQSYZIGKWVKR-UHFFFAOYSA-N 0.000 description 1
- 229960002969 Oleic Acid Drugs 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 229940071621 Omeprazole / Sodium Bicarbonate Drugs 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- ZKLXUUYLEHCAMF-UUWFMWQGSA-N Oripavine Chemical class C([C@@H](N(CC1)C)C2=CC=C3OC)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ZKLXUUYLEHCAMF-UUWFMWQGSA-N 0.000 description 1
- 229940051808 Oripavine derivatives analgesics Drugs 0.000 description 1
- 229960005010 Orotic Acid Drugs 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N Orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 229960003941 Orphenadrine Drugs 0.000 description 1
- QVYRGXJJSLMXQH-UHFFFAOYSA-N Orphenadrine Chemical compound C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 QVYRGXJJSLMXQH-UHFFFAOYSA-N 0.000 description 1
- 229940116315 Oxalic Acid Drugs 0.000 description 1
- 229960003617 Oxycodone Hydrochloride Drugs 0.000 description 1
- 229940105606 Oxycontin Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229940098901 POLIFEPROSAN 20 Drugs 0.000 description 1
- 229940100467 POLYVINYL ACETATE PHTHALATE Drugs 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 229940045258 Pancrelipase Drugs 0.000 description 1
- 108010067035 Pancrelipase Proteins 0.000 description 1
- GRHYHJAAOJVRSZ-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2N=C3[CH]C(OC(F)F)=CC=C3N=2)=C1OC GRHYHJAAOJVRSZ-UHFFFAOYSA-N 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 229960001476 Pentoxifylline Drugs 0.000 description 1
- WEYVCQFUGFRXOM-UHFFFAOYSA-N Perazine Chemical compound C1CN(C)CCN1CCCN1C2=CC=CC=C2SC2=CC=CC=C21 WEYVCQFUGFRXOM-UHFFFAOYSA-N 0.000 description 1
- 229960002195 Perazine Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N Picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N Piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N Pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 241001499740 Plantago alpina Species 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 229950004403 Polifeprosan Drugs 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 229920001283 Polyalkylene terephthalate Polymers 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229950005134 Polycarbophil Drugs 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 229920000903 Polyhydroxyalkanoate Polymers 0.000 description 1
- 229920001228 Polyisocyanate Polymers 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M Potassium bicarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K Potassium citrate Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- FSVJFNAIGNNGKK-UHFFFAOYSA-N Praziquantel Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 description 1
- JWHAUXFOSRPERK-UHFFFAOYSA-N Propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 1
- ZBAFFZBKCMWUHM-UHFFFAOYSA-N Propiram Chemical compound C=1C=CC=NC=1N(C(=O)CC)C(C)CN1CCCCC1 ZBAFFZBKCMWUHM-UHFFFAOYSA-N 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N Proprasylyt Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- JTTAUPUMOLRVRA-UHFFFAOYSA-N Prothipendyl Chemical group C1=CN=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 JTTAUPUMOLRVRA-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N Pyroglutamic acid Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N Quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- SXTZYIWTRUTYCY-UHFFFAOYSA-N Rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2N=C3[CH]C=CC=C3N=2)=C1C SXTZYIWTRUTYCY-UHFFFAOYSA-N 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N Raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004622 Raloxifene Drugs 0.000 description 1
- 229940089617 Risedronate Drugs 0.000 description 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N Ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 229940116736 Romycin Drugs 0.000 description 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N Ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N Salbutamol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 206010041232 Sneezing Diseases 0.000 description 1
- 229940010747 Sodium Hyaluronate Drugs 0.000 description 1
- 229940005550 Sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M Sodium stearate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- FBOUYBDGKBSUES-VXKWHMMOSA-N Solifenacin Chemical compound C1([C@H]2C3=CC=CC=C3CCN2C(O[C@@H]2C3CCN(CC3)C2)=O)=CC=CC=C1 FBOUYBDGKBSUES-VXKWHMMOSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- 229960001940 Sulfasalazine Drugs 0.000 description 1
- 241000388430 Tara Species 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229960000278 Theophylline Drugs 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N Thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- SUJUHGSWHZTSEU-FYBSXPHGSA-N Tipranavir Chemical compound C([C@@]1(CCC)OC(=O)C([C@H](CC)C=2C=C(NS(=O)(=O)C=3N=CC(=CC=3)C(F)(F)F)C=CC=2)=C(O)C1)CC1=CC=CC=C1 SUJUHGSWHZTSEU-FYBSXPHGSA-N 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229960003991 Trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N Trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- URAYPUMNDPQOKB-UHFFFAOYSA-N Triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 1
- 229960002622 Triacetin Drugs 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N Undecylenic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- WPVFJKSGQUFQAP-GKAPJAKFSA-N Valcyte Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)[C@@H](N)C(C)C)C=N2 WPVFJKSGQUFQAP-GKAPJAKFSA-N 0.000 description 1
- NLVXSWCKKBEXTG-UHFFFAOYSA-N Vinylsulfonic acid Chemical compound OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 description 1
- 229940088594 Vitamin Drugs 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229940046009 Vitamin E Drugs 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 229960000237 Vorinostat Drugs 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N Vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 229920002310 Welan gum Polymers 0.000 description 1
- DJWUNCQRNNEAKC-UHFFFAOYSA-L Zinc acetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O DJWUNCQRNNEAKC-UHFFFAOYSA-L 0.000 description 1
- HDOZVRUNCMBHFH-UHFFFAOYSA-N Zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 description 1
- WFPIAZLQTJBIFN-DVZOWYKESA-N Zuclopenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 description 1
- 229960004141 Zuclopenthixol Drugs 0.000 description 1
- DQEFEBPAPFSJLV-WLTGXWPBSA-N [(2R,3R,4S,5R,6S)-4,5,6-tri(propanoyloxy)-3-[(2S,3R,4S,5R,6R)-3,4,5-tri(propanoyloxy)-6-(propanoyloxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl propanoate Chemical compound CCC(=O)OC[C@H]1O[C@@H](OC(=O)CC)[C@H](OC(=O)CC)[C@@H](OC(=O)CC)[C@@H]1O[C@H]1[C@H](OC(=O)CC)[C@@H](OC(=O)CC)[C@H](OC(=O)CC)[C@@H](COC(=O)CC)O1 DQEFEBPAPFSJLV-WLTGXWPBSA-N 0.000 description 1
- GYNAYXFRCBVFOE-XBZOGAIXSA-J [(2S,3R,4S,6S)-2-[(2R,3S,4R,5R,6S)-6-[(2S,3R,4R,5R)-3,4-dihydroxy-5-[(2R,3R,4R,5R,6R)-6-hydroxy-2-(hydroxymethyl)-4,5-disulfonatooxyoxan-3-yl]oxyoxan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-4-hydroxy-6-(sulfonatooxymethyl)oxan-3-yl] sulfate Chemical compound O([C@@H]1CO[C@H]([C@@H]([C@H]1O)O)O[C@@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)O[C@H]1[C@@H]([C@@H](O)C[C@@H](COS([O-])(=O)=O)O1)OS([O-])(=O)=O)CO)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](OS([O-])(=O)=O)[C@@H]1OS([O-])(=O)=O GYNAYXFRCBVFOE-XBZOGAIXSA-J 0.000 description 1
- YSSBPECAUUPTPX-UHFFFAOYSA-N [3-[2-[(dimethylamino)methyl]cyclohexen-1-yl]phenyl] 2-[4-(2-methylpropyl)phenyl]propanoate Chemical compound C1=CC(CC(C)C)=CC=C1C(C)C(=O)OC1=CC=CC(C=2CCCCC=2CN(C)C)=C1 YSSBPECAUUPTPX-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- UGZICOVULPINFH-UHFFFAOYSA-N acetic acid;butanoic acid Chemical compound CC(O)=O.CCCC(O)=O UGZICOVULPINFH-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 150000001253 acrylic acids Chemical class 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 230000001476 alcoholic Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229960004607 alfuzosin Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005263 alkylenediamine group Chemical group 0.000 description 1
- 239000001774 alpinia officinarum Substances 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 229960002414 ambrisentan Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229960002430 atomoxetine Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 238000011087 biopharmaceutical technology Methods 0.000 description 1
- QUDWYFHPNIMBFC-UHFFFAOYSA-N bis(prop-2-enyl) benzene-1,2-dicarboxylate Chemical compound C=CCOC(=O)C1=CC=CC=C1C(=O)OCC=C QUDWYFHPNIMBFC-UHFFFAOYSA-N 0.000 description 1
- 229960000503 bisacodyl Drugs 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N bondronat Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 229960004037 bromperidol Drugs 0.000 description 1
- 229960000725 brompheniramine Drugs 0.000 description 1
- SOGAXMICEFXMKE-UHFFFAOYSA-N butyl 2-methylprop-2-enoate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 1
- 229930003833 capsaicin Natural products 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- QTAOMKOIBXZKND-PPHPATTJSA-N carbidopa Chemical compound O.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 QTAOMKOIBXZKND-PPHPATTJSA-N 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- VDHAWDNDOKGFTD-MRXNPFEDSA-N cinacalcet Chemical compound N([C@H](C)C=1C2=CC=CC=C2C=CC=1)CCCC1=CC=CC(C(F)(F)F)=C1 VDHAWDNDOKGFTD-MRXNPFEDSA-N 0.000 description 1
- 229960003315 cinacalcet Drugs 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229940018557 citraconic acid Drugs 0.000 description 1
- 239000009194 citrus pectin Substances 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 229960002604 colestipol Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- LAAPRQODJPXAHC-AATRIKPKSA-N coniferyl benzoate Chemical compound C1=C(O)C(OC)=CC(\C=C\COC(=O)C=2C=CC=CC=2)=C1 LAAPRQODJPXAHC-AATRIKPKSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 description 1
- 229960003572 cyclobenzaprine Drugs 0.000 description 1
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 description 1
- 229940006976 dalfampridine Drugs 0.000 description 1
- 229960002677 darifenacin Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N ddIno Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- 230000002542 deteriorative Effects 0.000 description 1
- 229960003568 dexlansoprazole Drugs 0.000 description 1
- 229960001042 dexmethylphenidate Drugs 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 229960000920 dihydrocodeine Drugs 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 235000019262 disodium citrate Nutrition 0.000 description 1
- 239000002526 disodium citrate Substances 0.000 description 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
- 229960001066 disopyramide Drugs 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960004199 dutasteride Drugs 0.000 description 1
- 229960002694 emetine Drugs 0.000 description 1
- AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000002587 enol group Chemical group 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229960004770 esomeprazole Drugs 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 229960002049 etravirine Drugs 0.000 description 1
- 229960004979 fampridine Drugs 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 235000013924 ferrous gluconate Nutrition 0.000 description 1
- 229960001645 ferrous gluconate Drugs 0.000 description 1
- 229960001781 ferrous sulfate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 229960002978 fesoterodine Drugs 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 229960002419 flupentixol Drugs 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229940013688 formic acid Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 229960002359 gabapentin enacarbil Drugs 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 235000002780 gingerol Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 125000004383 glucosinolate group Chemical group 0.000 description 1
- XVOUMQNXTGKGMA-UHFFFAOYSA-N glutaconic acid Chemical compound OC(=O)CC=CC(O)=O XVOUMQNXTGKGMA-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium(0) Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 229940027318 hydroxyurea Drugs 0.000 description 1
- 229960003210 hyoscyamine Drugs 0.000 description 1
- 229930005342 hyoscyamine Natural products 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- HLBWMQJLOGMNBR-XRDLMGPZSA-N iron;(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoic acid;hydrate Chemical compound O.[Fe].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O HLBWMQJLOGMNBR-XRDLMGPZSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 229960001848 lamotrigine Drugs 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- 229960004615 levomepromazine Drugs 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 229960001861 melperone Drugs 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229940072739 mesalamine Drugs 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 229960000939 metoprolol succinate Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 235000018342 monosodium citrate Nutrition 0.000 description 1
- 239000002524 monosodium citrate Substances 0.000 description 1
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 230000000701 neuroleptic Effects 0.000 description 1
- 229960004300 nicomorphine Drugs 0.000 description 1
- 229930015196 nicotine Natural products 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000001702 nutmeg Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 229940051807 opiod analgesics Morphinan derivatives Drugs 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940051803 opioid analgesics Phenylpiperidine derivatives Drugs 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 229960005434 oxybutynin Drugs 0.000 description 1
- MUZQPDBAOYKNLO-RKXJKUSZSA-N oxycodone hydrochloride Chemical compound [H+].[Cl-].O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C MUZQPDBAOYKNLO-RKXJKUSZSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229960001057 paliperidone Drugs 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M palmitate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229960005019 pantoprazole Drugs 0.000 description 1
- 229960003294 papaveretum Drugs 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000036961 partial Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- DBSDMAPJGHBWAL-UHFFFAOYSA-N penta-1,4-dien-3-ylbenzene Chemical compound C=CC(C=C)C1=CC=CC=C1 DBSDMAPJGHBWAL-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 230000003285 pharmacodynamic Effects 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229940114148 picric acid Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940075559 piperine Drugs 0.000 description 1
- 235000019100 piperine Nutrition 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 229920001484 poly(alkylene) Polymers 0.000 description 1
- 229920001483 poly(ethyl methacrylate) polymer Polymers 0.000 description 1
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 1
- 239000005015 poly(hydroxybutyrate) Substances 0.000 description 1
- 229920000218 poly(hydroxyvalerate) Polymers 0.000 description 1
- 229920000212 poly(isobutyl acrylate) Polymers 0.000 description 1
- 229920000205 poly(isobutyl methacrylate) Polymers 0.000 description 1
- 229920000196 poly(lauryl methacrylate) Polymers 0.000 description 1
- 229920000184 poly(octadecyl acrylate) Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000129 polyhexylmethacrylate Polymers 0.000 description 1
- 239000005056 polyisocyanate Substances 0.000 description 1
- 229920000197 polyisopropyl acrylate Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920000182 polyphenyl methacrylate Polymers 0.000 description 1
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 1
- 229920001290 polyvinyl ester Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 238000002459 porosimetry Methods 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229940094025 potassium bicarbonate Drugs 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229960002957 praziquantel Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229960000203 propafenone Drugs 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 229960000957 prothipendyl Drugs 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- 229960004157 rabeprazole Drugs 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 230000000717 retained Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229960000759 risedronic acid Drugs 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229960001879 ropinirole Drugs 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 229960005441 sevelamer carbonate Drugs 0.000 description 1
- 238000005029 sieve analysis Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- MSXHSNHNTORCAW-UHFFFAOYSA-M sodium 3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].OC1OC(C([O-])=O)C(O)C(O)C1O MSXHSNHNTORCAW-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- MAKUBRYLFHZREJ-JWBQXVCJSA-M sodium;(2S,3S,4R,5R,6R)-3-[(2S,3R,5S,6R)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylate Chemical compound [Na+].CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@H](O)[C@H]1O MAKUBRYLFHZREJ-JWBQXVCJSA-M 0.000 description 1
- 239000011973 solid acid Substances 0.000 description 1
- 229960003855 solifenacin Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000000576 supplementary Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 101700082413 tant Proteins 0.000 description 1
- 235000010491 tara gum Nutrition 0.000 description 1
- 239000000213 tara gum Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960000838 tipranavir Drugs 0.000 description 1
- 229950000300 tocopherol succinate Drugs 0.000 description 1
- 229960004045 tolterodine Drugs 0.000 description 1
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940113165 trimethylolpropane Drugs 0.000 description 1
- 229950002929 trinitrophenol Drugs 0.000 description 1
- 239000011791 tripotassium citrate Substances 0.000 description 1
- 235000015870 tripotassium citrate Nutrition 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 229960002149 valganciclovir Drugs 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 235000001892 vitamin D2 Nutrition 0.000 description 1
- 239000011653 vitamin D2 Substances 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 235000019509 white turmeric Nutrition 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 235000013904 zinc acetate Nutrition 0.000 description 1
- 229960004496 zotepine Drugs 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N α-Ketoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Abstract
Provided is a pharmaceutical dosage form for oral administration having a breaking strength of at least 300 N and comprising (i) a pharmacologically active ingredient; (ii) an opioid antagonist and/or an aversive agent; (iii) a polyalkylene oxide having an average molecular weight of at least 200,000 g/mol; and (iv) comprising an anionic polymer; and/or having a storage stability at 40°C of at least 3 months. In a preferred embodiment the dosage form includes an anionic polymer, and the aversive agent is selected from (a) substances which irritate the nasal passages and/or pharynx, (b) viscosity-increasing agents and/or gelling agents; (c) emetics; (d) dyes; (e) bitter substances; and (f) surfactants. 0 g/mol; and (iv) comprising an anionic polymer; and/or having a storage stability at 40°C of at least 3 months. In a preferred embodiment the dosage form includes an anionic polymer, and the aversive agent is selected from (a) substances which irritate the nasal passages and/or pharynx, (b) viscosity-increasing agents and/or gelling agents; (c) emetics; (d) dyes; (e) bitter substances; and (f) surfactants.
Description
TAMPER-RESISTANT ORAL PHARMACEUTICAL DOSAGE FORM COMPRISING A PHARMACOLOGICALLY
ACTIVE INGREDIENT, AN OPIOID ANTAGONIST AND/OR VE AGENT, POLYALKYLENE
OXIDE AND ANIONIC POLYMER
The invention relates to a pharmaceutical dosage form for oral administration having a
breaking strength of at least 300 N and sing (i) a pharmacologically active ingredient,
preferably an opioid agonist; (ii) an opioid antagonist and/or an aversive agent; (iii) a
polyalkylene oxide having an average molecular weight of at least 200,000 g/mol; and (a)
comprising (iv) an c polymer; and/or (b) having a storage ity at 40°C of at least 3
months.
Tamper-resistant pharmaceutical dosage forms ning opioid agonists have been known
for many years. Some concepts of rendering pharmaceutical dosage forms tamper resistant
rely on the presence of opioid antagonists.
In some embodiments, the opioid agonist is ed in releasable form and the opioid
antagonist is sequestered and not released when the pharmaceutical dosage form is
stered in the prescribed manner, i.e. intact and orally. Only when the pharmaceutical
dosage form is tampered with, e.g. by mechanical disruption such as pulverization, the opioid
antagonist is ed from the pharmaceutical dosage form y evolving its
antagonizing effect and avoiding misuse of the opioid agonist.
In other embodiments, the opioid nist is released from the pharmaceutical dosage
form upon prescribed administration, e.g. oral administration, but due to its chemical nature,
pharmacokinetic properties, and pharmacodynamic ties, the antagonizing effect of the
opioid antagonist does not evolve. This can be achieved by employing opioid antagonists
that have no or only a very poor bioavailability when being administered by the prescribed
route, e.g. orally. Only when the pharmaceutical dosage form is tampered with, e.g. by liquid
extraction of the constituents and administration of the liquid extract by another route,
typically parenterally such as intravenously, the opioid antagonist has a sufficient
bioavailability so that it evolves its antagonizing effects and can avoid misuse of the opioid
agonist.
EP 1 492 506 discloses pharmaceutical dosage forms containing a combination of the opioid
agonist oxycodone and the opioid antagonist ne which are both embedded in a
lipophilic matrix of ethylcellulose. Pharmaceutical dosage forms of this type are currently
commercialized as Targin®. Abuse by intravenous administration can be prevented by the
opioid antagonist naloxone. However, the dosage form can be misused by oral
stration, as naloxone is not bioavailable upon oral administration. Further, misuse of
the dosage form cannot be prevented either. The breaking strength of the dosage forms is
far below 300 N.
US 5 866 164 relates to osmotic dosage forms sing an opioid analgesic, an opioid
antagonist and a high molecular weight poly(alkylene) or a poly(carboxymethylcellulose).
ses a tamper resistant dosage form comprising melt-extruded
particulates which are present as a discontinuous phase in a matrix. The particulates
comprise a drug, e.g. an opioid agonist and optionally an opioid antagonist.
Other concepts of rendering ceutical dosage forms tamper resistant rely on the
mechanical properties of the pharmaceutical dosage forms, particularly a ntially
increased breaking strength (resistance to ng). The major advantage of such
pharmaceutical dosage forms is that comminuting, particularly pulverization, by conventional
means, such as grinding in a mortar or fracturing by means of a , is impossible or at
least substantially impeded. Thus, by conventional means that are available to an abuser,
such pharmaceutical dosage forms cannot be converted into a form suitable for abuse, e.g. a
powder for nasal administration.
Such pharmaceutical dosage forms may additionally contain ve agents such as opioid
antagonists, which are y separated from the opioid agonist in the ceutical
dosage form, i.e. the pharmaceutical dosage forms comprise subunits containing opioid
agonist but no opioid antagonist, and other ts containing opioid antagonist but no
opioid agonist. When these pharmaceutical dosage forms are administered in a prescribed
manner, the opioid antagonist is not released from the ceutical dosage form and thus,
does not exhibit any effect. In this regard it can be referred to e.g., , WO
2005/016314, WC 2005/ 063214, , , ,
, WO 82097, , and .
EP 1 897 545 discloses pharmaceutical dosage forms containing the opioid agonist
oxycodone which is embedded in a hydrophilic matrix of polyethylene oxide. The dosage
forms are manufactured by compression of a powder mixture and subsequent heating.
Pharmaceutical dosage forms of this type are currently commercialized as Oxycontin®.
These dosage forms do not contain an opioid antagonist.
The known tamper ant pharmaceutical dosage forms are not satisfactory in every
respect. Manufacture is complicated and laborious, as different subunits need to be prepared
separately and are mixed with one another subsequently, before the final ceutical
dosage form is formed. Under these circumstances, content uniformity and other
requirements are difficult to y. Further, the release profile of the opioid agonist typically
differs from that of the opioid antagonist. This is because due to their different chemical
nature, the dispersibility of the opioid agonist in the other excipients of the pharmaceutical
dosage form typically differs from the dispersibility of the opioid antagonist. The same applies
to their solubility in the release medium. Furthermore, storage stability and shelf-life of the
dosage forms need to be improved.
There is a demand for tamper resistant pharmaceutical dosage forms that contain opioid
agonists and that have advantages compared to the pharmaceutical dosage forms of the
prior art.
This object has been achieved by the subject-matter of the patent claims.
A first aspect of the invention relates to a ceutical dosage form for oral administration
having a breaking strength of at least 300 N and comprising (i) a pharmacologically active
ingredient, preferably an opioid agonist; (ii) an opioid antagonist and/or an aversive agent;
(iii) a polyalkylene oxide having an average molecular weight of at least 200,000 g/mol; and
(a) comprising (iv) an anionic polymer and/or (b) having a storage stability at 40°C of at least
3 months.
It has been surprisingly found that the following objects concerning tamper resistance can be
achieved simultaneously by means of the ceutical dosage form containing an opioid
antagonist according to the invention:
when the ceutical dosage form is not tampered with and is administered by the
ibed oral route, the opioid agonist ps its desired pharmacological effect and
the opioid antagonist, which is simultaneously released, does not r this effect of
the opioid agonist, especially as the opioid antagonist is preferably very poorly or not
bioavailable when being administered . Nevertheless, in the intestine the orally
administered opioid antagonist can locally block the opioid ors thereby preventing
obstipation, an undesired adverse event othenNise occurring due to ion by the
opioid agonist;
when the pharmaceutical dosage form is tampered with by liquid extraction of the active
ingredients and is then stered by the escribed, parenteral route, the opioid
antagonist is fully bioavailable and thus, fully develops its nizing effect thereby
avoiding misuse of the opioid agonist;
when attempts are made to mechanically disrupt the pharmaceutical dosage form by
tional means typically available to an abuser, particularly in order to prepare a
powder that is suitable for e.g. nasal administration, such attempts fail due to the
increased breaking strength of the pharmaceutical dosage form.
Further, it has been surprisingly found that the following objects concerning tamper
resistance can be achieved simultaneously by means of the pharmaceutical dosage form
ning an aversive agent ing to the invention:
when the pharmaceutical dosage form is not tampered with and is administered by the
prescribed oral route, the cologically active ingredient, preferably opioid agonist
develops its desired pharmacological effect and the aversive agent does not counter this
effect of the pharmacologically active ingredient, preferably opioid agonist;
when the pharmaceutical dosage form is tampered with by liquid extraction of the active
ingredients and is then administered by the non-prescribed, parenteral route, the
aversive agent fully develops its aversive effect thereby avoiding misuse of the
pharmacologically active ingredient, preferably opioid agonist;
when attempts are made to mechanically disrupt the pharmaceutical dosage form by
conventional means typically available to an , particularly in order to prepare a
powder that is suitable for e.g. nasal administration, such attempts fail due to the
increased breaking strength of the pharmaceutical dosage form.
Still further it has been surprisingly found that the shelf-life and storage stability of the
pharmaceutical dosage forms can be improved by adding an anionic polymer. Furthermore, it
has been surprisingly found that a certain ty of polyalkylene oxide, on which the
increased breaking strength of the ceutical dosage form typically rely, can be
replaced by anionic r without deteriorating the mechanical properties and the tamper
resistance of the ceutical dosage form.
The dosage form according to the invention is suitable for avoiding or at least substantially
impeding oral abuse, dose dumping by means of alcoholic liquids and unintentional misuse.
The pharmaceutical dosage form according to the invention comprises
(i) a pharmacologically active ingredient;
(ii) an opioid antagonist and/or an aversive agent; and
(iii) a polyalkylene oxide having an e molecular weight of at least 200,000 g/mol.
Furthermore,
- the pharmaceutical dosage form either (a) additionally comprises (iv) an c polymer
(alternative 1); or
- the pharmaceutical dosage form (b) has a storage stability at 40°C of at least 3 months
(alternative 2); or
- the pharmaceutical dosage form (a) additionally comprises (iv) an c polymer as
well as (b) has a storage stability at 40°C of at least 3 months (alternative 3).
The ceutical dosage form according to the invention comprises an opioid antagonist
and/or an aversive agent, i.e. the pharmaceutical dosage form comprises an opioid
antagonist but no aversive agent, or an aversive agent but no opioid nist, or both an
opioid antagonist as well as an ve agent.
In a red embodiment, the pharmaceutical dosage form contains an opioid antagonist.
Under these circumstances, the pharmacologically active ingredient is preferably an opioid
agonist. When the pharmaceutical dosage form contains no opioid agonist, the
pharmaceutical dosage form preferably contains no opioid antagonist either.
Preferably, the pharmacologically active ingredient, preferably opioid agonist and the opioid
nist are homogeneously distributed over the pharmaceutical dosage form or, when the
pharmaceutical dosage form comprises a film coating, over the coated core of the
ceutical dosage form. Preferably, the pharmacologically active ingredient, preferably
opioid agonist and the opioid antagonist are intimately mixed with one another and
homogeneously dispersed in the polyalkylene oxide and the preferably present anionic
polymer, ably in molecular disperse form.
Preferably, the pharmacologically active ient, preferably opioid agonist is not locally
separated from the opioid antagonist. Preferably, the pharmaceutical dosage form contains
neither any subunits comprising pharmacologically active ingredient, preferably opioid
agonist but no opioid antagonist, nor any subunits comprising opioid antagonist but no
pharmacologically active ingredient, preferably opioid agonist.
WO 72395
Preferably, the pharmacologically active ingredient, preferably opioid agonist and the opioid
antagonist are embedded in a prolonged release matrix comprising the polyalkylene oxide
and the preferably present anionic polymer. Thus, the prolonged release matrix is preferably
a hydrophilic matrix. It has been surprisingly found that the release of the pharmacologically
active ingredient, preferably opioid agonist and the opioid antagonist from the prolonged
release matrix relies on a ed mechanism that is ted by erosion and diffusion of
the e medium into the matrix.
Preferably, the pharmacologically active ingredient, which is preferably an opioid t, the
opioid antagonist, the polyalkylene oxide and the preferably present c polymer are
intimately mixed with one another forming a homogeneous mixture.
Preferably, the release profile of the pharmacologically active ingredient, preferably opioid
agonist is matrix-retarded. Preferably, the pharmacologically active ingredient, preferably
opioid agonist is embedded in a matrix comprising the kylene oxide and the preferably
present anionic polymer, said matrix controlling the release of the pharmacologically active
ient, preferably opioid agonist from the pharmaceutical dosage form.
Physiologically acceptable materials which are known to the person skilled in the art may be
used as supplementary matrix als. Polymers, particularly preferably cellulose ethers
and/or ose esters are preferably used as hydrophilic matrix materials. Ethylcellulose,
hydroxypropylmethylcellulose, ypropylcellulose, hydroxymethylcellulose, hydroxyethyl-
cellulose, and/or the derivatives thereof, such as the salts thereof are very particularly
preferably used as matrix materials.
It has been surprisingly found that the release of both, the pharmacologically active
ingredient, preferably opioid agonist and the opioid antagonist, from the prolonged release
matrix is substantially ndent from the pH value of the release medium.
In a preferred embodiment, the pharmaceutical dosage form according to the invention is
d for administration once daily. In another preferred embodiment, the pharmaceutical
dosage form according to the invention is adapted for administration twice daily. In still
another preferred embodiment, the ceutical dosage form according to the invention is
adapted for administration thrice daily, four times daily, five times daily, six times daily, or
even more frequently.
For the purpose of the specification, "twice daily" means equal or nearly equal time intervals,
i.e., about every 12 hours, or different time intervals, e.g., 8 and 16 hours or 10 and 14 hours,
between the individual administrations.
For the purpose of the specification, "thrice daily" means equal or nearly equal time intervals,
i.e., about every 8 hours, or different time intervals, e.g., 6, 6 and 12 hours; or 7, 7 and 10
hours, between the individual administrations.
In a preferred embodiment, in accordance with Ph. Eur., the in vitro release profile of the
pharmacologically active ingredient, preferably opioid agonist essentially ponds to, Le.
is essentially identical to or at least ling with the in vitro release profile of the opioid
antagonist. For the purpose of the specification, "essentially corresponds" preferably means
that pharmacologically active ingredient, preferably opioid agonist and opioid antagonist are
released ing to same order kinetics, preferably both according to a prolonged e
profile; preferably, however, "essentially corresponds" does not ass ceutical
dosage forms where one of the pharmacologically active ient, preferably opioid agonist
and the opioid antagonist is released ately, and the other one is released in a
prolonged fashion.
It has been surprisingly found that an essentially identical or at least resembling in vitro
release profile of pharmacologically active ingredient, preferably opioid agonist and opioid
antagonist can be achieved, though the pharmaceutical dosage form contains a polyalkylene
oxide, preferably in combination with an anionic polymer, i.e. hydrophilic polymers.
Polyalkylene oxide is necessary in order to achieve the substantially increased breaking
strength of at least 300 N of the pharmaceutical dosage form. It is known that pharmaceutical
dosage forms containing ne as opioid agonist and naloxone as opioid antagonist
embedded in a hydrophilic matrix do not provide such an essentially identical or at least
resembling in vitro release profile of opioid agonist and opioid antagonist (cf. EP 1 492 506,
paragraph [0026]). Rather, these pharmaceutical dosage forms exhibit an in vitro release
profile of the opioid agonist that ntially differs from the in vitro release profile of the
opioid antagonist. As it is desirable to have an essentially identical or at least ling in
vitro release profile of both, the pharmacologically active ingredient, preferably opioid agonist
and the opioid antagonist, attempts have been made in the art to somehow approximate both
in vitro release profiles. This could be achieved on the basis of hydrophobic matrix als
which, however, are typically not suitable for manufacturing ceutical dosage forms
having an increased breaking strength of at least 300 N. It has now been singly found
that the same can be ed even on the basis of a hydrophilic matrix material, namely
WO 72395
polyalkylene oxide, preferably in combination with an anionic polymer, and optionally in
combination with additional matrix polymers.
Preferably, at every point in time the in vitro release profile of the pharmacologically active
ingredient, preferably opioid agonist does absolutely not deviate by more than 10%, more
preferably not more than 9%, still more preferably not more than 8%, yet more preferably not
more than 7%, even more preferably not more than 6%, most preferably not more than 5%
and in particular not more than 4% or not more than 3% from the in vitro release profile of the
opioid antagonist. For example, if the pharmaceutical dosage form releases under in vitro
conditions in accordance with Ph. Eur. 23% of the opioid antagonist 2 h after administration,
it ably releases 23i10% (= from 13% to 33%) of the cologically active
ingredient, preferably opioid agonist 2 h after administration.
Preferably, the pharmaceutical dosage form according to the invention causes an at least
partially delayed or prolonged release of pharmacologically active ingredient, preferably
opioid agonist and opioid antagonist.
Controlled or prolonged release is understood according to the invention preferably to mean
a release profile in which the pharmacologically active ingredient, preferably opioid agonist
and the opioid antagonist is released over a relatively long period with reduced intake
frequency with the purpose of extended therapeutic action of the pharmacologically active
ingredient, preferably opioid agonist. Preferably, the meaning of the term "prolonged release"
is in ance with the European ine on the nomenclature of the e profile of
pharmaceutical dosage forms (CHMP). This is achieved in ular with peroral
administration. The sion "at least partially delayed or ged release" covers
according to the invention any pharmaceutical dosage forms which ensure modified release
of the pharmacologically active ingredient, ably opioid ts and opioid antagonists
contained therein. The pharmaceutical dosage forms preferably comprise coated or uncoa—
ted pharmaceutical dosage forms, which are produced with ic ary substances, by
particular ses or by a combination of the two possible options in order purposefully to
change the release rate or location of release.
In the case of the pharmaceutical dosage forms according to the invention, the release
profile of a controlled release form may be modified e.g. as follows: extended release, repeat
action release, prolonged release and sustained release.
For the purpose of the ication "controlled release" preferably means a product in which
the release of active compound over time is controlled by the type and composition of the
formulation. For the purpose of the specification "extended release" preferably means a
product in which the release of active compound is delayed for a finite lag time, after which
e is unhindered. For the purpose of the specification "repeat action release" preferably
means a t in which a first portion of active compound is released lly, ed by
at least one further portion of active compound being released uently. For the
purpose of the specification "prolonged release" ably means a product in which the rate
of release of active compound from the formulation after administration has been reduced
over time, in order to maintain therapeutic activity, to reduce toxic effects, or for some other
therapeutic purpose. For the purpose of the specification "sustained release" preferably
means a way of formulating a medicine so that it is released into the body steadily, over a
long period of time, thus reducing the dosing frequency. For further details, reference may be
made, for example, to K.H. Bauer, Lehrbuch der zeutischen Technologie, 6th edition,
WVG Stuttgart, 1999; and Eur. Ph.
The pharmaceutical dosage form according to the invention may comprise one or more
pharmacologically active ingredients, preferably opioid agonists and opioid antagonists
and/or ve agents at least in part in a further controlled release form, wherein controlled
release may be achieved with the assistance of conventional materials and processes known
to the person skilled in the art, for example by embedding the substances in a lled
release matrix or by ng one or more controlled release coatings. Substance release
must, however, be controlled such that addition of delayed-release materials does not impair
the necessary breaking strength. Controlled release from the pharmaceutical dosage form
ing to the invention is preferably achieved by embedding the cologically active
ingredient, preferably opioid agonist and the opioid antagonist and/or aversive agent in a
matrix. Preferably, the polyalkylene oxide and the preferably present anionic polymer serve
as matrix material, optionally in combination with auxiliary substances also acting as matrix
materials. The auxiliary substances acting as matrix materials control e. Matrix
als may, for example, be hydrophilic, gel-forming materials, from which release
proceeds mainly by erosion and diffusion.
Preferably, the release profile is ntially matrix controlled, preferably by embedding the
pharmacologically active ient, preferably opioid agonist and the opioid antagonist
and/or aversive agent in a matrix comprising the polyalkylene oxide, the preferably present
anionic r and optionally, additional matrix materials. Preferably, the release profile is
not osmotically driven. Preferably, release kinetics is not zero order.
2012/072678
In preferred embodiments, in accordance with Ph. Eur., the in vitro release profile of the
pharmacologically active ingredient, preferably opioid agonist or the in vitro release profile of
the opioid antagonist and/or aversive agent, ably the in vitro release profile of both, the
pharmacologically active ient, preferably opioid agonist as well as the opioid antagonist
and/or aversive agent in each case complies with any same single one of the following
release profiles F11 to R50:
A: Fl1
_30:281h 3 _ 30:24 30:22 30:20 30:18 30:18 30:14 30+12 30+10
4 h 60+35_ 60i33 60i31 60i29 60i27 60i25 60i23 60i21 60i19 60i17
_70:286h 7 _ 70:25 70:23 70:21 70:19 70:17 70:15 70+13 70+11
h _ 85:13 85:12 85:11 85:10 85:9 85:8 85:7 85:8 85i5
10h >70 272 274 278 278 280 282 284 286 288
12h 288 290 298
A: Fl11
1h 4 _ 40:38 40:34 40:32 40:30 40:28 40:28 40:24 40+22 40+20
4 h 70+28_ 70i26 70i24 70i22 70i20 70i18 70i16 70i14 70i12 70i10
_80:186h 8 _ 80:18 80:15 80:14 80:13 80:12 80:11 80+10 80+9
h _ 90:8 90:8 90:7 90i7 90i6 90i6 90i5 90i5 90:4
10h >85 287 289 290 290 291 291 292 292 292
12h 292 292 293
A: F121
_20:181h 2 _ 20:14 20:13 20:12 20:11 20:10 20:9 20+8_ 20+7_
6 h 6 _ 80:38 80:34 80:32 80:30 80:28 80:28 80:24 80+22_ 80+20_
h _ 70:28 70:28 70:24 70:22 70:20 70:18 70:18 70:14 70i12
10h >70 272 274 278 278 280 282 284 286 288
290 293
13i10 13i8 13i6 18i17 18i14
>9 9
___—A,R41 R42 R43 R44 R45 R46 R49
92:6 92:6 92:5 92:6
Suitable in vitro conditions are known to the skilled artisan. In this regard it can be referred
to, e.g., the Ph. Eur. Preferably, the in vitro release profile is measured under the following
ions: 600 ml of blank FeSSlF (pH 5.0) at temperature of 37°C with sinker (type 1 or 2).
The rotation speed of the paddle is adjusted to 150/min. The pharmacologically active
ingredient is detected by means of a spectrometric measurement with a wavelength of 218
Preferably, the release profile of the pharmaceutical dosage form ing to the invention
is stable upon storage, preferably upon storage at elevated temperature, e.g. 40°C, for 3
months in sealed ners. In this regard "stable" means that when comparing the l
release profile with the release profile after storage, at any given time point the release
profiles deviate from one another absolutely by not more than 20%, more preferably not
more than 15%, still more preferably not more than 10%, yet more preferably not more than
7.5%, most preferably not more than 5.0% and in particular not more than 2.5%.
Preferably, the pharmaceutical dosage form according to the invention is monolithic.
Preferably, the ceutical dosage form is a monolithic mass. The ceutical
dosage form is preferably prepared by thermoforming, particularly preferably by hot-melt
extrusion. The melt extruded s are preferably cut into monoliths, which are then
preferably formed into tablets. In this regard, the term "tablets" is preferably not to be
understood as ceutical dosage forms being made by compression of powder or
granules (compress) but rather, as shaped extrudates.
In another red embodiment, the pharmaceutical dosage form according to the invention
ns an ve agent. Under these circumstances, the pharmacologically active
ingredient may be an opioid agonist or no opioid agonist.
Aversive agents are known to the skilled artisan and are to be understood as agents that
impart an unpleasant (aversive) ion to an abuser when the dosage form is tampered
with so that tampering for the e of abusing the pharmacologically active ingredient,
preferably opioid agonist that is contained in the dosage form can be avoided or at least
substantially impeded.
Preferred aversive agents include but are not limited to:
(a) substances which irritate the nasal passages and/or pharynx (in the following also
referred to as nent (a)"),
(b) viscosity-increasing agents and/or gelling agents (in the following also ed to as
"component (b)"),
(c) emetics (in the following also referred to as "component (c)"),
(d) dyes (in the following also referred to as "component (d)"),
(e) bitter substances (in the following also referred to as "component (e)"),
(f) surfactants (in the following also referred to as "component (f)"),
and combinations of any of the foregoing, including (a)+(b), (a)+(c), (a)+(d), (a)+(e), (a)+(f);
(b)+(C), (b)+(d), ), (b)+(f); (C)+(d), (C)+(e), (C)+(f); (d)+(e), (d)+(f); and ((a)+(f)-
Preferred ternary combinations include: (a)+(b)+(c), )+(d), (a)+(b)+(e), (a)+(b)+(f);
(a)+(C)+(d), (a)+(C)+(e), (a)+(C)+(f); (a)+(d +(e), (a)+(d)+(f); (a)+(e)+(f); )+(d),
(b)+(C)+(e), )+(f); (b)+(d)+(e), (b)+(d)+(f); (b)+(e)+(f); (C)+(d)+(e), (C)+(d)+(f); (C)+(e)+(f);
(d)+(e)+(f)-
In a preferred embodiment, the dosage form according to the invention comprises
component (a), Le. a substance which irritates the nasal passages and/or pharynx.
red components (a), i.e. substances which irritate the nasal passages and/or pharynx
according to the invention, are any substances which, when administered abusively via the
nasal passages and/or pharynx, bring about a physical reaction which is either so unpleasant
for the abuser that he/she does not wish to or cannot continue administration, for example
burning, or logically counteracts taking of the corresponding opioid, for example due to
increased nasal secretion or sneezing. These substances which conventionally irritate the
nasal passages and/or pharynx may also bring about a very unpleasant sensation or even
unbearable pain when administered parenterally, in particular intravenously, such that the
abuser does not wish to or cannot continue taking the substance. Particularly suitable
substances which irritate the nasal passages and/or pharynx are those which cause burning,
itching, urge to sneeze, increased formation of secretions or a ation of at least two of
these stimuli. Appropriate substances and the ties thereof which are conventionally to
be used are known per se to the person skilled in the art or may be identified by simple
inary testing.
Component (a) is preferably based on one or more constituents or one or more plant parts of
at least one hot substance drug. Corresponding hot substance drugs are known per se to the
person skilled in the art and are described, for e, in "Pharmazeutische Biologie -
Drogen und ihre lnhaltsstoffe" by Prof. Dr. Hildebert Wagner, 2nd. revised edition, Gustav
Fischer Verlag, Stuttgart-New York, 1982, pages 82 et seq.
The dosage form obtained by the s according to the invention may preferably contain
the plant parts of the ponding hot nce drugs in a quantity of 0.01 to 30 wt.%,
particularly preferably of 0.1 to 0.5 wt.%, in each case relative to the total weight of the
dosage form. If one or more tuents of corresponding hot substance drugs are used, the
quantity f in a dosage unit obtained by the process according to the invention
preferably amounts to 0.001 to 0.005 wt.%, relative to the total weight of the dosage form.
One or more constituents of at least one hot substance drug selected from the group
comprising Allii sativi bulbus (garlic), Asari rhizoma cum herba (Asarum root and leaves),
Calami rhizoma (calamus root), Capsici fructus (capsicum), Capsici fructus acer (cayenne
pepper), Curcumae longae a (turmeric root), Curcumae xanthorrhizae rhizoma
(Javanese turmeric root), Galangae rhizoma (galangal root), Myristicae semen (nutmeg),
Piperis nigri s (pepper), Sinapis albae semen (white mustard seed), Sinapis nigri
semen (black mustard seed), Zedoariae rhizoma (zedoary root) and Zingiberis rhizoma
r root), particularly preferably from the group comprising Capsici fructus (capsicum),
Capsici fructus acer (cayenne pepper) and Piperis nigri fructus (pepper) may preferably be
contained as component (a) to the dosage form according to the invention.
The constituents of the hot substance drugs preferably comprise o-methoxy(methyl)phenol
compounds, acid amide compounds, mustard oils or sulfide compounds or compounds
derived therefrom. Particularly preferably, at least one constituent of the hot substance drugs
is ed from the group consisting of myristicin, elemicin, enol, d-asarone, safrole,
gingerols, xanthorrhizol, capsaicinoids, preferably capsaicin, cin derivatives, such as
N-vanillyl-9E-octadecenamide, dihydrocapsaicin, nordihydrocapsaicin, homocapsaicin,
saicin and nomorcapsaicin, piperine, preferably trans-piperine, glucosinolates,
preferably based on non-volatile mustard oils, particularly preferably based on p-
hydroxybenzyl mustard oil, methylmercapto mustard oil or methylsulfonyl mustard oil, and
compounds derived from these constituents.
In another preferred embodiment, the dosage form according to the invention comprises
component (b), Le. a viscosity-increasing agent and/or gelling agent, which, with the
assistance of a necessary minimum ty of an aqueous liquid, forms a gel with the
t obtained from the dosage form, which gel is virtually impossible to administer safely,
and preferably remains visually distinguishable when introduced into a further ty of an
aqueous liquid.
For the purposes of the specification, visually distinguishable means that the opioidcontaining
gel formed with the assistance of a necessary m quantity of aqueous
, when uced, preferably with the assistance of a hypodermic needle, into a further
quantity of aqueous liquid at 37°C, remains substantially insoluble and cohesive and cannot
straightfonNardly be dispersed in such a manner that it can safely be administered
parenterally, in particular intravenously. The al preferably remains visually
distinguishable for at least one minute, preferably for at least 10 s.
The increased viscosity of the extract makes it more difficult or even impossible for it to be
passed through a needle or injected. If the gel remains visually distinguishable, this means
that the gel obtained on introduction into a further ty of s liquid, for example by
injection into blood, initially remains in the form of a largely cohesive thread, which, while it
may indeed be broken up ically into smaller nts, cannot be dispersed or even
dissolved in such a manner that it can safely be administered parenterally, in particular
intravenously. Intravenous administration of such a gel would therefore most probably result
in serious damage to the health of the abuser. In combination with at least one optionally
present component (a) or (c) to (d), this additionally leads to unpleasant burning, vomiting,
bad flavor and/or visual deterrence.
In order to verify whether a viscosity-increasing agent and/or gelling agent is suitable as
component (b) in the dosage form according to the invention, the opioid is preferably mixed
with the viscosity-increasing agent and suspended in 10 ml of water at a temperature of
°C. If this results in the formation of a gel which fulfils the above-stated conditions, the
corresponding viscosity-increasing agent is le for preventing or ng abuse of the
dosage forms according to the invention.
Preferred viscosity-increasing agents and/or gelling agents include but are not limited to the
group consisting of microcrystalline cellulose, e.g. with 11 wt.% carboxymethylcellulose
sodium (Avicel® RC 591), carboxymethylcellulose sodium (Blanose®, CMC-Na C300P®,
Frimulsion® BLC-5, Tylose® C300 P), locust bean flour (Cesagum® LA-200, Cesagum®
0, Cesagum® LN-1), pectins such as citrus pectin ectin® HM Medium Rapid
Set), apple pectin, pectin from lemon peel, waxy maize starch (C*Gel® , sodium
alginate (Frimulsion® ALG (E401)), guar flour (Frimulsion® BM, Polygum® 26/1-75), iota
carrageenan (Frimulsion® D021), karaya gum, gellan gum (Kelcogel® F, Kelcogel® ,
galactomannan (Meyprogat® 150), tara stone flour um® 43/1 ), propylene glycol alginate
(Protanal®-Ester SD-LB), sodium hyaluronate, tragacanth, tara gum (Vidogum® SP 200),
fermented polysaccharide welan gum ), xanthan gum (Xantural® 180). The names
stated in brackets are the trade names by which exemplified materials are known
commercially. In general, a quantity of 0.1 to 5 wt.% of the viscosity-increasing agent(s) is
sufficient to fulfill the above-stated conditions. Component (b), where provided, is preferably
present in the dosage form according to the invention in quantities of 2 5 mg per dosage
form.
In a particularly preferred embodiment, the viscosity-increasing agents and/or gelling agents
that are present as component (b) are those which, on extraction from the dosage form with
the ary minimum quantity of aqueous liquid, form a gel which es air bubbles.
The resultant gels are distinguished by a turbid appearance, which provides the potential
abuser with an additional optical warning and discourages him/her from administering the gel
erally.
It is also le to formulate the viscosity-increasing agent and the other constituents in the
dosage form according to the invention in a mutually spatially separated arrangement.
In still another preferred embodiment, the dosage form according to the invention ses
component (C), Le. an emetic, which is preferably present in a spatially separated
arrangement from the other components of the dosage form ing to the invention and,
when correctly used, is intended not to exert its effect in the body.
Suitable emetics for preventing abuse of an opioid are known to the person skilled in the art
and may be present in the dosage form according to the ion as such or in the form of
corresponding derivatives, in particular esters or ethers, or in each case in the form of
corresponding physiologically acceptable compounds, in particular in the form of the salts or
solvates thereof. An emetic based on one or more constituents of ipecacuanha (ipecac) root,
preferably based on the constituent e may preferably be considered in the dosage
form according to the invention, as are, for example, described in "Pharmazeutische Biologie
- Drogen und ihre lnhaltsstoffe" by Prof. Dr. Hildebert Wagner, 2nd, revised n, Gustav
Fischer Verlag, Stuttgart, New York, 1982.
The dosage form according to the invention may preferably comprise the emetic e as
ent (0), preferably in a ty of 2 10 mg, particularly preferably of 2 20 mg and
very particularly preferably in a quantity of 2 40 mg per dosage form. Apomorphine may
likewise preferably be used as an emetic for additional abuse-proofing, preferably in a
quantity of preferably 2 3 mg, particularly preferably of 2 5 mg and very particularly preferably
of 2 7 mg per administration unit.
In yet another red embodiment, the dosage form according to the invention comprises
component (d), Le. a dye, which brings about an intense coloration of a corresponding
aqueous solution, in particular when the attempt is made to extract the opioid for eral,
preferably enous administration, which coloration may act as a deterrent to the potential
abuser. le dyes and the quantities ed for the necessary deterrence may be found
e.g. in WC 03/015531.
In another preferred embodiment, the dosage form according to the invention comprises
component (e), Le. a bittering agent. The consequent impairment of the flavor of the dosage
form additionally prevents oral and/or nasal abuse. Suitable bitter substances and the
quantities effective for use may be found in US-2003/0064099 A1. Suitable bitter substances
are ably aromatic oils, preferably peppermint oil, eucalyptus oil, bitter almond oil,
menthol, fruit aroma substances, preferably aroma substances from lemons, oranges, limes,
grapefruit or mixtures thereof, and/or denatonium benzoate.
Preferred components (f), i.e. surfactants according to the ion, are nonionic, anionic or
ic surfactants. Ionic surfactants are particularly preferred. It has been found that
surfactants can function as aversive agents when the opioid agonist is abused via a mucosa,
e.g. nasally, resulting in an unpleasant burning sensation.
In a preferred embodiment, the surfactant has a HLB value (hydrophilic-lipophilic-balance)
within the range of 10:9, more preferably 10i6, most preferably 10i3; or 1519, more
preferably 1516, most preferably 1513; or 20i9, more preferably 20i6, most ably 20i3;
or 2519, more ably 2516, most preferably 25i3; or 30i9, more preferably 30i6, most
ably 30i3; or 3519, more preferably 3516, most preferably 3513.
A red example of an anionic tant is sodium laurylsulfate.
Particularly when ents (c) and/or (e) are contained in the dosage form according to
the invention, care should taken to ensure that they are formulated in such a manner or are
present in such a low dose that, when correctly administered, the dosage form is able to
bring about virtually no aversive effect which impairs the patient or the efficacy of the opioid.
If the dosage form according to the invention contains component (c) and/or (e), the dosage
must be selected such that, when correctly orally administered, no negative effect is caused.
If, however, the intended dosage of the dosage form is exceeded inadvertently, in particular
by children, or in the event of abuse, nausea or an inclination to vomit or a bad flavor are
produced. The particular quantity of component (c) and/or (e) which can still be tolerated by
the patient in the event of correct oral stration may be determined by the person
skilled in the art by simple preliminary testing.
If, however, irrespective of the fact that the dosage form according to the invention is virtually
impossible to pulverize, the dosage form containing the components (0) and/or (e) is
provided with protection, these components should ably be used at a dosage which is
sufficiently high that, when abusively administered, they bring about an intense aversive
effect on the abuser.
This is preferably achieved by spatial separation of at least the opioid from components (c)
and/or (e), wherein the opioid is present in at least one subunit (X) and components (c)
and/or (e) is/are present in at least one subunit (Y), and wherein, when the dosage form is
correctly administered, components (0) and (e) do not exert their effect on taking and/or in
the body and the remaining components of the formulation are identical.
If the dosage form according to the ion comprises at least 2 of ents (c) or (e),
these may each be present in the same or different subunits (Y). Preferably, when present,
all the components (c) and (e) are present in one and the same subunit (Y). For the purposes
of the specification, subunits are solid formulations, which in each case, apart from
conventional auxiliary substances known to the person skilled in the art, n the opioid,
preferably also at least the polyalkylene oxide and optionally at least one of the ally
present components (a) and/or (b) and/or (c) and/or (d) and/or (e) and/or (f).
One substantial advantage of the separated formulation of opioids from components (c) or
(e) in subunits (X) and (Y) of the dosage form according to the invention is that, when
correctly administered, components (c) and/or (e) are hardly released in the body or are
ed in such small quantities that they exert no effect which impairs the patient or
therapeutic success or, on passing through the patient's body, they are only liberated in
locations where they cannot be sufficiently absorbed to be effective. When the dosage form
is correctly administered, preferably hardly any of components (c) and/or (e) is released into
the patient's body or they go unnoticed by the patient. The person skilled in the art will
understand that the above-stated ions may vary as a function of the particular
components (c) and/or (e) and of the ation of the subunits or the dosage form. The
m formulation for the particular dosage form may be determined by simple inary
testing.
Should, contrary to expectations, the abuser succeed in comminuting such a dosage form
according to the invention, which comprises components (c) and/or (d) and/or (e) and/or (f) in
subunits (Y), for the purpose of abusing the opioid and obtain a powder which is extracted
with a suitable extracting agent, not only the opioid but also the particular component (c)
and/or (d) and/or (e) and/or (f) will be obtained in a form in which it cannot readily be
separated from the opioid, such that when the dosage form which has been tampered with is
administered, in particular by oral and/or parenteral administration, it will exert its effect on
taking and/or in the body combined with an additional aversive effect on the abuser
corresponding to component (c) and/or (e) or, when the attempt is made to t the ,
the coloration caused by component (d) will act as a deterrent and so prevent abuse of the
dosage form.
A dosage form in which the opioid is spatially separated from components (c) and/or (d),
ably by formulation in different subunits, may be formulated ing to the invention
in many different ways, wherein the corresponding subunits of such a dosage form may each
be present in any desired spatial arrangement relative to one r, ed that the
above-stated conditions for the release of components (0) and/or (d) are fulfilled.
The person skilled in the art will understand that component(s) (a) and/or (b) and/or (f) which
are optionally also present may preferably be formulated in the dosage form according to the
ion both in the particular subunits (X) and (Y) and in the form of independent subunits
corresponding to subunits (X) and (Y), ed that neither the abuse-proofing nor the
opioid release in the event of t stration is impaired by the nature of the
formulation.
In a preferred embodiment of the dosage form according to the invention, subunits (X) and
(Y) are present in multiparticulate form, wherein granules, spheroids, beads or pellets are
preferred and the same form, i.e. shape, is selected for both subunit (X) and subunit (Y),
such that it is not possible to separate ts (X) from (Y) by mechanical selection. The
multiparticulate forms are preferably of a size in the range from 0.1 to 3 mm, preferably of 0.5
to 2 mm. The subunits (X) and (Y) in multiparticulate form may also preferably be press-
moulded into a tablet, wherein the final formulation in each case proceeds in such a manner
that the subunits (X) and (Y) are also retained in the resultant dosage form. The
multiparticulate subunits (X) and (Y) of identical shape should also not be visually
distinguishable from one another so that the abuser cannot te them from one another
by simple sorting. This may, for example, be achieved by the application of identical coatings
which, apart from this disguising function, may also incorporate further functions, such as, for
example, delayed e of one or more opioids or provision of a finish resistant to gastric
juices on the particular subunits.
In a further preferred embodiment of the present invention, subunits (X) and (Y) are in each
case arranged in layers relative to one another. The layered subunits (X) and (Y) are
preferably arranged for this purpose vertically or horizontally relative to one another in the
dosage form according to the invention, wherein in each case one or more layered subunits
(X) and one or more layered ts (Y) may be present in the dosage form, such that,
apart from the preferred layer sequences ) or (X)-(Y)-(X), any desired other layer
sequences may be considered, optionally in combination with layers containing components
(a) and/or (b).
r preferred dosage form according to the invention is one in which subunit (Y) forms a
core which is completely enclosed by t (X), wherein a separation layer (Z) may be
present between said layers. Such a structure is preferably also suitable for the above-stated
articulate forms, wherein both subunits (X) and (Y) and an optionally t
separation layer (Z), which should ably satisfy the ss requirement ing to
the invention, are then formulated in one and the same multiparticulate form using the
process according to the invention.
In a r preferred embodiment of the dosage form according to the invention, the subunit
(X) forms a core, which is enclosed by subunit (Y), wherein the latter comprises at least one
l which leads from the core to the surface of the dosage form.
The dosage form according to the ion may comprise, between one layer of the subunit
(X) and one layer of the subunit (Y), in each case one or more, preferably one, optionally
swellable separation layer (Z) which serves to separate subunit (X) spatially from (Y).
If the dosage form according to the invention comprises the layered subunits (X) and (Y) and
an ally present separation layer (Z) in an at least partially vertical or horizontal
arrangement, the dosage form preferably takes the form of a tablet, a coextrudate or a
laminate, which has been produced using the process according to the invention.
In one particularly preferred embodiment, the entirety of the free surface of subunit (Y) and
optionally at least part of the free surface of subunit(s) (X) and optionally at least part of the
free surface of the optionally present separation layer(s) (Z) may be coated with at least one
r layer (2') which prevents release of component (c) and/or (d) and/or (c) and/or (e)
and/or (f). The barrier layer (2') should preferably also fulfill the hardness conditions
according to the invention.
Another ularly preferred embodiment of the dosage form according to the ion
comprises a vertical or horizontal arrangement of the layers of subunits (X) and (Y) and at
least one push layer (p) arranged there between, and optionally a separation layer (Z), in
which dosage form the entirety of the free surface of the layer structure consisting of subunits
(X) and (Y), the push layer and the optionally present separation layer (Z) is provided with a
semipermeable coating (E), which is permeable to a release medium, i.e. conventionally a
physiological , but substantially impermeable to the opioid and to component (c) and/or
(e), and wherein this coating (E) comprises at least one opening for release of the opioid in
the area of subunit (X).
In a further red embodiment, the subunit (X) of the dosage form according to the
ion is in the form of a tablet, the edge face and optionally one of the two main faces of
which is covered with a barrier layer (2') containing component (c) and/or (e).
The person d in the art will understand that the auxiliary substances of the subunit(s) (X)
or (Y) and of the optionally present separation layer(s) (Z) and/or of the barrier layer(s) (2')
used in the production ing to the ion of the respective dosage form will vary as a
function of the arrangement f in the dosage form, the mode of administration and as a
function of the particular opioid of the optionally present components (a) and/or (b) and/or (d)
and of component (c) and/or (e). The materials which have the requisite properties are in
each case known per se to the person skilled in the art.
lf release of ent (c) and/or (e) from subunit (Y) of the dosage form according to the
invention is prevented with the assistance of a cover, preferably a barrier layer, the subunit
may consist of conventional materials known to the person skilled in the art, preferably
n the polyalkylene oxide and preferably be produced according to the ion.
If a corresponding barrier layer (2') is not provided to prevent e of component (c)
and/or (e), the materials of the subunits should be selected such that release of the ular
component (c) from subunit (Y) is virtually ruled out.
The materials which are stated below to be suitable for production of the barrier layer may
preferably be used for this purpose and should preferably contain the polyalkylene oxide for
fulfilling the hardness conditions.
Preferred materials are those which are selected from the group ting of alkylcelluloses,
hydroxyalkylcelluloses, glucans, scleroglucans, mannans, xanthans, copolymers of
poly[bis(p-carboxyphenoxy)propane : sebacic acid], preferably in a molar ratio of 20:80
(marketed under the name Polifeprosan 20®), carboxymethylcelluloses, cellulose ethers,
cellulose esters, nitrocelluloses, polymers based on (meth)acrylic acid and the esters thereof,
polyamides, polycarbonates, polyalkylenes, polyalkylene s, kylene oxides,
polyalkylene terephthalates, polyvinyl alcohols, polyvinyl ethers, polyvinyl esters,
halogenated polyvinyls, polyglycolides, loxanes and polyurethanes and the copolymers
thereof. Particularly suitable als may be selected from the group consisting of
methylcellulose, ethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose,
hydroxybutylmethylcellulose, cellulose acetate, cellulose propionate (of low, medium or high
molecular weight), cellulose acetate propionate, cellulose acetate butyrate, cellulose acetate
ate, carboxymethylcellulose, cellulose triacetate, sodium cellulose sulfate, polymethyl
rylate, polyethyl methacrylate, polybutyl rylate, polyisobutyl methacrylate,
polyhexyl methacrylate, polyisodecyl methacrylate, polylauryl methacrylate, polyphenyl
methacrylate, polymethyl acrylate, polyisopropyl acrylate, polyisobutyl acrylate, polyoctadecyl
acrylate, polyethylene, low density polyethylene, high density polyethylene, polypropylene,
polyethylene glycol, polyethylene oxide, polyethylene terephthalate, polyvinyl l,
polyvinyl isobutyl ether, polyvinyl acetate and polyvinyl chloride.
Particularly suitable copolymers may be selected from the group comprising copolymers of
butyl methacrylate and isobutyl rylate, copolymers of methyl vinyl ether and maleic
acid of high molecular weight, copolymers of methyl vinyl ether and maleic acid monoethyl
ester, copolymers of methyl vinyl ether and maleic anhydride and copolymers of vinyl alcohol
and vinyl acetate. Further materials which are ularly suitable for formulating the barrier
layer are starch-filled polycaprolactone, aliphatic teramides, aliphatic and aromatic
polyester urethanes, polyhydroxyalkanoates, in ular polyhydroxybutyrates, polyhydroxy-
valerates, casein, polylactides and copolylactides.
The above-stated materials may ally be d with further conventional ary
substances known to the person skilled in the art, preferably selected from the group
consisting of glyceryl monostearate, semi-synthetic triglyceride derivatives, semi-synthetic
glycerides, hydrogenated castor oil, glyceryl palmitostearate, glyceryl behenate, polyvinylpyrrolidone
, gelatine, ium stearate, stearic acid, sodium stearate, talcum, sodium
benzoate, boric acid and colloidal silica, fatty acids, substituted triglycerides, glycerides,
polyoxyalkylene glycols and the derivatives thereof.
If the dosage form according to the ion comprises a separation layer (2'), said layer,
like the uncovered subunit (Y), may ably consist of the above-stated materials
described for the barrier layer. The person skilled in the art will understand that release of the
opioid or of the aversive agent from the particular subunit may be controlled by the thickness
of the separation layer.
The pharmaceutical dosage form according to the invention comprises a polyalkylene oxide
having a weight average molecular weight Mw of at least 200,000 g/mol, preferably at least
500,000 g/mol, more preferably at least 750,000 g/mol, still more preferably at least
000 g/mol, yet more preferably at least 1,500,000 g/mol, most preferably at least
2,000,000 g/mol and in particular within the range of from 0 to 15,000,000 g/mol.
Preferably, the polyalkylene oxide is selected from the group consisting of thylene
oxide, polyethylene oxide and polypropylene oxide, the copolymers and mixtures thereof.
Polyalkylene oxide may comprise a single polyalkylene oxide having a ular average
molecular weight, or a mixture (blend) of different polymers, such as two, three, four or five
polymers, e.g., polymers of the same chemical nature but different e lar
weight, polymers of different chemical nature but same average molecular weight, or
polymers of different chemical nature as well as different molecular weight.
For the e of the specification, a polyalkylene glycol has a molecular weight of up to
,000 g/mol whereas a polyalkylene oxide has a molecular weight of more than 20,000
g/mol. In a preferred embodiment, the weight average over all molecular weights of all
polyalkylene oxides that are contained in the pharmaceutical dosage form is at least 200,000
g/mol. Thus, polyalkylene glycols, if any, are preferably not taken into consideration when
determining the weight average molecular weight of polyalkylene oxide.
Preferably, the content of the polyalkylene oxide is within the range of from 20 to 99 wt.-%,
more preferably 25 to 95 wt.-%, still more preferably 30 to 90 wt.-%, yet more preferably 30
to 85 wt.-%, most preferably 30 to 80 wt.-% and in particular 30 to 75 wt.-%, based on the
total weight of the ceutical dosage form.
In a preferred embodiment, the content of the polyalkylene oxide is at least 10 wt.-%, more
preferably at least 15 wt.-%, still more preferably at least 20 wt.-%, yet more preferably at
least 25 wt.-% and in particular at least 30 wt.-%, based on the total weight of the
pharmaceutical dosage form.
In a preferred embodiment, the t of the kylene oxide is at most 80 wt.-%, more
preferably at most 75 wt.-%, still more preferably at most 70 wt.-%, yet more preferably at
most 65 wt.-% and in particular at most 60 wt.-%, based on the total weight of the
pharmaceutical dosage form. In another preferred embodiment, the content of the
polyalkylene oxide is at most 55 wt.-%, more preferably at most 50 wt.-%, still more
preferably at most 48 wt.-%, yet more preferably at most 45 wt.-% and in particular at most
42 wt.-%, based on the total weight of the ceutical dosage form.
In a preferred embodiment, the overall t of polyalkylene oxide is within the range of
25i20 wt.-%, more preferably 25i15 wt.-%, most preferably 25i10 wt.-%, and in particular
25i5 wt.-%. In another preferred embodiment, the overall content of polyalkylene oxide is
within the range of 35:20 wt.-%, more preferably 35i15 wt.-%, most preferably 35i10 wt.-%,
and in particular 3515 wt.-%. In a preferred embodiment, the overall content of kylene
oxide is within the range of 40i20 wt.-%, more preferably 40i15 wt.-%, most preferably
40i10 wt.-%, and in particular 40i5 wt.-%. In still another preferred embodiment, the overall
content of polyalkylene oxide is within the range of 45:20 wt.-%, more preferably 45i15 wt.-
%, most preferably 45i10 wt.-%, and in particular 45i5 wt.-%. In yet another red
embodiment, the overall content of polyalkylene oxide is within the range of 55:20 wt.-%,
more ably 55i15 wt.-%, most preferably 55i10 wt.-%, and in particular 55i5 wt.-%. In
a r preferred embodiment, the overall content of polyalkylene oxide is within the range
of 65i20 wt.-%, more preferably 65i15 wt.-%, most preferably 65i10 wt.-%, and in particular
65i5 wt.-%. In still a further a preferred embodiment, the overall content of polyalkylene
oxide is within the range of 75i20 wt.-%, more preferably 75i15 wt.-%, most preferably
75i10 wt.-%, and in particular 75i5 wt.-%. In a still further a red embodiment, the
overall content of polyalkylene oxide is within the range of 80i15 wt.-%, more ably
80i10 wt.-%, and most preferably 80i5 wt.-%.
Preferably, the relative weight ratio of the polyalkylene oxide to the opioid agonist is at least
0.5:1, more preferably at least 1:1, at least 2:1, at least 3:1, at least 4:1, at least 5:1, at least
6:1, at least 7:1, at least 8:1 or at least 9:1. In a preferred embodiment, the relative weight
ratio of the kylene oxide to the pharmacologically active ingredient, preferably opioid
agonist is within the range of from 5:1 to 1:1, more preferably 4:1 to 2:1.
In a preferred embodiment, the polyalkylene oxide is homogeneously distributed in the
pharmaceutical dosage form according to the invention. Preferably, the polyalkylene oxide
forms a matrix in which the cologically active ingredient, preferably opioid agonist and
the opioid antagonist and/or aversive agent are embedded.
In a ularly preferred embodiment, the cologically active ingredient, preferably
opioid agonist, the opioid antagonist and/or aversive agent, the polyalkylene oxide and the
preferably present anionic polymer are intimately homogeneously distributed in the
pharmaceutical dosage form so that the pharmaceutical dosage form does not n any
segments where either pharmacologically active ingredient, preferably opioid agonist is
present in the absence of opioid antagonist and/or aversive agent and/or polyalkylene oxide
and/or preferably present anionic polymer, or where opioid antagonist and/or aversive agent
is t in the absence of cologically active ingredient, preferably opioid agonist
and/or polyalkylene oxide and/or preferably present anionic polymer or where polyalkylene
oxide is present in the absence of pharmacologically active ingredient, preferably opioid
agonist and/or opioid antagonist and/or ve agent and/or preferably present anionic
polymer or where ably present anionic polymer is present in the absence of
pharmacologically active ingredient, preferably opioid agonist and/or opioid antagonist and/or
aversive agent and/or polyalkylene oxide.
When the ceutical dosage form is film coated, the polyalkylene oxide is preferably
homogeneously distributed in the core of the pharmaceutical dosage form, i.e. the film
coating ably does not contain polyalkylene oxide, but may e.g. contain hylene
glycol. Nonetheless, the film coating as such may of course contain one or more polymers,
which however, preferably differ from the polyalkylene oxide ned in the core.
The polyalkylene oxide may be combined with one or more additional polymers selected
from the group consisting of polyalkylene oxide, preferably polymethylene oxide, polyethy-
lene oxide, polypropylene oxide; polyethylene, polypropylene, polyvinyl chloride, polycarbo-
nate, polystyrene, nylpyrrolidone, poly(hydroxy fatty acids), such as for example poly(3-
hydroxybutyrate-cohydroxyvalerate) (Biopol®), poly(hydroxyvaleric acid); polycapro-
lactone, nyl alcohol, polyesteramide, polyethylene succinate, polylactone,
polyglycolide, polyurethane, polyamide, polylactide, polyacetal (for example polysaccharides
optionally with modified side chains), polylactide/glycolide, polylactone, ycolide,
polyorthoester, hydride, block polymers of polyethylene glycol and polybutylene
terephthalate (Polyactive®), polyanhydride (Polifeprosan), copolymers thereof, block-
copolymers thereof, and mixtures of at least two of the stated polymers, or other polymers
with the above characteristics.
Preferably, the molecular weight dispersity Mw/Mn of polyalkylene oxide is within the range
of 25:20, more preferably 2.5:1.5, still more preferably 2.5i1.0, yet more preferably
2.5i0.8, most preferably 2.5i0.6, and in ular 25:04.
The polyalkylene oxide preferably has a ity at 25°C of 30 to 17,600 cP, more
preferably 55 to 17,600 cP, still more preferably 600 to 17,600 cP and most preferably 4,500
to 17,600 cP, measured in a 5 wt.-% aqueous solution using a model RVF Brookfield
imeter (spindle no. 2 / rotational speed 2 rpm); of 400 to 4,000 cP, more preferably 400
to 800 cP or 2,000 to 4,000 cP, measured on a 2 wt.-% aqueous on using the stated
viscosimeter (spindle no. 1 or 3 / rotational speed 10 rpm); or of 1,650 to 10,000 cP, more
preferably 1,650 to 5,500 cP, 5,500 to 7,500 cP or 7,500 to 10,000 cP, measured on a 1 wt.-
% aqueous solution using the stated viscosimeter (spindle no. 2 / rotational speed 2 rpm).
The pharmaceutical dosage form according to the ion, in addition to the polyalkylene
oxide, preferably contains an anionic polymer, which is preferably able by
polymerization of a monomer composition comprising an ethylenically rated monomer
bearing an anionic onal group, in protonated form or a physiologically able salt
thereof. Preferably, the anionic functional group is selected from carboxyl groups, sulfonyl
groups, sulfate , and phosphoryl groups.
Preferably, the anionic polymer comprises at least 3 repeating units (e.g. monomeric units),
more preferably at least 10 repeating units, still more preferably at least 100 repeating units,
most preferably at least 1,000 repeating units and in ular at least 10,000 repeating
units.
The pharmacologically active ient, preferably opioid agonist and the opioid antagonist
and/or aversive agent are then ably embedded in a controlled-release matrix
comprising the polyalkylene oxide as well as said anionic polymer.
Preferably, the anionic r comprises anionic functional groups selected from carboxyl
groups, sulfonyl groups, sulfate groups, and phosphoryl groups.
Preferably, the anionic polymer is neither an anionic oligosaccharide nor an anionic
polysaccharide. Examples of anionic oligosaccharides and anionic ccharides are
derived from uronic acids. More preferably, the anionic polymer is not a cellulose-derivative,
such as carboxymethylcellulose sodium or croscarmellose sodium.
Preferably, the pharmaceutical dosage form does not contain any anionic oligosaccharide or
anionic polysaccharide. More preferably, the ceutical dosage form does not contain
carboxymethylcellulose sodium or croscarmellose sodium.
Preferably, the anionic polymer is derived from a r selected from acrylic acid, alkyl
acrylates and alkyl alkacrylates, or a combination f.
Preferably, the anionic polymer is obtainable by polymerization of a monomer composition
comprising an ethylenically unsaturated monomer selected from nically unsaturated
carboxylic acids, ethylenically unsaturated carboxylic acid anhydrides, ethylenically
unsaturated sulfonic acids and mixtures thereof.
Preferred nically unsaturated carboxylic acid and ethylenically unsaturated carboxylic
acid anhydride monomers include the acrylic acids typified by acrylic acid itself, methacrylic
acid, ethacrylic acid, alpha-chloracrylic acid, alpha-cyano acrylic acid, beta-methyl-acrylic
acid nic acid), alpha-phenyl acrylic acid, beta-acryloxy nic acid, sorbic acid,
alpha-chloro sorbic acid, angelic acid, cinnamic acid, p-chloro cinnamic acid, beta-styryl
acrylic acid (1-carboxyphenyl butadiene-1,3), itaconic acid, citraconic acid, mesaconic
acid, glutaconic acid, aconitic acid, maleic acid, fumaric acid, tricarboxy ethylene and maleic
acid anhydride.
Preferred ethylenically unsaturated sulfonic acids include aliphatic or ic vinyl ic
acids such as vinylsulfonic acid, allyl sulfonic acid, vinyltoluenesulfonic acid and styrene
sulfonic acid; acrylic and rylic sulfonic acid such as sulfoethyl acrylate, sulfoethyl
methacrylate, sulfopropyl acrylate, sulfopropyl methacrylate, 2—hydroxyacryloxy propyl
sulfonic acid, 2—hydroxymethacryloxy propyl sulfonic acid and 2-acrylamidomethyl
propane sulfonic acid.
Preferably, the monomer composition comprises acrylic acid, methacrylic acid, and/or 2-
midomethyl propane sulfonic acid. Acrylic acid is especially preferred.
The c polymer is obtainable by rization of such a monomer composition. This
does not necessarily require that it has been obtained from such a r composition
indeed. In other words, the anionic polymer is a polymer comprising at least one repeating
unit which results from polymerization of an ethylenically rated monomer bearing an
anionic functional group, in protonated form or a physiologically acceptable salt thereof.
The anionic polymer may be linear or branched or cross-linked.
ably, anionic polymer is hydrophilic, more preferably water-soluble or water-swellable.
The c polymer may be a homopolymer or a copolymer. When anionic polymer is a
homopolymer, it comprises a single type of repeating unit, i.e. is the polymerization product
of a monomer composition sing a single type of monomer. A lymer of acrylic
acid, i.e. polyacrylic acid, is particularly preferred. When anionic polymer is a mer, it
may comprise two, three or more different repeating units, i.e. may be the polymerization
product of a monomer composition comprising two, three or more different monomers.
In a red embodiment, the anionic polymer is a copolymer, comprising from about 50
mol-% to 99.999 mol-%, and more preferably from about 75 mol-% to 99.99 mol-% repeating
units bearing anionic functional groups, preferably acid groups, more preferably carboxylic
groups.
Preferably, the anionic polymer has an average equivalent weight of 76i50 g/mol, more
preferably of 76i30 g/mol, still more ably of 76i20 g/mol and most preferably of 76i10
g/mol per carboxyl group.
In a preferred ment, the monomer composition from which anionic polymer is
derivable, further comprises a cross-linking agent, i.e. in this embodiment the anionic
polymer is cross-linked.
Suitable cross-linking agents include
compounds having at least two rizable double bonds, e.g. ethylenically
unsaturated functional groups;
compounds having at least one polymerizable double bond, e.g. an ethylenically
unsaturated functional group, and at least one functional group that is capable of
reacting with another functional group of one or more of the repeating units of anionic
polymer;
compounds having at least two onal groups that are capable of reacting with other
functional groups of one or more of the repeating units of anionic r; and
polyvalent metal nds which can form ionic linkages, e.g. through the
anionic functional groups.
Cross-linking agents having at least two polymerizable double bonds, preferably allyl groups,
are particularly preferred.
Cross-linking agents having at least two polymerizable double bonds include (i) di- or
polyvinyl compounds such as divinylbenzene and divinyltoluene; (ii) di- or poly-esters of
unsaturated mono- or poly-carboxylic acids with s including, for example, di- or
triacrylic acid esters of polyols such as ethylene glycol, trimethylol propane, glycerine, or
polyoxyethylene glycols; (iii) bisacrylamides such as thylenebisacrylamide; (iv)
carbamyl esters that can be obtained by reacting polyisocyanates with hydroxyl group-
containing monomers; (v) di- or poly-allyl ethers of polyols; (vi) di- or poly-allyl esters of
polycarboxylic acids such as diallyl phthalate, diallyl adipate, and the like; (vii) esters of
rated mono- or arboxylic acids with mono-allyl esters of polyols such as acrylic
acid ester of polyethylene glycol monoallyl ether; and (viii) di- or triallyl amine.
In a preferred embodiment, divinyl glycol (1,5—hexadiene-3,4-diol) is contained as cross-
linking agent, whereas allyl or vinyl derivatives of polyols, such as allylsucrose or allyl
pentaerythritol, are less preferred. This embodiment is preferably realized by polyacrylic acid
polymers of polycarbophil type according to USP.
In another preferred embodiment, allyl derivatives of polyols, such as allylsucrose or allyl
pentaerythritol, are contained as linking agent, whereas divinyl glycol (1,5-hexadiene-
3,4-diol) is less preferred. This ment is ably realized by polyacrylic acid
polymers of carbomer type according to USP or Ph. Eur.
Cross-linking agents having at least one polymerizable double bond and at least one
functional group capable of reacting with other functional groups of one or more of the
repeating units of anionic r include N-methylol acrylamide, yl acrylate, and the
like.
Suitable cross-linking agents having at least two functional groups capable of reacting with
other onal groups of one or more of the repeating units of anionic polymer include
glyoxal; polyols such as ethylene glycol; polyamines such as alkylene diamines (e.g.,
ethylene diamine), polyalkylene polyamines, polyepoxides, di- or polyglycidyl ethers and the
like.
Suitable polyvalent metal cross-linking agents which can form ionic cross-linkages include
oxides, hydroxides and weak acid salts (e.g., carbonate, acetate and the like) of alkaline
earth metals (e.g., calcium magnesium) and zinc, including, for example, m oxide and
zinc diacetate.
Of all of these types of linking agents, the most red for use herein are diol
derivatives and polyol derivatives, more specifically those ed from the group consisting
of allyl sucrose, allyl pentaerythritol, divinyl glycol, l polyethylene glycol and
acrylic acid esters of diols.
In a preferred embodiment, the monomer composition from which the anionic polymer is
derivable comprises the cross-linking agent in an amount of at most 1.0 mol-%, more
preferably at most 0.1 mol-%, even more preferably at most about 0.01 mol-%, and most
preferably at most 0.005 mol-% based on all monomers forming anionic polymer.
In a preferred embodiment, anionic polymer is a homopolymer of acrylic acid, optionally
cross-linked, preferably with allyl sucrose or allyl pentaerythritol, in particular with allyl
pentaerythritol. In another preferred ment, anionic r is a mer of acrylic
acid and C10-C30-alkyl te, optionally cross-linked, preferably with allyl pentaerythritol. In
another red embodiment, anionic polymer is a so-called interpolymer, namely a
homopolymer of acrylic acid, optionally cross-linked, preferably with allyl sucrose or allyl
pentaerythritol; or a copolymer of acrylic acid and C10-C30-alkyl acrylate, ally cross-
linked, preferably with allyl pentaerythritol; which contain a block copolymer of polyethylene
glycol and a long chain alkyl acid, preferably a C8-C30-alkyl acid. Polymers of this type are
commercially available, e.g. under the trademark Carbopol®.
In another preferred embodiment, anionic polymer, preferably the pharmaceutical dosage
form according to the invention does not contain a block copolymer of polyethylene glycol
and an alkyl acid ester.
When anionic polymer is an interpolymer, it preferably has a viscosity in 1.0 wt.-% solution at
pH 7.5 within the range of from 47,000 to 77,000 mPa-s, more preferably 52,000 to 72,000
mPa-s, still more preferably 57,000 to 67,000 mPa-s.
Preferably, at least some of the anionic functional groups ned in the anionic polymer
are present in neutralized form, i.e. they are not present in their protonated forms, but are
salts with salt-forming cations instead. Suitable salt-forming cations include alkali metal,
ammonium, substituted ammonium and amines. More ably, at least some of the
anionic functional groups, e.g. carboxylate and/or ate anions, are salts of sodium or
potassium cations.
This percentage of neutralized anionic onal , based on the total amount of
anionic functional groups, is ed to herein as the "degree of lization." In a
preferred embodiment, the degree of neutralization is within the range of from 2.5i2.4%,
more preferably 2.5i2.0%, still more ably 2.5i1.5%, yet more preferably 2.5i1.0%, and
most preferably 2.5i0.5%. In another preferred embodiment, the degree of neutralization is
within the range of 35i30%, more preferably 35i25%, still more preferably 35i20%, yet
more preferably 35i15%, most preferably 35i10%, and in particular 35i5%. In yet another
preferred embodiment, the degree of neutralization is in the range of 65i30%, more
preferably 65i25%, still more preferably 65i20%, yet more preferably , most
preferably 65i10%, and in particular 65i5%.
The content of anionic polymer ranges preferably from 0.1 wt.-% to 95 wt.-%, more
preferably from 0.5 wt.-% to 80 wt.-%, still more preferably from 1.0 wt.-% to 50 wt.-%, and
most preferably from 1.5 wt.-% to 20% wt.-%, and in ular 2.0 wt.-% to 10 wt.-%, based
on the total weight of the pharmaceutical dosage form.
In a preferred embodiment, the content of anionic polymer s to 0.5 to 25 wt.-%, more
ably 1.0 to 20 wt.-%, still more preferably 2.0 to 22.5 wt.-%, yet more preferably 3.0 to
wt.-% and most preferably 4.0 to 17.5 wt.-% and in particular 5.0 to 15 wt.-%, based on
the total weight of the pharmaceutical dosage form.
In a preferred embodiment, the content of anionic r is within the range of 5.0i4.5 wt.-
%, more preferably 5.0:r4.0 wt.-%, still more preferably 5.0i3.5 wt.-%, yet more preferably
.0i3.0 wt.-%, most preferably 5.0:r2.5 wt.-%, and in particular .0 wt.-%, based on the
total weight of the pharmaceutical dosage form.
In another preferred embodiment, the t of anionic polymer is within the range of 10i9
wt.-%, more preferably 10i8 wt.-%, still more preferably 10i7 wt.-%, yet more preferably
10i6 wt.-%, most preferably 10i5 wt.-%, and in particular 10i2.5 wt.-%, based on the total
weight of the pharmaceutical dosage form.
In still another preferred embodiment, the content of anionic polymer is within the range of
15i14 wt.-%, more preferably 15:12.5 wt.-%, still more preferably 15i10 wt.-%, yet more
preferably 15i7.5 wt.-%, most preferably 15i5 wt.-%, and in particular 15i2.5 wt.-%, based
on the total weight of the pharmaceutical dosage form.
In yet another preferred embodiment, the content of anionic polymer is within the range of
20i15 wt.-%, more preferably 20i12.5 wt.-%, still more preferably 20i10 wt.-%, yet more
ably 20i7.5 wt.-%, most ably 20i5 wt.-%, and in particular 20i2.5 wt.-%, based
on the total weight of the pharmaceutical dosage form.
In a preferred embodiment, the anionic polymer has a weight average molecular weight (MW)
of at least 0 g/mol, preferably at least 200,000 g/mol or at least 400,000 g/mol, more
preferably in the range of about 500,000 g/mol to about 5,000,000 g/mol, and most
preferably in the range of about 600,000 g/mol to about 2,000,000 g/mol. Suitable methods
to determine MW are known to a person skilled in the art. For instance, MW can be determined
by gel permeation chromatography (GPC).
In a preferred ment, the pKA of the anionic polymer is 6.0:r2.0, more preferably
6.0:r1.5, even more preferably 6.0:r1.0, and most ably 6.0i0.5. In another preferred
embodiment, the pKA of the anionic polymer is 70:20, more preferably 5, even more
preferably 0, and most preferably 7.0i0.5. In still another preferred embodiment, the
pKA of the anionic polymer is 80:20, more preferably 8.0:r1.5, even more preferably
8.0:r1.0, and most preferably 8.0i0.5.
In a preferred embodiment, the pH (in 1 wt% aqueous dispersion) of the anionic polymer is
3.0:r3.0, more preferably 3.0:r2.0, even more preferably 3.0:r1.5, and most preferably
:10.
In another preferred embodiment, the pH (in 1 wt% aqueous dispersion) of the anionic
r is 6.0:r3.0, more preferably .0, even more preferably 6.0:r1.5, and most
preferably 6.0i1.0.
The anionic polymer preferably exhibits a viscosity of 2,000 to 100,000 mPa-s (cp), more
preferably 3,000 to 80,000 mPa-s, still more preferably 4,000 to 60,000 mPa-s, and in
particular 4,000 to 11,000 mPa-s measured by means of a Brookfield viscometer (RVF, 20
rpm) in a 0.5 wt.-% aqueous solution at pH 7.5 and 25°C.
In a preferred embodiment, the anionic polymer exhibits a viscosity of more than 10,000
mPa-s (cp), ably at least 11,000 mPa-s, more preferably at least 15,000 mPa-s, still
more preferably at least 20,000 mPa-s or at least 30,000 mPa-s, measured by means of a
Brookfield viscometer (RVF, 20 rpm) in a 0.5 wt.-% aqueous solution at pH 7.5 and 25°C.
In a preferred embodiment the relative weight ratio of said polyalkylene oxide and said
anionic r is within the range of from 20:1 to 1:20, more preferably 18:1 to 1:10, still
more ably 16:1 to 1:5, yet more preferably 14:1 to 1:1, most preferably 12:1 to 2:1 and
in particular 10:1 to 3:1. In a preferred embodiment, the relative weight ratio of said
polyalkylene oxide and said anionic polymer is within the range of from 15:1 to 7:1, more
preferably 10:1 to 6:1, most preferably 9:1 to 7:1.
Preferably, the content of said anionic r amounts to 0.5 to 25 wt.-%, more preferably
1.0 to 20 wt.-%, still more preferably 1.5 to 22.5 wt.-%, yet more preferably 2.0 to 20 wt.-%
and most preferably 2.5 to 17.5 wt.-% and in particular 3.0 to 15 wt.-%, based on the total
weight of the pharmaceutical dosage form.
In a preferred embodiment, the prolonged e matrix comprises an additional matrix
polymer.
In a preferred embodiment according to the invention, the polyalkylene oxide having a weight
average molecular weight of at least 200,000 g/mol and the anionic polymer are r
combined with at least one additional polymer, preferably but not arily having a weight
e molecular weight (Mw) of at least 200,000 g/mol, selected from the group consisting
of polyethylene, polypropylene, polyvinyl chloride, polycarbonate, polystyrene, poly(hydroxy
fatty acids), polycaprolactone, polyvinyl alcohol, polyesteramide, polyethylene succinate,
polylactone, ycolide, polyurethane, polyvinylpyrrolidone, polyamide, polylactide,
polylactide/glycolide, ctone, ycolide, polyorthoester, hydride, block
polymers of polyethylene glycol and polybutylene terephthalate, hydride, polyacetal,
cellulose esters, cellulose ethers and copolymers thereof. Cellulose esters and cellulose
ethers are particularly preferred, e.g. methylcellulose, ethylcellulose, hydroxymethylcellulose,
hydroxyethylcellulose, hydroxypropylcellulose ypropylmethylcellulose, carboxymethyl-
cellulose, and the like.
In a preferred embodiment, said additional polymer is neither a polyalkylene oxide nor a poly-
alkylene glycol nor an anionic polymer. Nonetheless, the pharmaceutical dosage form may
contain polyalkylene glycol, e.g. as plasticizer, but then, the ceutical dosage form
preferably is a quaternary mixture of polymers: polyalkylene oxide + anionic polymer +
onal polymer + plasticizer.
In a particularly preferred embodiment, said additional polymer is a hydrophilic cellulose ester
or cellulose ether, preferably hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose
(HPC) or hydroxyethylcellulose (HEC), preferably having an average viscosity (preferably
measured by capillary imetry or rotational viscosimetry) of 1,000 to 150,000 mPas,
more preferably 3,000 to 0. In a preferred embodiment, the average viscosity is within
the range of 110,000i50,000 mPas, more preferably 110,000i40,000 mPas, still more
preferably 110,000i30,000 mPas, most preferably 110,000i20,000 mPas, and in particular
100,000:10,000 mPas.
In a preferred embodiment the relative weight ratio of said polyalkylene oxide and said
additional polymer is within the range of from 20:1 to 1:20, more preferably 15:1 to 1:10, still
more preferably 10:1 to 1:5, yet more preferably 8:1 to 1:1, most preferably 8:1 to 2:1 and in
particular 8:1 to 3:1. In a preferred ment, the relative weight ratio of said polyalkylene
oxide and said additional polymer is within the range of from 10:1 to 2:1, more preferably 6:1
to 2:1, most preferably 3:1 to 2:1.
Preferably, the content of said additional polymer amounts to 0.5 to 25 wt.-%, more
preferably 1.0 to 20 wt.-%, still more preferably 2.0 to 22.5 wt.-%, yet more preferably 3.0 to
wt.-% and most preferably 4.0 to 17.5 wt.-% and in particular 5.0 to 15 wt.-%, based on
the total weight of the pharmaceutical dosage form.
In a preferred embodiment, the additional polymer is a cellulose ester or cellulose ether,
preferably HPMC, having a content within the range of 10i8 wt.-%, more preferably 10i6 wt.-
%, still more preferably 10i5 wt.-%, yet more preferably 1014 wt.-%, most ably 10i3
wt.-%, and in particular 10i2 wt.-%, based on the total weight of the pharmaceutical dosage
form.
In another red embodiment, the additional polymer is a cellulose ester or cellulose
ether, preferably HPMC, having a content within the range of 15:8 wt.-%, more ably
15i6 wt.-%, still more preferably 1515 wt.-%, yet more preferably 1514 wt.-%, most
preferably 15i3 wt.-%, and in particular 15i2 wt.-%, based on the total weight of the
pharmaceutical dosage form.
All polymers are preferably employed as powders. They can be soluble in water.
Preferably, the pharmaceutical dosage form according to the invention is thermoformed,
more preferably hot-melt extruded, although also other methods of forming may be
used in order to manufacture the pharmaceutical dosage form according to the invention,
such as press-molding at ed temperature or heating of tablets that were manufactured
by conventional compression in a first step and then heated above the softening temperature
of the polymer in the tablet in a second step to form hard tablets. In this regards,
thermoforming means forming or molding of a mass after the application of heat. In a
preferred ment, the pharmaceutical dosage form is thermoformed by hot-melt
extrusion.
In a preferred embodiment, the pharmaceutical dosage form according to the invention has
an overall density within the range of 1.19i0.30 g/cm3, more preferably .25 g/cm3, still
more ably 1.19i0.20 g/cm3, yet more preferably .15 g/cm3, most preferably
1.19i0.10 g/cm3, and in particular 1.19i0.05 g/cm3. Preferably, the l density of the
ceutical dosage form according to the invention is 1.17i0.02 g/cm3, 1.19i0.02 g/cm3
or 1.21i0.02 g/cm3. Methods for measuring the density of a ceutical dosage form are
known to a person skilled in the art. The overall y of a pharmaceutical dosage form can
for example be determined by means of the mercury porosimetry method or the helium
pycnometer method as described in Ph. Eur.
In a preferred embodiment, the pharmaceutical dosage form has a total weight within the
range of 100i75 mg, more preferably 100i50 mg, most preferably 100i25 mg. In another
preferred embodiment, the pharmaceutical dosage form has a total weight within the range of
200i75 mg, more preferably 200i50 mg, most ably 200i25 mg. In another red
embodiment, the pharmaceutical dosage form has a total weight within the range of 250i75
mg, more preferably 250i50 mg, most preferably 250i25 mg. In still r preferred
embodiment, the pharmaceutical dosage form has a total weight within the range of 300i75
mg, more preferably 300i50 mg, most preferably 300i25 mg. In yet another preferred
embodiment, the pharmaceutical dosage form has a total weight within the range of 400i75
mg, more preferably 400i50 mg, most preferably 400i25 mg.
In a preferred embodiment, the pharmaceutical dosage form has a total weight within the
range of 500i250 mg, more preferably 0 mg, most preferably 500i150 mg. In another
preferred embodiment, the pharmaceutical dosage form has a total weight within the range of
750i250 mg, more preferably 750i200 mg, most preferably 750i150 mg. In another
preferred embodiment, the pharmaceutical dosage form has a total weight within the range of
50 mg, more ably 1000i200 mg, most preferably 1000i150 mg. In still another
preferred embodiment, the pharmaceutical dosage form has a total weight within the range of
1250i250 mg, more preferably 1250i200 mg, most preferably 12501450 mg.
The pharmaceutical dosage form ing to the invention contains, as pharmacologically
active ingredient, preferably an opioid agonist, preferably oxymorphone or oxycodone. For
the purpose of the specification, the term pharmacologically active ingredient, preferably
opioid agonist also includes the free base and the physiologically acceptable salts thereof.
According to the ATC index, opioid agonists (opioids) are divided into natural opium
alkaloids, phenylpiperidine derivatives, diphenylpropylamine derivatives, benzomorphan
derivatives, oripavine derivatives, morphinan derivatives and others. Examples of natural
opium alkaloids are morphine, opium, hydromorphone, nicomorphine, one,
dihydrocodeine, diamorphine, papaveretum, and codeine. r opioid agonists are, for
example, ethylmorphine, odone, phone, and the physiologically acceptable
derivatives thereof or compounds, preferably the salts and solvates thereof, preferably the
hydrochlorides thereof, physiologically acceptable enantiomers, stereoisomers,
diastereomers and racemates and the physiologically acceptable derivatives thereof,
preferably , esters or amides.
Further preferred opioid agonists include N-(1-methyl-2—piperidinoethyl)-N-(2—pyridyl)propion-
amide, (1 R,2R)(3-dimethylaminoethyl-2—methyl-propyl)phenol (tapentadol), (1 R,2R,4S)—
2—(dimethylamino)methyl(p-fluorobenzyloxy)(m-methoxyphenyl)cyclohexanol, (1 R,2R)—
3-(2—dimethylaminomethyl-cyclohexyl)phenol, (1 S,28)(3-dimethylamino-1 -ethyl-2—methylpropyl
l, (2R,3R)—1-dimethylamino-3(3-methoxyphenyl)methyl-pentanol, (1R8,
3R8,6RS)—6-dimethylaminomethyl(3-methoxypheny|)-cyclohexane-1,3-diol, preferably as
te, 3-(2—dimethylaminomethylhydroxy-cyclohexyl)phenyl 2—(4-isobutyl-phenyl)—
nate, 3-(2—dimethylaminomethylhydroxy-cyclohexyl)phenyl ethoxy-naphthalenyl
)propionate, 3-(2—dimethylaminomethyl-cyclohexenyl)-phenyl 2—(4-isobutyl-phenyl)—
propionate, imethylaminomethyl-cyclohexenyl)-phenyl 2—(6-methoxy-naphthalen
y|)propionate, (RR-SS)—2—acetoxytrif|uoromethyl-benzoic acid 3-(2—dimethylaminomethyl
hydroxy-cyclohexyl)-phenyl ester, (RR-SS)—2—hydroxytrifluoromethyl-benzoic acid 3-(2—
dimethylaminomethylhydroxy-cyclohexyl)-phenyl ester, )—4-chloro-2—hydroxy-ben-
zoic acid 3-(2—dimethylaminomethylhydroxy-cyclohexyl)-phenyl ester, (RR-SS)-2—hydroxy-
4-methyl-benzoic acid 3-(2—dimethylaminomethylhydroxy-cyclohexyl)—phenyl ester, (RR-
SS)-2—hydroxymethoxy-benzoic acid 3-(2—dimethylaminomethylhydroxy-cyclohexyl)-
phenyl ester, (RR-SS)hydroxynitro-benzoic acid 3-(2—dimethylaminomethylhydroxy-
cyclohexyl)-phenyl ester, (RR-SS)—2’,4’-difluorohydroxy-biphenylcarboxylic acid 3-(2—
dimethylaminomethylhydroxy-cyclohexyl)-phenyl ester, 1,1-(3-dimethylaminophenyl-
pentamethylen)—6-fluor-1,3,4,9-tetrahydropyrano[3,4-b]indole, in particular its hemicitrate;
1,1-[3-dimethylamino(2—thienyl)pentamethylen]—1,3,4,9-tetrahydropyrano[3,4-b]indole, in
particular its citrate; and 1,1-[3-dimethy|amino(2—thienyl)pentamethy|en]-1,3,4,9-tetrahydropyrano
[3,4-b]fluoro-indole, in ular its hemicitrate, and ponding stereo-
isomeric compounds, in each case the corresponding derivatives thereof, physiologically
acceptable enantiomers, stereoisomers, diastereomers and tes and the physiolo-
gically acceptable derivatives thereof, e.g. ethers, esters or amides, and in each case the
physiologically acceptable compounds thereof, in particular the salts thereof and solvates,
e.g. hydrochlorides.
ularly preferred opioid agonists include oxymorphone, oxycodone, hydromorphone, and
the physiologically acceptable salts thereof. In a particularly preferred embodiment, the
opioid agonist is oxycodone or a physiologically able salt thereof.
WO 72395
In another preferred ment, the pharmacologically active ingredient is selected from
the group consisting of acetaminophen, albuterol, alendronate, alfuzosin, a|prazo|am,
ambrisentan, amoxicillin, amphetamine salts, aspirin, atomoxetine, benzonatate,bisacodyl,
an, brompheniramine, budesonide, bupropion, carbamazepine, cefuroxime, chloral
hydrate, cinacalcet, ciprofloxacin, ciprofloxicin, clarithromycin, ine, colestipol,
cyclobenzaprine, cyclophosphamide, dabigatran, dalfampridine, darifenacin, dasatinib,
dexlansoprazole, dexmethylphenidate, diclofenac, didanosine, diltiazem, disopyramide,
divalproex, docusate, zil, doxazosin, cline, tine, dutasteride,
dutasteride/tamsulosin, ergocalciferol, ergotamine, erythromycin, razole, etravirine,
everolismus, felodipine, fentanyl, ferrous gluconate, ferrous sulfate, fesoterodine, finasteride,
tine, fluvastatin, fluvoxamine, gabapentin enacarbil, gabapentin, galantamine,
ganciclovir, glipizide, guaifenesin, guanfacine, hydromorphone, hydroxyurea, hyoscyamine,
ibandronate, ibuprofen, imatinib,indinavir, indomethacin, isosorbide, isotretinoin, isradipine,
lamotrigine, lansoprazole, lenadilomide, racetam, pa/carbidopa, lithium,
lovastatin, lubiprostone, memantine, mesalamine, metformin, methylphenidate, metoprolol
succinate, metronidazole, minocycline, morphine sulfate, morphine, mycophenolate,
naproxen, en/esomeprazole, nevirapine, nicardipine, nicotine, nicotinic acid,
nifedipine, nilotinib, nisoldipine, nitroglycerin, omeprazole, omeprazole/sodium bicarbonate,
orphenadrine e, oxybutynin, oxycodone, pabcreaslipase, paliperidone, pancrelipase,
pantoprazole, paroxetine, pazopanib, pentoxifylline, piroxicam, potassium bicarbonate,
potassium chloride, potassium citrate, potassium, praziquantel, propafenone, propanolol,
pyridosigmine, quetiapine, rabeprazole, raloxifene, zine, risedronate, ritonavir,
ropinirole, sevelamer carbonate, mer, sirolismus, solifenacin, sulfasalazine,
osin, tapentadol, romycin, temozolomide, theophylline, tipranavir, tolterodine,
topiramate, tramadol, trazodone, valganciclovir, venlafaxine, mil, vorinostat,
zileutonzolpidem, and the physiologically acceptable salts thereof.
The content of the pharmacologically active ingredient, preferably opioid agonist in the
pharmaceutical dosage form is not limited.
Preferably, the content of the pharmacologically active ingredient, preferably opioid agonist is
within the range of from 0.01 to 80 wt.-%, more preferably 0.1 to 50 wt.-%, still more
ably 1 to 25 wt.-%, based on the total weight of the pharmaceutical dosage form. In a
preferred embodiment, the content of pharmacologically active ingredient, preferably opioid
agonist is within the range of from 7i6 wt.-%, more ably 7i5 wt.-%, still more preferably
514 wt.-%, 714 wt.-% or 914 wt.-%, most preferably 513 wt.-%, 7i3 wt.-% or 9i3 wt.-%, and
in particular 5i2 wt.-%, 7i2 wt.-% or 9i2 wt.-%, based on the total weight of the
pharmaceutical dosage form. In another preferred embodiment, the content of
pharmacologically active ingredient, preferably opioid agonist is within the range of from
11i10 wt.-%, more preferably 11i9 wt.-%, still more preferably 9i6 wt.-%, 11i6 wt.-%, 13i6
wt.-% or 15i6 wt.-%, most ably 1114 wt.-%, 13i4 wt.-% or 15i4 wt.-%, and in
particular 11i2 wt.-%, 13i2 wt.-% or 15i2 wt.-%, based on the total weight of the
pharmaceutical dosage form. In a further preferred embodiment, the content of
pharmacologically active ingredient, preferably opioid agonist is within the range of from 20i6
wt.-%, more preferably 20i5 wt.-%, still more preferably 2014 wt.-%, most preferably 20i3
wt.-%, and in particular 20i2 wt.-%, based on the total weight of the pharmaceutical dosage
form.
Preferably, the total amount of the pharmacologically active ingredient, preferably opioid
agonist that is ned in the pharmaceutical dosage form is within the range of from 0.01
to 200 mg, more preferably 0.1 to 190 mg, still more preferably 1.0 to 180 mg, yet more
preferably 1.5 to 160 mg, most preferably 2.0 to 100 mg and in particular 2.5 to 80 mg.
In a preferred embodiment, the pharmacologically active ingredient, preferably opioid agonist
is contained in the pharmaceutical dosage form in an amount of 7.5:r5 mg, 10i5 mg, 20i5
mg, 30i5 mg, 40i5 mg, 50i5 mg, 60i5 mg, 70i5 mg, 80i5 mg, 90i5 mg, 100i5 mg, 110i5
mg, 120i5 mg, 130i5, 140i5 mg, 150i5 mg, or 160i5 mg. In another preferred
embodiment, the pharmacologically active ient, preferably opioid agonist is contained
in the pharmaceutical dosage form in an amount of 552.5 mg, 5 mg, 10:2.5 mg,
15i2.5 mg, 20i2.5 mg, 25i2.5 mg, 30i2.5 mg, 35i2.5 mg, 40i2.5 mg, 45i2.5 mg, 50i2.5
mg, 55i2.5 mg, 60i2.5 mg, 65i2.5 mg, 70i2.5 mg, 75i2.5 mg, 80i2.5 mg, 85:2.5 mg,
90i2.5 mg, 95i2.5 mg, 100i2.5 mg, 105i2.5 mg, 110i2.5 mg, 115i2.5 mg, 120i2.5 mg,
125i2.5 mg, 130i2.5 mg, 135i2.5 mg, 5 mg, 145i2.5 mg, 5 mg, 155i2.5 mg,
or 160i2.5 mg.
In a preferred embodiment, opioid agonist is oxymorphone, preferably its HCI salt, and the
pharmaceutical dosage form is adapted for administration twice daily. In this embodiment,
opioid t is ably contained in the pharmaceutical dosage form in an amount of
from 5 to 60 mg. In r particularly preferred embodiment, the opioid agonist is
oxymorphone, preferably its HCI salt, and the pharmaceutical dosage form is adapted for
administration once daily. In this embodiment, opioid agonist is preferably contained in the
pharmaceutical dosage form in an amount of from 10 to 100 mg.
In another preferred embodiment, opioid agonist is oxycodone, preferably its HCI salt, and
the pharmaceutical dosage form is adapted for administration twice daily. In this embodi-
ment, opioid agonist is preferably contained in the ceutical dosage form in an amount
of from 5 to 80 mg, ably 5 mg, 10 mg, 20 mg or 40 mg. In another particularly preferred
ment, the opioid agonist is oxycodone, preferably its HCI salt, and the ceutical
dosage form is adapted for administration once daily. In this embodiment, opioid agonist is
preferably contained in the ceutical dosage form in an amount of from 10 to 320 mg.
In still another particularly preferred embodiment, opioid agonist is hydromorphone,
ably its HCI, and the pharmaceutical dosage form is adapted for stration twice
daily. In this embodiment, opioid agonist is preferably contained in the pharmaceutical
dosage form in an amount of from 2 to 52 mg. In another particularly red embodiment,
opioid agonist is hydromorphone, preferably its HCI salt, and the pharmaceutical dosage
form is adapted for administration once daily. In this embodiment, opioid agonist is preferably
contained in the pharmaceutical dosage form in an amount of from 4 to 104 mg.
The ceutical dosage form according to the invention is characterized by excellent
storage stability. Preferably, the pharmaceutical dosage form according to the invention has
a storage stability at 40°C for at least 3 months, more preferably at least 4 months, still more
preferably at least 5 months, yet more preferably at least 6 months, even more preferably at
least 7 months, most preferably at least 8 months, and in particular at least 9 months.
Storage stability is preferably determined in accordance with the EMEA Guideline
CPMP/lCH/2736/99-ICH Q1A (R2), preferably in the n valid for 2012, and/or the
pharmaceutical dosage form according to the invention preferably fulfills the impurity limits
given by the API aphs Ph. Eur. (7th edition, 2011) after 3 months of storage at 40°C
and 75% RH.
Preferably, after storage for 4 weeks at 40°C and 75% rel. humidity, the content of
pharmacologically active ingredient, preferably opioid agonist and opioid antagonist and/or
aversive agent in each case amounts to at least 90%, more preferably at least 91%, still
more preferably at least 92%, yet more preferably at least 93%, most preferably at least 94%
and in particular at least 95%, of its original content before storage. Suitable methods for
measuring the content of the cologically active ingredient, preferably opioid agonist
and opioid antagonist and/or ve agent in the pharmaceutical dosage form are known to
the skilled artisan. In this regard it is referred to the Eur. Ph. or the USP, ally to
reversed phase HPLC analysis. Preferably, the pharmaceutical dosage form is stored in
closed, preferably sealed containers, most preferably being equipped with an oxygen
scavenger, in particular with an oxygen scavenger that is effective even at low relative
humidity.
In a preferred embodiment, after oral administration of the pharmaceutical dosage form
ing to the invention, in vivo the average peak plasma level (Cmax) of the
pharmacologically active ingredient, preferably opioid agonist is on average reached after tmax
3.0i2.5 h, more preferably after tmax 3.0i2.0 h, still more ably after tmax 3.0i1.5 h, most
preferably after tmax 3.0i1.0 h and in particular after tmax 3.0:rO.5 h. In a preferred
embodiment, after oral administration of the pharmaceutical dosage form ing to the
invention, in vivo the average peak plasma level (Cmax) of the pharmacologically active
ingredient, preferably opioid agonist is on e reached after tmax 4.0i2.5 h, more
ably after tmax 4.0i2.0 h, still more preferably after tmax 4.0i1.5 h, most preferably after
tmax 4.0i1.0 h and in particular after tmax 4.0:rO.5 h. In another preferred ment, after
oral administration of the pharmaceutical dosage form according to the invention, in vivo the
average peak plasma level (Cmax) of the pharmacologically active ingredient, preferably
opioid agonist is on average d after tmax 5.0i2.5 h, more preferably after tmax 5.0i2.0 h,
still more preferably after tmax 5.0i1.5 h, most preferably after tmax 5.0i1.0 h and in particular
after tmax 5.0:rO.5 h. In still another preferred embodiment, after oral administration of the
pharmaceutical dosage form according to the invention, in vivo the average peak plasma
level (Cmax) of the pharmacologically active ingredient, preferably opioid agonist is on
average reached after tmax 6.0i2.5 h, more preferably after tmax 6.0i2.0 h, still more
preferably after tmax 6.0i1.5 h, most preferably after tmax 0 h and in particular after tmax
6.0:05 h.
In a preferred embodiment, the average value for t1/2 of the pharmacologically active
ingredient, preferably opioid agonist after oral administration of the pharmaceutical dosage
form according to the invention in vivo is 3.0i2.5 h, more preferably 3.0i2.0 h, still more
preferably 3.0i1.5 h, most preferably 0 h, and in particular 3.0:rO.5 h. In a preferred
ment, the average value for t1/2 of the cologically active ient, ably
opioid agonist after oral administration of the pharmaceutical dosage form according to the
ion in vivo is 4.0i2.5 h, more preferably 4.0i2.0 h, still more preferably 4.0i1.5 h, most
preferably 4.0i1.0 h, and in particular 4.0:rO.5 h. In another preferred embodiment, the
average value for t1/2 of the pharmacologically active ingredient, preferably opioid agonist
after oral administration of the pharmaceutical dosage form according to the invention in vivo
is preferably 5.0i2.5 h, more preferably 5.0i2.0 h, still more preferably 5.0i1.5 h, most
preferably 5.0i1.0 h, and in particular 5.0:rO.5 h. In still another preferred embodiment, the
average value for t1/2 of the pharmacologically active ingredient, ably opioid agonist
after oral administration of the pharmaceutical dosage form according to the invention in vivo
is ably 6.0i2.5 h, more preferably 6.0i2.0 h, still more ably 6.0:r1.5 h, most
preferably 6.0:r1.0 h, and in ular 6.0i0.5 h.
Preferably, Cmax of the pharmacologically active ingredient, preferably opioid agonist does not
exceed 0.01 ng/ml, or 0.05 ng/ml, or 0.1 ng/ml, or 0.5 ng/ml, or 1.0 ng/ml, or 2.5 ng/ml, or 5
ng/ml, or 10 ng/ml, or 20 ng/ml, or 30 ng/ml, or 40 ng/ml, or 50 ng/ml, or 75 ng/ml, or 100
ng/ml, or 150 ng/ml, or 200 ng/ml, or 250 ng/ml, or 300 ng/ml, or 350 ng/ml, or 400 ng/ml, or
450 ng/ml, or 500 ng/ml, or 750 ng/ml, or 1000 ng/ml.
In a preferred embodiment, the opioid antagonist is selected from the group consisting of
naltrexone, naloxone and its ues such as naltrexol, naltrexamine and naloxol
derivatives, nalmefene, cyclazacine, levallorphan, nalmefene, , nalmexone, nalorphine,
naluphine, pharmaceutically acceptable salts thereof and mixtures thereof.
Opioid nists that are not or only poorly bioavailable upon oral administration, but much
better bioavailable upon parenteral administration, are particularly preferred.
Opioid antagonists suitable for a given opioid agonist are known to the person skilled in the
art and may be t as such or in the form of ponding derivatives, in particular
esters or ethers, or in each case in the form of corresponding physiologically acceptable
compounds, in particular in the form of the salts or solvates thereof. The pharmaceutical
dosage form according to the ion preferably contains an opioid nist selected
from the group consisting of naloxone, naltrexone, nalmefene, nalide, nalmexone, nalorphine
or naluphine, in each case optionally in the form of a corresponding physiologically
acceptable nd, in ular in the form of a base, a salt or solvate.
Naloxone and nalmexone as well as their physiologically acceptable salts are preferred
opioid antagonists.
Naloxone is particularly preferred as opioid antagonist, preferably its hydrochloride, more
preferably the dihydrate of the hydrochloride.
The content of the opioid antagonist in the pharmaceutical dosage form is not limited.
Preferably, the content of the opioid antagonist in the pharmaceutical dosage form according
to the invention is such that it is at least sufficient to locally block the opioid receptors in the
2012/072678
intestine thereby suppressing obstipation that would otherwise be induced by the opioid
agonist. Preferably, however, the content of the opioid antagonist is increased to an amount
sufficient to counter the effect of the opioid agonist when the pharmaceutical dosage form is
tampered with, particularly by liquid extraction of the active ingredients and eral
administration of the liquid extract. There is indication that the ty needed for this effect
is higher than the quantity needed for suppression of obstipation.
Preferably, the content of the opioid antagonist is within the range of from 0.01 to 80 wt.-%,
more preferably 0.1 to 50 wt.-%, still more ably 1 to 25 wt.-%, based on the total weight
of the pharmaceutical dosage form. In a preferred embodiment, the content of opioid
nist is within the range of from 7i6 wt.-%, more preferably 71r5 wt.-%, still more
preferably 51r4 wt.-%, 714 wt.-% or 914 wt.-%, most preferably 5i3 wt.-%, 7i3 wt.-% or 9i3
wt.-%, and in particular 512 wt.-%, 7i2 wt.-% or 9i2 wt.-%, based on the total weight of the
pharmaceutical dosage form. In another preferred embodiment, the content of opioid
antagonist is within the range of from 11i10 wt.-%, more preferably 11i9 wt.-%, still more
ably 9i6 wt.-%, 11i6 wt.-%, 13i6 wt.-% or 15i6 wt.-%, most preferably 1114 wt.-%,
13i4 wt.-% or 15i4 wt.-%, and in particular 11i2 wt.-%, 13i2 wt.-% or 15i2 wt.-%, based on
the total weight of the pharmaceutical dosage form. In a further preferred ment, the
content of opioid antagonist is within the range of from 20i6 wt.-%, more preferably 20i5 wt.-
%, still more preferably 2014 wt.-%, most preferably 20i3 wt.-%, and in particular 20i2 wt.-
%, based on the total weight of the pharmaceutical dosage form.
Preferably, the total amount of the opioid antagonist that is contained in the pharmaceutical
dosage form is within the range of from 0.01 to 200 mg, more preferably 0.1 to 190 mg, still
more preferably 1.0 to 180 mg, yet more preferably 1.5 to 160 mg, most preferably 2.0 to 100
mg and in ular 2.5 to 80 mg.
In a preferred embodiment, the opioid antagonist is contained in the pharmaceutical dosage
form in an amount of 1.0i0.5 mg, 2.0i1.0 mg, 3.0:r1.0 mg, 4.0i1.0 mg, 0 mg, 7.5:r5
mg, 10i5 mg, 20i5 mg, 30i5 mg, 40i5 mg, 50i5 mg, 60i5 mg, 70i5 mg, 80i5 mg, 90i5
mg, 100i5 mg, 110i5 mg, 120i5 mg, 130i5, 140i5 mg, 150i5 mg, or 160i5 mg. In another
preferred embodiment, the opioid antagonist is contained in the pharmaceutical dosage form
in an amount of 51r2.5 mg, 7.5i2.5 mg, 10i2.5 mg, 15i2.5 mg, 20i2.5 mg, 25i2.5 mg,
30i2.5 mg, 35i2.5 mg, 40i2.5 mg, 45i2.5 mg, 50i2.5 mg, 55i2.5 mg, 60i2.5 mg, 65i2.5
mg, 70:2.5 mg, 75:2.5 mg, 80:2.5 mg, 85i2.5 mg, 90i2.5 mg, 95i2.5 mg, 100i2.5 mg,
105i2.5 mg, 110i2.5 mg, 115i2.5 mg, 120i2.5 mg, 125i2.5 mg, 130i2.5 mg, 135i2.5 mg,
140i2.5 mg, 145i2.5 mg, 5 mg, 155i2.5 mg, or 160i2.5 mg.
Preferably, the relative weight ratio of the opioid agonist and the opioid antagonist is within
the range of from 20:1 to 1:5, more preferably 15:1 to 1:4, still more preferably 10:1 to 1:3,
yet more preferably 5:1 to 1:2, even more preferably 3.5:1 to 1:15, most preferably 3:1 to
1:1, and in particular 2.5:1 to 15:1.
The purpose of the opioid antagonist that is ned in the pharmaceutical dosage form
according to the invention is on the one hand ated with the tamper resistance of the
pharmaceutical dosage form, especially when the ceutical dosage form is
administered by a non-prescribed route of administration, particularly intravenous
administration of a liquid extract. Under these circumstances, the opioid antagonist
preferably evolves its antagonizing effect thereby avoiding misuse of the opioid agonist. On
the other hand, the purpose of the opioid antagonist is preferably to reduce undesired
adverse , particularly to counter obstipation that would be othenNise induced by the
opioid agonist. This is achieved by y blocking the pharmacological effect of the opioid
t at the opioid receptors in the intestine upon prescribed oral stration of the
pharmaceutical dosage form.
In a particularly preferred ment, the opioid antagonist is naloxone, preferably its HCI
salt, and the pharmaceutical dosage form is adapted for stration twice daily. In this
embodiment, the opioid antagonist is preferably contained in the pharmaceutical dosage
form in an amount of from 1.0 to 40 mg.
In a particularly preferred embodiment, the opioid agonist is oxycodone, preferably its
hydrochloride, and the opioid antagonist is naloxone, preferably its hydrochloride. Preferred
contents A1 to A24 of said opioid agonist and said opioid antagonist for this embodiment are
summarized in the table here below:
opioid agonist 20i2.0 25i2.0 30i2.0
opioid antagonist 12.5i12.0 15i14.5
mg A7 A10 A1 1 A12
opioid agonist 35i2.0 60i2.0 70i2.0 80i2.0
opioid nist 17.5:r17.0 30i29.5 35i34.5 40i39.5
mg A13 A16 A18
opioid agonist 5.0i2.0 20i2.0 25i2.0 30i2.0
In a preferred embodiment, after oral administration of the pharmaceutical dosage form
according to the invention, in vivo the average peak plasma level (Cmax) of the opioid
antagonist is on average reached after tmax 3.0i2.5 h, more ably after tmax 3.0i2.0 h,
still more preferably after tmax 3.0i1.5 h, most preferably after tmax 3.0i1.0 h and in particular
after tmax 3.0i0.5 h. In another preferred embodiment, after oral administration of the
pharmaceutical dosage form according to the invention, in vivo the average peak plasma
level (Cmax) of the opioid antagonist is on average reached after tmax 3.4i2.5 h, more
preferably after tmax 3.4i2.0 h, still more preferably after tmax 3.4i1.5 h, most ably after
tmax 3.4i1.0 h and in particular after tmax 3.4i0.5 h. In still another red embodiment,
after oral administration of the pharmaceutical dosage form according to the invention, in vivo
the e peak plasma level (Cmax) of the opioid antagonist is on average reached after
tmax 4.0i2.5 h, more preferably after tmax 4.0i2.0 h, still more preferably after tmax 4.0i1.5 h,
most preferably after tmax 4.0i1.0 h and in particular after tmax 4.0i0.5 h. In yet another
preferred ment, after oral administration of the pharmaceutical dosage form according
to the invention, in vivo the e peak plasma level (Cmax) of the opioid antagonist is on
e reached after tmax 5.0i2.5 h, more preferably after tmax 5.0i2.0 h, still more
preferably after tmax 5.0i1.5 h, most preferably after tmax 5.0i1.0 h and in particular after tmax
.0i0.5 h. In still another preferred embodiment, after oral administration of the
pharmaceutical dosage form according to the invention, in vivo the average peak plasma
level (cm) of the opioid antagonist is on average reached after tmax 5 h, more
preferably after tmax 6.0i2.0 h, still more preferably after tmax 6.0i1.5 h, most preferably after
tmax 6.0i1.0 h and in particular after tmax 6.0i0.5 h.
In a red embodiment, the average value for t1/2 of the opioid antagonist after oral
administration of the pharmaceutical dosage form according to the invention in vivo is
4.0i2.5 h, more preferably 4.0i2.0 h, still more ably 4.0i1.5 h, most preferably 4.0i1.0
h, and in particular 4.0i0.5 h. In another preferred embodiment, the average value for t1/2 of
the opioid antagonist after oral administration of the pharmaceutical dosage form according
to the invention in vivo is 4.3i2.5 h, more preferably 4.3i2.0 h, still more preferably 4.3i1.5
h, most ably 4.3i1.0 h, and in particular 4.3i0.5 h. In still another preferred
embodiment, the average value for t1/2 of the opioid antagonist after oral administration of the
pharmaceutical dosage form according to the invention in vivo is ably 5.0i2.5 h, more
preferably 5.0:r2.0 h, still more preferably 5.0i1.5 h, most preferably 0 h, and in
particular 5.0i0.5 h. In yet another preferred embodiment, the average value for t1/2 of the
opioid antagonist after oral administration of the pharmaceutical dosage form according to
the ion in vivo is preferably 6.0i2.5 h, more preferably 6.0i2.0 h, still more preferably
6.0:r1.5 h, most preferably 6.0:r1.0 h, and in particular 6.0i0.5 h.
In a preferred embodiment, Cmax of the opioid antagonist is below Cmax of the opioid agonist.
ably, Cmax of the opioid antagonist is at most 90%, more ably at most 80%, still
more preferably at most 70%, yet more preferably at most 65%, even more preferably at
most 60%, most preferably at most 55% and in particular at most 50% of Cmax of the opioid
agonist.
Preferably, Cmax of the opioid antagonist does not exceed 0.01 ng/ml, or 0.05 ng/ml, or 0.1
ng/ml, or 0.5 ng/ml, or 1.0 ng/ml, or 2.5 ng/ml, or 5 ng/ml, or 10 ng/ml, or 20 ng/ml, or 30
ng/ml, or 40 ng/ml, or 50 ng/ml, or 75 ng/ml, or 100 ng/ml, or 150 ng/ml, or 200 ng/ml, or 250
ng/ml, or 300 ng/ml, or 350 ng/ml, or 400 ng/ml, or 450 ng/ml, or 500 ng/ml, or 750 ng/ml, or
1000 ng/ml.
Preferably, at any point in time during 8 h, more preferably 10 h, most preferably 12 h, after
oral administration of the pharmaceutical dosage form, the plasma concentration of the
opioid antagonist is below the plasma concentration of the opioid agonist. Preferably, at any
point in time during 8 h, more preferably 10 h, most preferably 12 h, after oral administration
of the pharmaceutical dosage form, the plasma concentration of the opioid antagonist is at
most 90%, more preferably at most 80%, still more preferably at most 70%, yet more
preferably at most 65%, even more preferably at most 60%, most preferably at most 55%
and in particular at most 50% of the plasma tration of the opioid agonist at the same
point in time.
In a preferred embodiment, the pharmaceutical dosage form according to the invention
ns an opioid nist but no substances which irritate the nasal passages and/or
pharynx, i.e. substances which, when administered via the nasal passages and/or pharynx,
bring about a physical reaction which is either so unpleasant for the patient that he/she does
not wish to or cannot continue stration, for example burning, or physiologically
counteracts taking of the corresponding active compound, for example due to increased
nasal secretion or ng. Further es of substances which irritate the nasal
passages and/or pharynx are those which cause burning, g, urge to sneeze, increased
formation of secretions or a combination of at least two of these stimuli. Corresponding
substances and the quantities thereof which are conventionally to be used are known to the
person skilled in the art. Some of the substances which te the nasal passages and/or
pharynx are accordingly based on one or more constituents or one or more plant parts of a
hot substance drug. Corresponding hot nce drugs are known per se to the person
skilled in the art and are described, for example, in "Pharmazeutische Biologie - Drogen und
ihre lnhaltsstoffe" by Prof. Dr. Hildebert Wagner, 2nd., revised edition, Gustav Fischer
Verlag, Stuttgart-New York, 1982, pages 82 et seq.. The corresponding description is hereby
introduced as a reference and is deemed to be part of the disclosure.
The pharmaceutical dosage form according to the invention furthermore preferably contains
an opioid nist but no emetic. Emetics are known to the person skilled in the art and
may be present as such or in the form of corresponding derivatives, in particular esters or
ethers, or in each case in the form of ponding physiologically acceptable compounds,
in particular in the form of the salts or solvates thereof. The pharmaceutical dosage form
according to the invention preferably contains no emetic based on one or more constituents
of ipecacuanha (ipecac) root, for e based on the constituent emetine, as are, for
example, described in "Pharmazeutische Biologie - Drogen und ihre lnhaltsstoffe" by Prof.
Dr. Hildebert Wagner, 2nd, d n, Gustav Fischer Verlag, Stuttgart, New York,
1982. The corresponding literature description is hereby introduced as a reference and is
deemed to be part of the disclosure. The ceutical dosage form according to the
invention preferably also contains no apomorphine as an emetic.
The pharmaceutical dosage form according to the invention preferably also contains an
opioid antagonist but no bitter substance. Bitter substances and the quantities effective for
use may be found in US-2003/0064099 A1, the corresponding disclosure of which should be
deemed to be the disclosure of the t application and is hereby introduced as a
reference. Examples of bitter substances are aromatic oils, such as peppermint oil,
eucalyptus oil, bitter almond oil, menthol, fruit aroma substances, aroma substances from
lemons, oranges, limes, grapefruit or mixtures thereof, and/or denatonium benzoate.
The ceutical dosage form according to the invention accordingly preferably contains
an opioid antagonist but no aversive agent, i.e. neither substances which irritate the nasal
es and/or pharynx, nor emetics, nor bitter substances.
Preferably, the ceutical dosage form according to the invention contains no
neuroleptics, for example a compound selected from the group consisting of haloperidol,
promethacine, fluphenazine, nazine, levomepromazine, dazine, perazine,
chlorpromazine, chlorprothixine, zuclopenthixol, flupentixol, prothipendyl, zotepine,
benperidol, erone, melperone and bromperidol.
s (i) the pharmacologically active ingredient, preferably opioid agonist, (ii) the opioid
antagonist and/or the aversive agent, (iii) the kylene oxide and (iv) the c polymer,
the pharmaceutical dosage form according to the invention may contain further constituents,
such as conventional pharmaceutical excipients.
Preferably, the pharmaceutical dosage form according to the ion contains a plasticizer.
The plasticizer improves the processability of the polyalkylene oxide. A preferred plasticizer
is polyalkylene glycol, like polyethylene glycol, triacetin, fatty acids, fatty acid esters, waxes
and/or microcrystalline waxes. Particularly preferred plasticizers are hylene glycols,
such as PEG 6000.
Preferably, the content of the plasticizer is within the range of from 0.1 to 25 wt.-%, more
preferably 0.5 to 22.5 wt.-%, still more preferably 1.0 to 20 wt.-%, yet more preferably 2.5 to
17.5 wt.-%, most preferably 5.0 to 15 wt.-% and in ular 7.5 to 12.5 wt.-%, based on the
total weight of the pharmaceutical dosage form.
In a preferred embodiment, the plasticizer is a polyalkylene glycol having a content within the
range of 514 wt.-%, more preferably 5135 wt.-%, still more preferably 5i3 wt.-%, yet more
preferably 5i2.5 wt.-%, most preferably 512 wt.-%, and in particular 5115 wt.-%, based on
the total weight of the pharmaceutical dosage form.
In another preferred embodiment, the plasticizer is a polyalkylene glycol having a content
within the range of 10i8 wt.-%, more preferably 10i6 wt.-%, still more preferably 10i5 wt.-%,
yet more preferably 1014 wt.-%, most preferably 10i3 wt.-%, and in particular 10i2 wt.-%,
based on the total weight of the pharmaceutical dosage form.
In still another preferred embodiment, the plasticizer is a polyalkylene glycol having a content
within the range of 15:8 wt.-%, more preferably 15i6 wt.-%, still more ably 15i5 wt.-%,
yet more preferably 1514 wt.-%, most preferably 15i3 wt.-%, and in ular 15i2 wt.-%,
based on the total weight of the pharmaceutical dosage form.
Preferably, the pharmaceutical dosage form according to the invention contains an
antioxidant.
WO 72395
Suitable antioxidants include ascorbic acid, oc-tocopherol (vitamin E), butylhydroxyanisol,
butylhydroxytoluene, salts of ascorbic acid (vitamin C), ascorbylic palmitate, monothio-
glycerine, coniferyl benzoate, nordihydroguajaretic acid, ga||us acid esters, phosphoric acid,
and the derivatives thereof, such as vitamin E-succinate or vitamin E-palmitate and/or
sodium bisulphite, more preferably butylhydroxytoluene (BHT) or butylhydroxyanisol (BHA)
and/or oc-tocopherol.
Preferably, the content of the antioxidant is within the range of from 0.001 to 5.0 wt.-%, more
preferably 0.002 to 2.5 wt.-%, more preferably 0.003 to 1.5 wt.-%, still more preferably 0.005
to 1.0 wt.-%, yet more preferably 0.01 to 0.5 wt.-%, most preferably 0.05 to 0.4 wt.-% and in
particular 0.1 to 0.3 wt.-%, based on the total weight of the pharmaceutical dosage form.
A particularly preferred antioxidant is opherol.
In a preferred embodiment, the t of oc-tocopherol is within the range of 0.2i0.18 wt.-%,
more preferably 0.2:rO.15 wt.-%, still more preferably 0.2:rO.12 wt.-%, yet more preferably
0.2i0.09 wt.-%, most preferably 06 wt.-%, and in particular 0.2i0.03 wt.-%, based on
the total weight of the pharmaceutical dosage form.
In a preferred embodiment, when the pharmaceutical dosage form additionally comprises an
acid, the relative weight ratio of the acid, preferably citric acid, and the idant, preferably
opherol, is within the range of from 10:1 to 1:10, more preferably 8:1 to 1:8, still more
preferably 6:1 to 1:6, yet more preferably 5:1 to 1:4, most preferably 4:1 to 1:3 and in
particular 3:1 to 1:2.
The pharmaceutical dosage form according to the invention preferably contains a free
physiologically acceptable acid in an amount of from 0.001 to 5.0 wt.-%, based on the total
weight of the pharmaceutical dosage form. The acid may be organic or inorganic, liquid or
solid. Solid acids are preferred, particularly crystalline organic or inorganic acids.
ably, the acid is free. This means that the acidic functional groups of the acid are not
all together constituents of a salt of the pharmacologically active ingredient, preferably opioid
agonist and the opioid antagonist, tively. If the pharmacologically active ient,
preferably opioid agonist and/or the opioid antagonist is present as a salt of an acid, e.g. as
hydrochloride, the pharmaceutical dosage form according to the invention preferably
contains as acid another, chemically different acid which is not present as a constituent of
the salt of the pharmacologically active ingredient, preferably opioid agonist and the opioid
antagonist, respectively. In other words, monoacids that form a salt with pharmacologically
active ingredient, preferably opioid agonist or opioid antagonist are not to be considered as
free acids in the g of the invention. When acid has more than a single acidic
functional group (e.g. phosphoric acid), the acid may be present as a constituent of a salt of
the pharmacologically active ingredient, preferably opioid t or the opioid antagonist,
provided that at least one of the acidic functional groups of the acid is not involved in the
formation of the salt, i.e. is free. Preferably, however, each and every acidic functional group
of acid is not involved in the formation of a salt with pharmacologically active ingredient,
preferably opioid agonist and opioid antagonist. It is also possible, however, that free acid
and the acid forming a salt with pharmacologically active ingredient, preferably opioid agonist
or opioid antagonist are cal. Under these circumstances the acid is ably present
in molar excess ed to pharmacologically active ingredient, preferably opioid agonist
and opioid antagonist, respectively.
In a preferred embodiment, the acid contains at least one acidic functional group (e.g. -
C02H, -SOsH, -POsH2, -OH and the like) having a pKA value within the range of 2.00i1.50,
more preferably 2.00i1.25, still more preferably 2.00i1.00, yet more preferably 2.00i0.75,
most preferably 2.00i0.50 and in particular 2.00i0.25. In r preferred embodiment, the
acid contains at least one acidic functional group having a pKA value within the range of
2.25:1.50, more preferably 2.25:1.25, still more preferably 2.25i1.00, yet more preferably
2.25i0.75, most preferably .50 and in particular 2.25i0.25. In another preferred
embodiment, the acid contains at least one acidic onal group having a pKA value within
the range of .50, more preferably 2.50i1.25, still more preferably 2.50i1.00, yet more
preferably 2.50i0.75, most preferably .50 and in particular .25. In another
preferred embodiment, the acid contains at least one acidic functional group having a pKA
value within the range of 2.75i1.50, more preferably .25, still more preferably
2.75:1.00, yet more preferably 2.75i0.75, most preferably .50 and in particular
2.75:0.25. In another preferred embodiment, the acid contains at least one acidic functional
group having a pKA value within the range of 3.00i1.50, more ably 3.00i1.25, still more
preferably 3.00i1.00, yet more preferably 3.00i0.75, most preferably 3.00i0.50 and in
particular 3.00i0.25. In still another preferred embodiment, the acid contains at least one
acidic functional group having a pKA value within the range of 3.25i1.50, more preferably
3.25:1.25, still more preferably .00, yet more preferably 3.25i0.75, most preferably
3.25i0.50 and in particular 3.25:0.25.
In yet another preferred embodiment, the acid contains at least one acidic functional group
having a pKA value within the range of 4.50i1.50, more preferably 4.501425, still more
preferably 4.50i1.00, yet more preferably 4.50i0.75, most ably 4.50i0.50 and in
particular 4.50i0.25. In yet another preferred embodiment, the acid contains at least one
acidic functional group having a pKA value within the range of 4.75i1.50, more preferably
4.75i1.25, still more preferably 4.75i1.00, yet more preferably .75, most preferably
4.75i0.50 and in particular 4.75i0.25. In yet another preferred embodiment, the acid
contains at least one acidic functional group having a pKA value within the range of
.00i1.50, more preferably .25, still more preferably 5.00i1.00, yet more preferably
.00i0.75, most preferably 5.00i0.50 and in particular 5.00i0.25.
Preferably, the acid is an organic carboxylic or sulfonic acid, particularly a carboxylic acid.
Multicarboxylic acids and/or y-carboxylic acids are ally preferred.
In case of multicarboxylic acids, the partial salts f are also to be regarded as multi-
carboxylic acids, e.g. the l sodium, potassium or ammonium salts. For example, citric
acid is a multicarboxylic acid having three carboxyl groups. As long as there remains at least
one carboxyl group protonated (e.g. sodium dihydrogen citrate or disodium hydrogen citrate),
the salt is to be regarded as a arboxylic acid. Preferably, however, all carboxyl groups
of the multicarboxylic acid are protonated.
ably, the acid is of low molecular weight, i.e., not polymerized. Typically, the molecular
weight of the acid is below 500 g/mol.
Examples of acids e saturated and unsaturated monocarboxylic acids, saturated and
unsaturated bicarboxylic acids, tricarboxylic acids, oc-hydroxyacids and B-hydroxylacids of
monocarboxylic acids, oc-hydroxyacids and B-hydroxyacids of bicarboxylic acids, oc-hydroxy-
acids and B-hydroxyacids of tricarboxylic acids, ids, oc-ketoacids, B-ketoacids, of the
polycarboxylic acids, of the polyhydroxy monocarboxylic acids, of the polyhydroxy bicar-
boxylic acids, of the polyhydroxy tricarboxylic acids.
Preferably, the acid is selected from the group consisting of benzenesulfonic acid, citric acid,
oc-glucoheptonic acid, D-gluconic acid, glycolic acid, lactic acid, malic acid, malonic acid,
mandelic acid, oic acid, succinic acid, tartaric acid (d, l, or oil), tosic acid ne-
sulfonic acid), valeric acid, palmitic acid, pamoic acid, sebacic acid, stearic acid, lauric acid,
acetic acid, adipic acid, glutaric acid, 4-chlorobenzenesulfonic acid, ethanedisulfonic acid,
ethylsuccinic acid, fumaric acid, galactaric acid (mucic acid), D-glucuronic acid, 2-oxo-glutaric
acid, glycerophosphoric acid, hippuric acid, isethionic acid (ethanolsulfonic acid), lactobionic
acid, maleic acid, maleinic acid, 1,5-naphthalene-disulfonic acid, 2-naphthalene-sulfonic acid,
pivalic acid, terephthalic acid, thiocyanic acid, cholic acid, n-dodecyl sulfate, 3-hydroxy
naphthoic acid, 1-hydroxynaphthoic acid, oleic acid, undecylenic acid, ascorbic acid, (+)-
camphoric acid, d-camphorsulfonic acid, dichloroacetic acid, sulfonic acid, formic acid,
methanesulfonic acid, nicotinic acid, orotic acid, oxalic acid, picric acid, L-pyroglutamic acid,
saccharine, salicylic acid, ic acid, and/or amidobenzoic acid.
The content of the acid is preferably within the range of from 0.001 to 5.0 wt.-%, preferably
0.005 to 2.5 wt.-%, more preferably 0.01 to 2.0 wt.-%, still more preferably 0.05 to 1.5 wt.-%,
most preferably 0.1 to 1.0 wt.-% and in particular 0.2 to 0.9 wt.-%, based on the total weight
of the ceutical dosage form.
Preferably, the acid is a multicarboxylic acid. More preferably, the multicarboxylic acid is
selected from the group consisting of citric acid, maleic acid and fumaric acid.
Citric acid is particularly preferred.
The arboxylic acid, preferably citric acid, may be present in its anhydrous form or as a
solvate and hydrate, respectively, e.g., as monohydrate.
In a preferred embodiment, the content of the acid, preferably citric acid, is within the range
of 0.2i0.18 wt.-%, more ably 0.2i0.15 wt.-%, still more preferably 0.2i0.12 wt.-%, yet
more preferably 0.2i0.09 wt.-%, most preferably 06 wt.-%, and in particular 0.2i0.03
wt.-%, based on the total weight of the pharmaceutical dosage form.
In another preferred embodiment, the content of the acid, preferably citric acid, is within the
range of 0.3i0.18 wt.-%, more preferably 0.3i0.15 wt.-%, still more preferably 0.3i0.12 wt.-
%, yet more ably 0.3i0.09 wt.-%, most ably 0.3i0.06 wt.-%, and in particular
0.3i0.03 wt.-%, based on the total weight of the pharmaceutical dosage form.
In still another preferred embodiment, the content of the acid, preferably citric acid, is within
the range of 0.4i0.18 wt.-%, more preferably 0.4i0.15 wt.-%, still more preferably 12
wt.-%, yet more preferably 0.4i0.09 wt.-%, most preferably 0.4i0.06 wt.-%, and in particular
0.4i0.03 wt.-%, based on the total weight of the pharmaceutical dosage form.
In yet another preferred embodiment, the content of the acid, ably citric acid, is within
the range of 18 wt.-%, more preferably 0.5i0.15 wt.-%, still more preferably 12
wt.-%, yet more preferably 0.5i0.09 wt.-%, most preferably 0.5i0.06 wt.-%, and in particular
0.5i0.03 wt.-%, based on the total weight of the pharmaceutical dosage form.
In yet another preferred embodiment, the content of the acid, ably citric acid, is within
the range of 0.6i0.18 wt.-%, more preferably 0.6i0.15 wt.-%, still more preferably 0.6i0.12
wt.-%, yet more preferably 0.6i0.09 wt.-%, most preferably 0.6i0.06 wt.-%, and in particular
0.6i0.03 wt.-%, based on the total weight of the pharmaceutical dosage form.
In yet another preferred embodiment, the content of the acid, ably citric acid, is within
the range of 0.7i0.18 wt.-%, more preferably 0.7:rO.15 wt.-%, still more preferably 0.7:rO.12
wt.-%, yet more preferably 0.7i0.09 wt.-%, most preferably 0.7i0.06 wt.-%, and in particular
0.7i0.03 wt.-%, based on the total weight of the ceutical dosage form.
In yet another preferred embodiment, the content of acid, preferably citric acid, is within the
range of 0.8i0.18 wt.-%, more preferably 0.8i0.15 wt.-%, still more preferably 0.8:rO.12 wt.-
%, yet more ably 0.8i0.09 wt.-%, most preferably 0.8i0.06 wt.-%, and in particular
0.8i0.03 wt.-%, based on the total weight of the pharmaceutical dosage form.
In yet r preferred ment, the content of the acid, preferably citric acid, is within
the range of 0.85i0.18 wt.-%, more preferably 0.85i0.15 wt.-%, still more preferably
0.85i0.12 wt.-%, yet more preferably 0.85i0.09 wt.-%, most preferably 0.85i0.06 wt.-%, and
in particular 0.85i0.03 wt.-%, based on the total weight of the pharmaceutical dosage form.
In still another preferred embodiment, the content of the acid, preferably citric acid, is within
the range of 0.9i0.18 wt.-%, more preferably 0.9i0.15 wt.-%, still more preferably 0.9i0.12
wt.-%, yet more preferably 09 wt.-%, most preferably 0.9i0.06 wt.-%, and in particular
0.9i0.03 wt.-%, based on the total weight of the pharmaceutical dosage form.
In a further preferred embodiment, the t of the acid, preferably citric acid, is within the
range of 1.0i0.18 wt.-%, more preferably 1.0i0.15 wt.-%, still more preferably 1.0:rO.12 wt.-
%, yet more preferably 1.0i0.09 wt.-%, most preferably 1.0i0.06 wt.-%, and in particular
1.0i0.03 wt.-%, based on the total weight of the pharmaceutical dosage form.
The pharmaceutical dosage form ing to the invention may also contain a natural,
semi-synthetic or synthetic wax. Waxes with a softening point of at least 50 °C, more
2012/072678
preferably 60 °C are preferred. Carnauba wax and beeswax are particularly preferred,
especially carnauba wax.
Preferably, the pharmaceutical dosage form according to the invention contains a coating,
preferably a film-coating. Suitable g als are known to the skilled . Suitable
coating materials are commercially available, e.g. under the trademarks Opadry® and
Eudragit®.
Examples of suitable materials include cellulose esters and cellulose ethers, such as methyl-
cellulose (MC), ypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC),
hydroxyethylcellulose (H EC), sodium carboxymethylcellulose (Na-CMC), ethylcellulose (EC),
cellulose acetate phthalate (CAP), hydroxypropylmethylcellulose phthalate (HPMCP);
poly(meth)acrylates, such as lkylmethacrylate copolymers, ethylacrylate methyl-
methacrylate copolymers, methacrylic acid methylmethacrylate copolymers, methacrylic acid
methylmethacrylate copolymers; vinyl polymers, such as polyvinylpyrrolidone, polyvinyl-
acetatephthalate, polyvinyl alcohol, polyvinylacetate; and natural film formers, such as
shellack.
In a particularly preferred ment, the coating is water-soluble. In a preferred
ment, the coating is based on polyvinyl alcohol, such as polyvinyl alcohol-part.
hydrolyzed, and may onally contain polyethylene glycol, such as macrogol 3350, and/or
pigments. In another preferred embodiment, the coating is based on hydroxypropylmethyl-
ose, ably hypromellose type 2910 having a viscosity of 3 to 15 mPas.
The coating of the ceutical dosage form can increase its storage stability.
The coating can be resistant to gastric juices and ve as a function of the pH value of
the release environment. By means of this coating, it is possible to ensure that the
pharmaceutical dosage form according to the invention passes through the stomach
undissolved and the active compound is only released in the intestines. The coating which is
resistant to gastric juices preferably dissolves at a pH value of between 5 and 7.5.
Corresponding materials and methods for the delayed release of active compounds and for
the application of coatings which are resistant to gastric juices are known to the person
skilled in the art, for example from "Coated Pharmaceutical dosage forms - Fundamentals,
Manufacturing ques, Biopharmaceutical Aspects, Test Methods and Raw als"
by Kurt H. Bauer, K. Lehmann, Hermann P. OstenNald, Rothgang, Gerhart, 1st edition, 1998,
Medpharm Scientific Publishers.
The pharmaceutical dosage form according to the invention is preferably tamper-resistant.
Preferably, tamper-resistance is achieved based on the mechanical properties of the
pharmaceutical dosage form so that comminution is avoided or at least substantially
impeded. According to the invention, the term comminution means the pulverization of the
pharmaceutical dosage form using conventional means usually available to an , for
example a pestle and mortar, a hammer, a mallet or other conventional means for pulverizing
under the action of force. Thus, tamper-resistance preferably means that pulverization of the
ceutical dosage form using tional means is avoided or at least substantially
impeded.
Preferably, the mechanical properties of the ceutical dosage form according to the
invention, particularly its breaking strength, substantially rely on the presence and l
bution of the polyalkylene oxide, although its mere presence does typically not suffice in
order to achieve said properties. The ageous mechanical properties of the
pharmaceutical dosage form according to the invention may not automatically be achieved
by simply processing pharmacologically active ingredient, preferably opioid agonist, opioid
antagonist, polyalkylene oxide, and ally further excipients by means of conventional
methods for the preparation of pharmaceutical dosage forms. In fact, usually suitable
apparatuses must be selected for the ation and critical processing parameters must be
adjusted, particularly re/force, temperature and time. Thus, even if conventional
apparatuses are used, the process protocols usually must be d in order to meet the
ed criteria.
Furthermore, tamper-resistance is achieved based on the poor solubility properties of the
pharmaceutical dosage form in alcohol, especially ethanol, thereby effectively preventing
alcohol dose dumping.
The pharmaceutical dosage form according to the invention has a breaking strength of at
least 300 N, preferably at least 400 N, more preferably at least 500 N, still more preferably at
least 750 N, yet more preferably at least 1000 N, most preferably at least 1250 N and in
particular at least 1500 N.
The "breaking strength" (resistance to crushing) of a pharmaceutical dosage form is known to
the d person. In this regard it can be referred to, e.g., W.A. Ritschel, Die Tablette, 2.
Auflage, Editio Cantor Verlag Aulendorf, 2002; H Liebermann et al., Pharmaceutical dosage
forms: Tablets, Vol. 2, Informa care; 2 edition, 1990; and Encyclopedia of Pharma-
ceutical Technology, Informa Healthcare; 1 edition.
For the purpose of the specification, the breaking strength is preferably defined as the
amount of force that is ary in order to fracture the pharmaceutical dosage form (=
breaking force). Therefore, for the purpose of the specification the pharmaceutical dosage
form does preferably not exhibit the desired breaking strength when it breaks, i.e., is
fractured into at least two independent parts that are separated from one another. In another
red embodiment, however, the pharmaceutical dosage form is regarded as being
broken if the force decreases by 25% (threshold value) of the highest force ed during
the measurement (see below).
The pharmaceutical dosage forms according to the invention are distinguished from
conventional pharmaceutical dosage forms in that, due to their ng strength, they
cannot be pulverized by the application of force with conventional means, such as for
example a pestle and mortar, a hammer, a mallet or other usual means for pulverization, in
particular devices ped for this purpose (tablet crushers). In this regard "pulverization"
preferably means crumbling into small particles that would immediately release the
pharmacologically active compound (A) in a suitable medium. Avoidance of pulverization
virtually rules out oral or parenteral, in particular intravenous or nasal abuse.
Conventional s typically have a breaking strength well below 200 N in any direction of
ion. The breaking th of conventional round tablets may be ted according
to the following empirical formula: Breaking Strength [in N] = 10 x Diameter Of The Tablet [in
mm]. Thus, according to said cal formula, a round tablet having a ng strength of
at least 300 N would require a diameter of at least 30 mm). Such a tablet, however, could not
be swallowed. The above empirical formula preferably does not apply to the pharmaceutical
dosage forms of the invention, which are not conventional but rather special.
Further, the actual mean chewing force is about 220 N (cf., e.g., P.A. Proeschel et al., J Dent
Res, 2002, 81(7), 464-468). This means that conventional tablets having a breaking strength
well below 200 N may be crushed upon spontaneous chewing, whereas the ceutical
dosage forms according to the invention may not.
Still further, when applying a gravitational ration of about 9.81 m/s2, 300 N correspond
to a gravitational force of more than 30 kg, i.e. the pharmaceutical dosage forms ing to
the invention can preferably withstand a weight of more than 30 kg without being pulverized.
Methods for measuring the breaking strength of a pharmaceutical dosage form are known to
the skilled artisan. Suitable devices are commercially available.
For example, the breaking th (resistance to crushing) can be measured in accordance
with the Eur. Ph. 5.0, 2.9.8 or 6.0, 2.09.08 "Resistance to Crushing of Tablets". The test is
intended to determine, under defined conditions, the resistance to crushing of s,
measured by the force needed to disrupt them by crushing. The tus consists of 2 jaws
facing each other, one of which moves towards the other. The flat es of the jaws are
perpendicular to the direction of movement. The crushing surfaces of the jaws are flat and
larger than the zone of contact with the tablet. The apparatus is ated using a system
with a precision of 1 Newton. The tablet is placed between the jaws, taking into account,
where applicable, the shape, the break-mark and the inscription; for each measurement the
tablet is oriented in the same way with respect to the direction of application of the force (and
the direction of extension in which the breaking strength is to be measured). The
measurement is carried out on 10 s, taking care that all fragments of tablets have been
removed before each determination. The result is expressed as the mean, minimum and
maximum values of the forces measured, all expressed in Newton.
A similar description of the breaking strength (breaking force) can be found in the USP. The
breaking strength can alternatively be measured in accordance with the method described
therein where it is stated that the breaking strength is the force required to cause a tablet to
fail (i.e., break) in a specific plane. The tablets are generally placed between two plates, one
of which moves to apply sufficient force to the tablet to cause fracture. For conventional,
round (circular section) tablets, loading occurs across their diameter (sometimes
referred to as diametral loading), and fracture occurs in the plane. The ng force of
tablets is commonly called hardness in the ceutical literature; however, the use of this
term is misleading. ln material science, the term hardness refers to the resistance of a
surface to penetration or ation by a small probe. The term crushing strength is also
frequently used to describe the resistance of tablets to the application of a compressive load.
Although this term describes the true nature of the test more accurately than does ss,
it implies that tablets are actually crushed during the test, which is often not the case.
Alternatively, the ng strength (resistance to crushing) can be ed in accordance
with WC 2005/ 016313, WO 16314, and , which can be ed as
a modification of the method described in the Eur. Ph. The tus used for the
measurement is preferably a "Zwick Z 2.5" materials tester, Fmax = 2.5 kN with a maximum
draw of 1150 mm, which should be set up with one column and one spindle, a clearance
behind of 100 mm and a test speed adjustable between 0.1 and 800 mm/min together with
testControl software. Measurement is performed using a pressure piston with screw-in
inserts and a er (diameter 10 mm), a force transducer, Fmax. 1 kN, er = 8 mm,
class 0.5 from 10 N, class 1 from 2 N to ISO 7500-1, with manufacturer's test certificate M
according to DIN 55350-18 (Zwick gross force Fmax = 1.45 kN) (all apparatus from Zwick
GmbH & Co. KG, Ulm, Germany) with Order No BTC-FR 2.5 TH. D09 for the tester, Order
No BTC-LC 0050N. P01 for the force transducer, Order No BO 70000 806 for the centring
device.
In a preferred embodiment of the invention, the breaking strength is ed by means of a
breaking strength tester e.g. Sotax®, type HT100 or type HT1 (Allschwil, Switzerland). Both,
the Sotax® HT100 and the Sotax® HT1 can measure the breaking strength according to two
ent measurement principles: constant speed (where the test jaw is moved at a nt
speed adjustable from 5-200 mm/min) or constant force (where the test jaw increases force
linearly adjustable from 5-100 N/sec). In principle, both measurement principles are suitable
for measuring the breaking strength of the pharmaceutical dosage form according to the
invention. Preferably, the breaking strength is measured at constant speed, preferably at a
nt speed of 120 .
In a preferred embodiment, the pharmaceutical dosage form is regarded as being broken if it
is fractured into at least two separate pieces.
The pharmaceutical dosage form according to the invention preferably ts mechanical
strength over a wide temperature range, in addition to the ng strength (resistance to
crushing) ally also sufficient hardness, impact resistance, impact elasticity, tensile
strength and/or modulus of elasticity, optionally also at low temperatures (e.g. below -24 °C,
below -40 °C or in liquid nitrogen), for it to be virtually impossible to pulverize by spontaneous
chewing, grinding in a mortar, ng, etc. Thus, preferably, the comparatively high
breaking strength of the ceutical dosage form according to the invention is main-
tained even at low or very low temperatures, e.g., when the pharmaceutical dosage form is
initially chilled to increase its brittleness, for example to temperatures below -25°C, below -40
°C or even in liquid nitrogen.
The pharmaceutical dosage form according to the invention is characterized by a certain
degree of breaking strength. This does not mean that the pharmaceutical dosage form must
also exhibit a certain degree of hardness. Hardness and breaking strength are different
physical properties. Therefore, the tamper resistance of the pharmaceutical dosage form
does not necessarily depend on the hardness of the pharmaceutical dosage form. For
instance, due to its breaking strength, impact strength, elasticity modulus and tensile
strength, respectively, the pharmaceutical dosage form can preferably be deformed, e.g.
plastically, when exerting an al force, for example using a hammer, but cannot be
pulverized, i.e., crumbled into a high number of fragments. In other words, the
pharmaceutical dosage form according to the invention is characterized by a certain degree
of breaking strength, but not necessarily also by a certain degree of form stability.
Therefore, in the meaning of the specification, a pharmaceutical dosage form that is
deformed when being exposed to a force in a particular direction of extension but that does
not break (plastic deformation or plastic flow) is preferably to be regarded as having the
desired breaking strength in said direction of extension.
In a preferred embodiment, when
(i) stirring an intact pharmaceutical dosage form according to the invention for 30 minutes
in 30 mL of purified water at ambient temperature;
(ii) separating the overhead liquid solution from the remainder, e.g., by means of a
syringe, equipped with a tte filter and a canula, 0.80 x 40 mm BL/LB; 21 G x 1
1/2", and
(iii) determining the pharmacologically active nd content in the drawn liquid by
HPLC is;
the content of extracted pharmacologically active compound (in each case pharmacologically
active ingredient, preferably opioid t and opioid antagonist) in the overhead liquid
amounts to at most 80 wt.-%, 77.5 wt.-%, 75 wt.-%, or 72.5 wt.-%, more preferably at most
70 wt.-%, 67.5 wt.-%, 65 wt.-%, or 62.5 wt.-%, still more preferably at most 60 wt.-%, 57.5
wt.-%, 55 wt.-%, or 52.5 wt.-%, yet more preferably at most 50 wt.-%, 49 wt.-%, 48 wt.-%, or
47 wt.-%, even more ably at most 46 wt.-%, 45 wt.-%, 44 wt.-%, or 43 wt.-%, most
more preferably at most 42 wt.-%, 41 wt.-%, 40 wt.-%, or 39 wt.-%, and in particular at most
38 wt.-%, 37 wt.-%, 36 wt.-%, or 35 wt.-%, relative to the original total t of the
pharmacologically active compound in the pharmaceutical dosage form, i.e. before it was
subjected to the extraction test. Preferably, the quantity of ted pharmacologically active
ingredient, preferably opioid t and the quantity of ted opioid antagonist do not
deviate from one another by more than 3.0 wt.-%, more preferably not more than 2.8 wt.-%,
still more preferably not more than 2.6 wt.-%, yet more preferably not more than 2.4 wt.-%,
even more ably not more than 2.2 wt.-%, most preferably not more than 2.0 wt.-% and
in particular not more than 1.8 wt.-%, wherein the tages mean te values with
respect to the amount of pharmacologically active ingredient, preferably opioid agonist and
antagonist, respectively, that was originally contained in the pharmaceutical dosage form.
In another preferred embodiment, when
(i) g an intact pharmaceutical dosage form according to the invention into 30 mL of
boiling purified water (~100 °C) and allowing the water to cool down over 30 minutes;
(ii) supplementing lost water, if any;
(iii) separating a defined quantity of the overhead liquid solution from the remainder, e.g.,
by means of a syringe, equipped with a canula, 0.80 x 40 mm BL/LB; 21 G x 1 1/2",
(iv) determining the pharmacologically active compound content in the drawn liquid by
HPLC analysis;
the t of extracted pharmacologically active compound (in each case pharmacologically
active ingredient, preferably opioid agonist and opioid antagonist) in the overhead liquid
amounts to at most 21.5 wt.-%, 21.0 wt.-%, 20.5 wt.-%, or 20.0 wt.-%, more preferably at
most 19.5 wt.-%, 19.0 wt.-%, 18.5 wt.-%, or 18.0 wt.-%, still more preferably at most 17.5 wt.-
%, 17.0 wt.-%, 16.5 wt.-%, or 16.0 wt.-%, yet more preferably at most 15.5 wt.-%, 15.0 wt.-%,
14.5 wt.-%, or 14.0 wt.-%, even more preferably at most 13.5 wt.-%, 13.0 wt.-%, 12.5 wt.-%,
or 12.0 wt.-%, most more preferably at most 11.5 wt.-%, 11.0 wt.-%, 10.5 wt.-%, or 10.0 wt.-
%, and in particular at most 9.5 wt.-%, 9.0 wt.-%, 8.5 wt.-%, or 8.0 wt.-%, ve to the
original total content of the cologically active compound in the pharmaceutical dosage
form, i.e. before it was subjected to the extraction test. Preferably, the quantity of extracted
cologically active ingredient, ably opioid agonist and the quantity of extracted
opioid antagonist do not deviate from one another by more than 3.0 wt.-%, more preferably
not more than 2.8 wt.-%, still more preferably not more than 2.6 wt.-%, yet more preferably
not more than 2.4 wt.-%, even more preferably not more than 2.2 wt.-%, most preferably not
more than 2.0 wt.-% and in particular not more than 1.8 wt.-%, wherein the percentages
mean absolute values with respect to the amount of cologically active ingredient,
preferably opioid agonist and antagonist, respectively, that was originally contained in the
pharmaceutical dosage form.
In still another red embodiment, when
(i) stirring an intact pharmaceutical dosage form according to the invention for 30 minutes
in 30 mL of aqueous ethanol (40% (v/v)) (ambient temperature);
2012/072678
(ii) ting the overhead liquid solution from the remainder, e.g., by means of a
e, equipped with a cigarette filter and a canula, 0.80 x 40 mm BL/LB; 21 G x 1
1/2", and
(iii) determining the pharmacologically active compound content in the drawn liquid by
HPLC analysis;
the content of extracted cologically active compound (in each case pharmacologically
active ingredient, preferably opioid agonist and opioid antagonist) in the overhead liquid
amounts to at most 18.5 wt.-%, 18.0 wt.-%, 17.5 wt.-%, or 17.0 wt.-%, more preferably at
most 16.5 wt.-%, 16.0 wt.-%, 15.5 wt.-%, or 15.0 wt.-%, still more preferably at most 14.5 wt.-
%, 14.0 wt.-%, 13.5 wt.-%, or 13.0 wt.-%, yet more preferably at most 12.5 wt.-%, 12.0 wt.-%,
11.5 wt.-%, or 11.0 wt.-%, even more preferably at most 10.5 wt.-%, 10.0 wt.-%, 9.5 wt.-%, or
9.0 wt.-%, most more preferably at most 8.5 wt.-%, 8.0 wt.-%, 7.5 wt.-%, or 7.0 wt.-%, and in
particular at most 6.5 wt.-%, 6.0 wt.-%, 5.5 wt.-%, or 5.0 wt.-%, ve to the original total
content of the pharmacologically active compound in the pharmaceutical dosage form, i.e.
before it was subjected to the extraction test. Preferably, the quantity of extracted
pharmacologically active ingredient, preferably opioid agonist and the quantity of extracted
opioid antagonist do not deviate from one another by more than 3.0 wt.-%, more preferably
not more than 2.8 wt.-%, still more preferably not more than 2.6 wt.-%, yet more preferably
not more than 2.4 wt.-%, even more preferably not more than 2.2 wt.-%, most preferably not
more than 2.0 wt.-% and in particular not more than 1.8 wt.-%, wherein the percentages
mean absolute values with respect to the amount of pharmacologically active ingredient,
preferably opioid t and antagonist, respectively, that was originally contained in the
pharmaceutical dosage form.
Preferably, when a ceutical dosage form according to the invention is treated with a
commercial coffee mill, preferably type Bosch MKM6000, 180W, Typ KM13 for 2 minutes,
42i17.5 wt.-%, more preferably 42i15 wt.-%, still more preferably 5 wt.-%, yet more
preferably 42i10 wt.-%, even more preferably 42:7.5 wt.-%, most preferably 42i5 wt.-%,
and in particular 42:2.5 wt.-%, of the total weight of the thus obtained material passes a
sieve having a mesh size of 125 um but does not pass a sieve having a mesh size of 1.000
Preferably, when a pharmaceutical dosage form according to the invention is treated with a
commercial coffee mill, preferably type Bosch MKM6000, 180W, Typ KM13, for 2 minutes,
57:17.5 wt.-%, more ably 57i15 wt.-%, still more preferably 57i12.5 wt.-%, yet more
ably 57i10 wt.-%, even more preferably 57i7.5 wt.-%, most preferably 57i5 wt.-%,
and in particular 57i2.5 wt.-%, of the total weight of the thus obtained material does not pass
a sieve having a mesh size of 1.000 mm.
Preferably, when a pharmaceutical dosage form according to the ion is treated with a
commercial coffee mill, preferably type Bosch MKM6000, 180W, Typ KM13, for 2 minutes, at
least 50 wt.-%, more preferably at least 55 wt.-%, still more preferably at least 60 wt.-%, yet
more preferably at least 65 wt.-%, even more ably at least 70 wt.-%, most preferably at
least 75 wt.-%, and in particular at least 80 wt.-%, of the total weight of the thus obtained
material does not pass a sieve having a mesh size of 1.000 mm.
Preferably, the ceutical dosage form for oral stration
- has a breaking strength of at least 400 N, more preferably at least 500 N, still more
preferably at least 750 N, yet more preferably at least 1000 N, most preferably at least
1500 N; and/or
- comprises an opioid agonist selected from oxycodone and the physiologically
acceptable salts thereof; and/or
- comprises an opioid antagonist selected from ne and the logically
acceptable salts thereof, and/or an aversive agent; and/or
- is configured for oral administration twice daily; and/or
- contains at least 30 wt.-%, more ably at least 35 wt.-%, still more preferably at
least 40 wt.-% of a polyalkylene oxide having an average molecular weight of at least
500,000 g/mol, more preferably at least 1,000,000 g/mol, relative to the total weight of
the pharmaceutical dosage form; and/or
- contains as anionic polymer an optionally cross-linked homo- or copolymer of acrylic
acid; and/or
- contains a cizer, preferably polyethylene glycol; and/or
- ns an antioxidant, preferably oc-tocopherol; and/or
- optionally, contains a free acid, preferably citric acid; and/or
- optionally, contains an additional matrix polymer, preferably a cellulose ether, more
preferably HPMC.
The pharmaceutical dosage form according to the invention may be produced by different
processes, the particularly preferred of which are explained in greater detail below. Several
suitable processes have already been described in the prior art. In this regard it can be
referred to, e.g., WC 2005/ 016313, , , ,
, , , , and WO
2006/082099.
The invention also s to pharmaceutical dosage forms that are obtainable by any of the
processes described here below.
In general, the process for the production of the pharmaceutical dosage form according to
the invention preferably comprises the following steps:
a) mixing all ingredients;
b) optionally pre-forming the mixture obtained from step (a), preferably by applying heat
and/or force to the mixture obtained from step (a), the quantity of heat supplied
ably not being sufficient to heat the polyalkylene oxide up to its softening point;
c) hardening the e by applying heat and force, it being possible to supply the heat
during and/or before the application of force and the quantity of heat supplied being
ient to heat the kylene oxide at least up to its softening point;
d) optionally singulating the hardened mixture;
e) optionally shaping the pharmaceutical dosage form; and
f) optionally providing a film coating.
Heat may be supplied directly, e.g. by contact or by means of hot gas such as hot air, or with
the ance of ultrasound. Force may be applied and/or the pharmaceutical dosage form
may be shaped for example by direct tabletting or with the assistance of a suitable extruder,
particularly by means of a screw extruder equipped with two screws (twin-screw-extruder) or
by means of a ary gear extruder.
The final shape of the pharmaceutical dosage form may either be provided during the
hardening of the mixture by applying heat and force (step (c)) or in a subsequent step (step
(e)). In both cases, the mixture of all components is preferably in the plastified state, i.e.
ably, shaping is performed at a temperature at least above the softening point of the
kylene oxide. However, ion at lower temperatures, e.g. ambient temperature, is
also possible and may be preferred.
Shaping can be performed, e.g., by means of a tabletting press comprising die and punches
of appropriate shape.
A particularly preferred process for the manufacture of the pharmaceutical dosage form of
the ion es lt extrusion. In this process, the pharmaceutical dosage form
according to the invention is produced by thermoforming with the ance of an extruder,
preferably without there being any able consequent discoloration of the extrudate. It
has been surprisingly found that acid is capable of suppressing discoloration. In the e
of acid, the extrudate tends to develop beige to yellowish coloring whereas in the presence of
acid the extrudates are substantially colorless, i.e. white.
This process is characterized in that
a) all components are mixed,
b) the resultant mixture is heated in the extruder at least up to the softening point of the
polyalkylene oxide and extruded through the outlet orifice of the extruder by application of
force,
c) the still plastic extrudate is singulated and formed into the pharmaceutical dosage form or
d) the cooled and optionally reheated singulated extrudate is formed into the pharmaceutical
dosage form.
Mixing of the components according to process step a) may also proceed in the extruder.
The components may also be mixed in a mixer known to the person skilled in the art. The
mixer may, for e, be a roll mixer, shaking mixer, shear mixer or sory mixer.
Before blending with the remaining components, polyalkylene oxide is preferably provided
according to the invention with an antioxidant, preferably oc-tocopherol. This may proceed by
mixing the two components, the polyalkylene oxide and the antioxidant, preferably by
dissolving or suspending the antioxidant in a highly volatile t and homogeneously
mixing this solution or suspension with kylene oxide and removing the solvent by
drying, preferably under an inert gas atmosphere.
The, preferably molten, mixture which has been heated in the extruder at least up to the
softening point of polyalkylene oxide is ed from the extruder through a die with at least
one bore.
The process according to the ion es the use of suitable extruders, preferably
screw extruders. Screw extruders which are equipped with two screws (twin-screw-extruders)
are particularly preferred.
The extrusion is preferably performed so that the expansion of the strand due to extrusion is
not more than 30%, Le. that when using a die with a bore having a diameter of e.g. 6 mm,
the extruded strand should have a diameter of not more than 8 mm. More preferably, the
expansion of the strand is not more than 25%, still more preferably not more than 20%, most
preferably not more than 15% and in particular not more than 10%.
Preferably, extrusion is performed in the absence of water, i.e., no water is added. However,
traces of water (e.g., caused by atmospheric humidity) may be present.
The extruder preferably comprises at least two temperature zones, with heating of the
mixture at least up to the softening point of the polyalkylene oxide proceeding in the first
zone, which is ream from a feed zone and optionally mixing zone. The hput of
the mixture is preferably from 1.0 kg to 15 kg/hour. In a preferred embodiment, the
throughput is from 1 to 3.5 kg/hour. In r red embodiment, the throughput is from
4 to 15 kg/hour.
In a preferred embodiment, the die head pressure is within the range of from 25 to 100 bar.
The die head pressure can be adjusted inter alia by die geometry, temperature profile and
extrusion speed.
The die geometry or the geometry of the bores is freely selectable. The die or the bores may
accordingly exhibit a round, oblong or oval cross-section, wherein the round cross-section
preferably has a diameter of 0.1 mm to 15 mm and the oblong cross-section preferably has a
maximum lengthwise extension of 21 mm and a crosswise extension of 10 mm. Preferably,
the die or the bores have a round cross-section. The casing of the er used ing
to the invention may be heated or cooled. The corresponding temperature control, i.e.
heating or cooling, is arranged in such a way that the mixture to be extruded exhibits at least
an average temperature (product temperature) ponding to the softening ature of
the polyalkylene oxide and does not rise above a temperature at which the pharmacologically
active ingredient, preferably opioid agonist to be processed may be damaged. Preferably, the
temperature of the e to be extruded is adjusted to below 180 °C, preferably below 150
°C, but at least to the softening temperature of kylene oxide. Typical extrusion
temperatures are 120 °C and 130 °C.
2012/072678
In a preferred embodiment, the extruder torque is within the range of from 30 to 95%.
Extruder torque can be adjusted inter alia by die ry, temperature profile and extrusion
speed.
After extrusion of the molten mixture and optional cooling of the extruded strand or extruded
strands, the extrudates are preferably singulated. This singulation may preferably be
med by g up the extrudates by means of revolving or rotating knives, water jet
cutters, wires, blades or with the ance of laser cutters.
Preferably, intermediate or final storage of the optionally singulated extrudate or the final
shape of the ceutical dosage form according to the ion is performed under
-free atmosphere which may be achieved, e.g., by means of oxygen-scavengers.
The singulated extrudate may be press-formed into tablets in order to impart the final shape
to the pharmaceutical dosage form.
The application of force in the extruder onto the at least plasticized mixture is adjusted by
controlling the rotational speed of the conveying device in the extruder and the geometry
thereof and by dimensioning the outlet orifice in such a manner that the pressure necessary
for extruding the plasticized mixture is built up in the extruder, preferably immediately prior to
extrusion. The extrusion parameters which, for each particular composition, are ary to
give rise to a pharmaceutical dosage form with desired mechanical properties, may be
established by simple preliminary testing.
For example but not limiting, extrusion may be performed by means of a twin-screw-extruder
type ZSE 18 or ZSE27 (Leistritz, Niirnberg, Germany), screw diameters of 18 or 27 mm.
Screws having eccentric ends may be used. A heatable die with a round bore having a
diameter of 4, 5, 6, 7, 8, or 9 mm may be used. The extrusion parameters may be adjusted
e.g. to the following values: rotational speed of the : 120 Upm; delivery rate 1 kg/h for
a ZSE 18 or 8-10 kg/h for a ZSE27; t temperature: in front of die 125 °C and behind
die 135 °C; and jacket temperature: 110 °C.
Preferably, extrusion is med by means of twin-screw-extruders or planetary-gear-
extruders, twin-screw extruders (co-rotating or contra-rotating) being particularly preferred.
The pharmaceutical dosage form according to the invention is preferably produced by
thermoforming with the assistance of an extruder t any observable consequent
discoloration of the extrudates.
The process for the preparation of the pharmaceutical dosage form according to the
invention is preferably performed continuously. Preferably, the s involves the extrusion
of a homogeneous mixture of all ents. It is particularly advantageous if the thus
obtained intermediate, e.g. the strand obtained by extrusion, exhibits uniform properties.
Particularly desirable are uniform density, uniform distribution of the active nd,
m mechanical ties, uniform porosity, m ance of the surface, etc.
Only under these circumstances the uniformity of the pharmacological properties, such as
the stability of the release profile, may be ensured and the amount of rejects can be kept low.
A further aspect of the invention relates to the use of an pharmacologically active ingredient,
preferably opioid agonist in combination with an opioid antagonist for the cture of the
pharmaceutical dosage form as described above for the treatment of pain, preferably
moderate to severe pain such as moderate to severe low back pain.
A further aspect of the invention relates to the use of a pharmaceutical dosage form as
described above for avoiding or hindering the abuse of the pharmacologically active
ient, preferably opioid agonist contained therein.
A further aspect of the ion relates to the use of a pharmaceutical dosage form as
described above for avoiding or hindering the unintentional overdose of the
pharmacologically active ingredient, preferably opioid agonist ned therein.
In this regard, the invention also relates to the use of a pharmacologically active ingredient,
ably opioid agonist as described above and/or a opioid antagonist as bed above
and/or a polyalkylene oxide as described above for the manufacture of the pharmaceutical
dosage form according to the invention for the prophylaxis and/or the treatment of a disorder,
thereby preventing an overdose of the pharmacologically active ingredient, preferably opioid
agonist, particularly due to comminution of the pharmaceutical dosage form by mechanical
action.
Further, the invention relates to a method for the prophylaxis and/or the treatment of a
disorder comprising the administration of the pharmaceutical dosage form according to the
invention, thereby preventing an overdose of the pharmacologically active ingredient,
preferably opioid agonist, particularly due to comminution of the pharmaceutical dosage form
by ical . Preferably, the mechanical action is selected from the group consisting
of chewing, grinding in a mortar, pounding, and using apparatuses for pulverizing
conventional pharmaceutical dosage forms.
The following es further illustrate the invention but are not to be construed as limiting
its scope.
General procedure:
Polyethylene oxide, pherol, oxycodone hydrochloride, naloxone hydrochloride and all
other excipients were weighted and sieved to each other.
The powder was mixed and dosed gravimetrically to an extruder. Hot-melt extrusion was
performed by means of a twin screw extruder of type ZSE18 PH 40D ritz, NUrnberg,
Germany) that was equipped with medium shear screws and a heatable round die having a
diameter of 5 or 7mm. Extrusion was performed at 100 rpm at a dosing rate of 1 kg/h.
The hot extrudate was cooled by ambient air and the cooled extrusion strand was
comminuted to cut pieces. The cut pieces were shaped by means of an excenter press which
was ed with punches of various size and shape.
The breaking strength of the pharmaceutical dosage forms was measured by means of a
Sotax® HT100. A tablet was regarded as g the breaking strength test when during the
measurement the force dropped below the threshold value of 25% of the maximum force that
was observed during the measurement, regardless of whether the dosage form was
fractured into separate pieces or not. All values are given as a mean of 10 measurements.
The in vitro e profile of the pharmacologically active ient (Oxycodone HCI and
ne HCI) was measured in 600 ml of blank FeSSlF (pH 5.0) at temperature of 37°C
with sinker (type 1 or 2). The rotation speed of the paddle was adjusted to 150/min. The
pharmacologically active ingredient was detected by means of a spectrometric measurement
with a wavelength of 218 nm.
Example I:
Composition of formulations
2012/072678
The following compositions were prepared and hot-melt extruded:
Ox codone HCI 16.00% 16.00%
800%
40-00%
-00%
-00
020%
0130%
500%
tablet weioht 250.00 mo 250.00 mo
Tablet formats
Tablets were manufactured from the crude extrudates by means of round punch and oblong
punch, respectively (no engraving). Tablets having the following formats were prepared from
the cut extrudates by means of the corresponding punches:
# oofextrusion die tablets unch format
9 mm round
radius of curvature 7.2 mm
o Iconvex 9 mm round
R=15l1 biconvex
C-15°'ong oblong
9 mm round
radius of curvature 7.2 mm
o Iconvex 9 mm round
R=15l1 biconvex
C-25°'°ng oblong
9 mm round
radius of curvature 7.2 mm
olCOnVeX 9 mm round
R=15l1 biconvex
l-15°'°ng oblong
6X15 mm
Analytical tests - in vitro release
Figure 1A shows the in vitro release e of one from the tablets C-17r°”“d, C-
17biconvex, and long rent tablet formats) as manufactured from composition C-1 in
comparison to commercial Targin® tablets.
WO 72395
Figure 1B shows the in vitro release profile of oxycodone from the tablets as manufactured
from composition 'ong in different release media (blank Fessif, pH 1.2, pH 6.8, and
aqueous ethanol 40% (v/v)).
Figure 2A shows the in vitro release profile of oxycodone from the tablets C-27r°”“d, C-
27biconvex, and C-25°b'°ng (different tablet formats) as manufactured from composition 0-2 in
comparison to commercial Targin® tablets.
Figure 2B shows the in vitro release profile of oxycodone from the tablets as manufactured
from composition 0-250“ong in different release media (blank Fessif, pH 1.2, pH 6.8, and
s ethanol 40% (v/v)).
Figure 3A shows the in vitro release e of oxycodone from the tablets I-17r°““d, l-hbiconvex,
and I-15oblong (different tablet formats) as manufactured from composition H in comparison to
commercial Targin® tablets.
Figure 3B shows the in vitro release profile of oxycodone from the tablets as ctured
from composition l-15Oblong in ent release media (blank Fessif, pH 1.2, pH 6.8, and
aqueous ethanol 40% (v/v)).
Analytical tests - content and breaking th
The content of oxycodone, naloxone and oc-tocopherol was analytically quantified in
accordance with Ph. Eur. and the breaking strength of the tablets was ed. The results
are summarized in the table here below:
ng strength
96.5% 98.25% 94.50% >1000N
96.2% 98.28% 94.75% >1000N
95.5% 97.14% 94.73% >1000N
Analytical tests - attempts of tampering
a) Tampering in order to render the dosage form administrable by the nasal route
Coffee grinder pulverization
Hammer stroke pulverization, brittle fracture
WO 72395
Breaking strength pulverization
The tablets were treated by means of o commercially available household coffee mill, type
Bosch MKM6000, 180W, Typ KM13. Subsequently, the thus obtained material was analyzed
by means of a sieving tower (Haver & Boecker, is sieve, diameter 50 mm) equipped
with a bottom plate, displacement ring, lid, and 14 sieves the mesh sizes ranging from 0.045
mm to 4.000 mm, namely 0.045 mm; 0.063 mm; 0.090 mm; 0.125 mm; 0.180 mm; 0.250
mm; 0.355 mm; 0.500 mm; 0.710 mm; 1.000 mm; 1.400 mm; 2.000 mm; 2.800 mm; 4.000
mm. The amplitude was set to 1.5 mm.
The hammer stroke test was performed by means of a free falling weight testing device Type
40001, 40011 ff, Coesfeld GmbH & Co. KG, Germany. The following parameters
were set:
Falling : 1000 mmir1%
Falling weight: 500 gir2%
Form of falling weight/ impact area: 25 mm x 25 mm
on of sample: loosely positioned in the center of the sample holder
The measuring result was qualified according to the following scale:
(A) tablet apparently undamaged
AAAA B ) tablet has been compressed but is widely undamagedC) tablet has been compressed and is lacerated at its edgesD) tablet has been disrupted into several piecesE ) tablet has been pulverized
The results are ized in the table here below:
Test Targin°' ong
ation
a) Coffee grinder (2 min);
Sieve analysis [um] (mean 3 x,
n=1)
<125 um:
125-1000 um:
>1000 m:
b) Hammer stroke
c) Breaking strength (n=10)
Min: 78 N
Max: 100 N
b) Tampering in order to render the dosage form administrable by the intravenous route
Boiling for 5 min with 5 mL water (intact tablet, grinded tablet); drawing up with filter and
large (G21) needle
The extractable t of pharmacologically active compound was determined by
(i) subjecting a tablet for 5 minutes in 5.0 mL of boiling water,
(ii) supplementing lost water, if any,
(iii) separating the overhead liquid solution from the remainder by means of a e,
equipped with a cigarette filter and a canula, 0.80 x 40 mm BL/LB; 21 G x 1 1/2", and
(iv) determining the pharmacologically active compound content in the drawn liquid by HPLC
analysis.
The following extracted contents were ined:
An undestroyed tablet was d for 2 min by a coffee mill. The thus obtained material was
boiled in 5 mL water for 5 min and the supernatant liquid was drawn up by means of a
syringe, equipped with 21 G canula and filter.
The following extracted contents were ined:
Compared to commercial product TarginOb'ong, substantially less opioid agonist and opioid
antagonist could be extracted from the dosage forms C-15°b'°“9, C-25°b'°“9, and l-15°b'°“9.
Furthermore, approximately the same amount of opioid agonist and opioid nist could
be extracted from the dosage forms C-15°b'°“9, C-25°b'°“9, and l-15°b'°“9. From the commercial
product TarginOb'ong, however, more opioid agonist could be extracted than opioid antagonist;
this effect is disadvantageous with respect to the avoidance of abuse.
c) ing in order to render the dosage form administrable by the oral route
Extraction for 30 min with 30 mL of water or 40% Ethanol
Extraction for 30 min with 30 mL of boiling water (tea) [water boils in the beginning and is
then allowed to cool down during the 30 min]
intacttablet+30m|water 21.6 21.1 11.8 11.0 14.0 12.6 13.2 12.2
ambient temoerature 30 min
intact tablet + 30 ml water/ethanol 40%
WV 30 min shakino
WWWWW
boilino once 30 min WWWWWWWW
oxy. = one
nal. = naloxone
Analytical tests - storage ity
The storage stability of the dosage forms C-15°b'°“9, C-25°b'°“9, and l-15Oblong was investigated.
IWh-IMMWWWWI25°C 40°C 75%RH
___—I
___—I
___—I
____—I
-—__—I
ng strength >1000 N >1000 N >1000 N
n=9 n=9 n=8
All assays are normalized with respect to the tablet weight.
Figure 4A shows the in vitro release profile of oxycodone from the tablets C-15Oblong before
and after storage under the various storage conditions.
Figure 4B shows the in vitro release profile of naloxone from the s C-15Oblong before and
after storage under the various storage conditions.
IWh-IMMWWWWI25°C 40°C 75%RH
973% I 100.9% 102-2%
Zox codone C+D+N-oxide 0.06% I 0.14% 0.15%
989% I 1007% 101-2%
__0-00% 0I-45% 041%
-—92-9% I95-6% 924%
breaking strength >1000 N >1000 N >1000 N
n=10 n=10 n=9
All assays are ized with respect to the tablet weight.
Figure 5A shows the in vitro release profile of oxycodone from the tablets C-25°b'°ng before
and after storage under the various storage conditions.
Figure SB shows the in vitro release profile of naloxone from the tablets C-25°b'°ng before and
after storage under the various e conditions.
_--I25°C 40 °C 75%RH
96.4% I 99.1% 99.0%
Zox codone C+D+N-oxide 0.06% I 0.15% 0.14%
99.2% I 100.5% 101.4%
__0-00% I0-30% 022%
-—93-1%I94-4% 928%
breaking strength >1000 N >1000 N >1000 N
n=6 n=6 n=4
All assays are normalized with respect to the tablet weight.
Figure 6A shows the in vitro release e of oxycodone from the tablets I-15Oblong before and
after e under the various storage conditions.
Figure GB shows the in vitro release profile of naloxone from the tablets I-15Oblong before and
after e under the various storage conditions.
All three tested formulations fulfill the impurity limits given by the API monographs Ph. Eur.
(7th n, 2011) after 3 months of e at 40°C and 75% RH. However, the dosage
form according to the invention I-15Oblong is clearly the formulation with best ity
characteristics within this test period.
Comparative Example:
Composition of formulations
Round tablets having a diameter of 10 mm, a radius of curvature of 8 mm and a mass of
333.0 mg were prepared from mixtures of the following components:
Tramadol HCI and polyethylene oxide were weighed and mixed for 15 minutes in a rolling
glass mixer at 14 rpm. Then, the mixtures were compressed at ambient temperature on a
Korsch EKO (punch format 10 mm, radius of curvature 8 mm) at two different pressure
forces. The breaking strength was measured by means of a Zwick breaking strength tester
(average value over 10 tablets).
The results of the measurements are summarized in the table here below:
# 1 # 2
MW 600,000 MW 7,000,000
ressure force N 7000 =40000 5000 =38000
breakino strenoth N .13- IE!-
The above mental data demonstrate that pharmaceutical dosage forms having an
increased breaking strength, Le. a breaking strength of at least 300 N, cannot be obtained by
direct compression at room ature.
However, when performing the same process of ation at elevated temperature, i.e.
when compressing the cal powder mixture at elevated temperature, dosage forms
having a breaking strength of at least 300 N can be obtained.
Similar to d and graphite, which both consist of pure carbon, the chemical
composition does not tell much about the mechanical properties.
WE
Claims (15)
1. A pharmaceutical dosage form for oral administration having a breaking strength of at least 300 N and sing (i) a pharmacologically active ingredient; (ii) an opioid antagonist and/or an aversive agent; (iii) a polyalkylene oxide having an average molecular weight of at least 200,000 g/mol; and (iv) an anionic polymer; wherein said aversive agent imparts an unpleasant (aversive) sensation to an abuser when the dosage form is tampered with so that tampering for the purpose of abusing the phamacologically active ingredient that is contained in the dosage form can be avoided or at least substantially impeded and wherein said aversive agent is selected from the group consisting of (a) substances which irritate the nasal passages and/or pharynx, (b) viscosity-increasing agents and/or gelling agents; (c) emetics; (d) dyes; (e) bitter substances; and (f) surfactants.
2. The pharmaceutical dosage form according to claim 1, wherein the anionic polymer comprises anionic onal groups selected from carboxyl groups, sulfonyl groups, sulfate groups, and phosphoryl groups.
3. The pharmaceutical dosage form according to claim 1 or 2, wherein the anionic polymer is d from a monomer selected from acrylic acid, alkyl acrylates and alkyl ylates, or a combination thereof.
4. The pharmaceutical dosage form ing to any one of the preceding claims, wherein in accordance with Ph. Eur. the in vitro release profile of the pharmacologically active ient opioid agonist essentially ponds to the in vitro release profile of the opioid antagonist and/or the aversive agent.
5. The pharmaceutical dosage form according to any one of the ing claims, wherein the pharmacologically active ingredient opioid agonist and the opioid antagonist and/or the aversive agent are homogeneously buted over the pharmaceutical dosage form or, when the ceutical dosage form comprises a film g, over the coated core of the pharmaceutical dosage form.
6. The pharmaceutical dosage form according to any one of the preceding claims, wherein the pharmacologically active ingredient opioid agonist and the opioid antagonist and/or the aversive agent are embedded in a prolonged e matrix comprising the polyalkylene oxide and the anionic polymer. AH26(10859953_1):RTK
7. The pharmaceutical dosage form ing to any one of the preceding claims, which is configured for administration once daily or twice daily.
8. The pharmaceutical dosage form according to any one of the preceding claims, which is monolithic.
9. The pharmaceutical dosage form according to any one of the ing claims, wherein the content of the polyalkylene oxide is at least 30 wt.-%, and/or the content of anionic polymer is within the range of 5.0±4.5 wt.-%, in each case based on the total weight of the ceutical dosage form.
10. The pharmaceutical dosage form according to any one of the preceding claims, which is thermoformed.
11. The pharmaceutical dosage form according to claim 10, which is hot-melt extruded.
12. The pharmaceutical dosage form according to any one of the preceding claims, which is tamper-resistant.
13. The ceutical dosage form according to any one of the preceding claims, wherein the pharmacologically active ingredient is oxycodone or a physiologically acceptable salt thereof.
14. The pharmaceutical dosage form according to any one of the preceding claims, wherein the opioid antagonist is selected from the group ting of naltrexone, naloxone, ene, acine, levallorphan, pharmaceutically acceptable salts thereof and mixtures thereof.
15. The pharmaceutical dosage form according to any one of the preceding claims, which contains a plasticizer and/or an antioxidant. Grünenthal GmbH By the Attorneys for the Applicant SPRUSON & FERGUSON Per: AH26(10859953_1):RTK
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11009129 | 2011-11-17 | ||
EP11009129.5 | 2011-11-17 | ||
EP12001295 | 2012-02-28 | ||
EP12001295.0 | 2012-02-28 | ||
PCT/EP2012/072678 WO2013072395A1 (en) | 2011-11-17 | 2012-11-15 | Tamper-resistant oral pharmaceutical dosage form comprising a pharmacologically active ingredient, an opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ623291A NZ623291A (en) | 2016-01-29 |
NZ623291B2 true NZ623291B2 (en) | 2016-05-03 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012338872B2 (en) | Tamper-resistant oral pharmaceutical dosage form comprising a pharmacologically active ingredient, an opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer | |
AU2012320496B2 (en) | Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist | |
US9655853B2 (en) | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer | |
AU2010275754B2 (en) | Tamper-resistant dosage form for oxidation-sensitive opioids | |
CN105682643B (en) | Tamper resistant dosage form containing ethylene-vinyl acetate polymer | |
JP5933553B2 (en) | Tamper resistant dosage forms containing anionic polymers | |
JP2018065810A (en) | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc | |
EA036444B1 (en) | Modified release abuse deterrent dosage forms | |
NZ623291B2 (en) | Tamper-resistant oral pharmaceutical dosage form comprising a pharmacologically active ingredient, an opioid antagonist and/or aversive agent, polyalkylene oxide and anionic polymer | |
NZ620252B2 (en) | Tamper-resistant oral pharmaceutical dosage form comprising opioid agonist and opioid antagonist |